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Sum m ary
In the past decade considerable advances have been made in both the 
investigation and treatment of various disorders of bone and calcium 
metabolism. The progress in investigative techniques has taken place in many 
different directions including biochemical evaluation, parathyroid imaging and 
bone densitometric measurement Advances have also taken place in therapeutics 
with, in particular, the introduction into clinical practice of the bisphosphonates. 
These drugs are potent inhibitors of bone resorption and are therefore potentially 
useful in conditions where bone resorption is increased such as in most cases of 
hypercalcaemia, Paget's disease of bone and some cases of osteoporosis.
Accurate evaluation of serum parathyroid hormone (PTH) concentrations and 
parathyroid hormone-like activity by use of indirect biochemical indices such as 
nephrogenous cyclic adenosine monophosphate (NcAMP) and renal tubular 
threshold for phosphate reabsorption (TmP04), led to the discovery that in many 
instances cancer-associated hypercalcaemia is due to the production by the 
tumour of a factor with PTH-like activity. This, in turn, led to the identification 
of this factor as PTH-related protein (PTHrP), a peptide with significant 
structural homology to PTH itself.
It has generally become apparent that PTHrP driven hypercalcaemia is more 
common in the presence of squamous cancer whereas hypercalcaemia due to 
direct invasion of bone by lytic metastases is more common in conditions such as 
myeloma. Traditionally breast cancer-associated hypercalcaemia has been 
considered to be due to direct metastatic invasion of bone, though more recent 
evidence suggests that humoral factors, such as PTHrP, may also play a 
significant role. A retrospective analysis of 20 patients with breast cancer- 
associated hypercalcaemia was carried out (chapter 3.1). This study indicated
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that on the basis of elevated levels of urinary cAMP (UcAMP) excretion and/or 
depressed TmP04 (in the presence of undetectable serum PTH), hypercalcaemia 
associated with the presence of a PTH-like factor was present in between 45- 
60% patients.
Recent evidence has suggested a number of potential physiological roles for 
PTHrP. One such example is in the active transfer of calcium into milk in the 
breast and the active transfer of calcium from mother to fetus in pregnancy by an 
action at the placenta. In the physiological situation, where PTHrP and PTH 
concentrations are likely to be within the normal reference range, it is unlikely 
that measurement of UcAMP, NcAMP or TmP04 will give accurate indication 
of plasma PTHrP concentrations. In this context direct measurement of PTHrP is 
essential. A prospective study of 10 normal women through pregnancy (chapter
3.2) showed that plasma PTHrP concentrations rise throughout pregnancy 
reaching their highest concentration around term. Thereafter levels continue to 
rise into the puerperium. PTHrP levels during pregnancy correlated closely with 
serum alkaline phosphatase (ALP) concentrations suggesting a placental source 
to this PTHrP. Post-partum, however, it is likely that the continued rise in PTHrP 
was due to the onset of lactation and production of PTHrP by the breast. As 
expected, concentrations of NcAMP did not change significantly during the 
period of study.
The importance of the vitamin D/PTH axis has been known for a number of 
years. The availability of precise and accurate biochemical assays for 1,25- 
dihydroxyvitamin D3 (l,25(OH)2D3) (the principal active metabolite of vitamin 
D3 in man) and intact PTH(l-84) has allowed detailed investigation of their 
inter-relationship in vivo. l,25(OH)2D3 and other active metabolites of vitamin 
D3 such as la-hydroxycholecalciferol (alfacalcidol) have recently been used 
therapeutically in the treatment of hypocalcaemia (including that associated with
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hypoparathyroidism), osteoporosis and renal osteodystrophy. Recent evidence 
has suggested an advantage in using these drugs by intravenous routes such that 
significant PTH suppression may be achieved though not at the expense of the 
development of hypercalcaemia. The acute (first 24hours) effect of intravenous 
administration of alfacalcidol upon serum concentrations of l,25(OH)2D3, PTH 
and osteocalcin was studied prospectively in 6 normal males, 6 patients with 
primary hyperparathyroidism (PHPT) and 6 women with osteoporosis (chapter
3.3). Significant increases in serum concentrations of l,25(OH)2D3 were seen in 
each group 2-3 hours after administration of alfacalcidol. The increase in 
l,25(OH)2D3 observed was greatest in those patients with PHPT. In the first 24 
hours after administration, suppression of PTH concentrations or elevations in 
serum concentration of osteocalcin were not observed. This would suggest that 
changes normally seen in the longer term with these parameters are effected via 
changes in hormone synthesis rather than secretion.
The introduction of dual-energy X-ray absorptiometry (DXA) in the late 1980's 
allowed more accurate and precise measurement of bone density at both the 
lumbar spine (L2-4) and neck of femur - both sites where osteoporotic fractures 
are relatively common and may be associated with significant morbidity or, in 
the case of neck of femur, mortality. DXA has the advantages of faster scan 
times than was possible with dual-photon densitometry, and lower exposure to 
ionising radiation. This technique has a precision of generally <1% at L2-4 and 
an accuracy of <2%. This, therefore, allows cross-sectional studies to evaluate 
bone density in a number of situations. Examples of this are described in chapter
4.1 and 4.2.
The association of diabetes mellitus with osteoporosis has been suggested for 
many years, however the evidence for this remains inconclusive. In chapter 4.1, 
L2-4 and neck of femur bone densities were measured in 20 premenopausal
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females with type I diabetes mellitus and 27 age-matched controls. Results 
showed that L2-4 bone density was significantly higher in the diabetic patients, 
though no change was noted in the neck of femur densities. Serum ALP and 
urinary excretion of hydroxyproline were also measured in these subjects as 
biochemical markers of bone formation and resorption respectively and were 
both significantly elevated in the diabetic patients indicating the presence of a 
high bone turnover status.
Following the unexpected presentation of two young men suffering from severe 
haemophilia A with, in one case, vertebral compression fractures and, in the 
other, a neck of femur fracture, a similar study was carried out in a group of 19 
males with severe haemophilia (chapter 4.2). This showed that patients with 
haemophilia had significantly lower bone densities than age/sex matched 
controls. In addition though serum testosterone levels were significantly higher 
in the haemophiliac patients, sex hormone binding globulin was also 
significantly elevated meaning that these patients had a reduced free androgen 
index and relative hypogonadism.
Although the value of routine pre-operative imaging remains controversial in 
primary hyperparathyroidism (PHPT), considerable advances have been made in 
the technologies available. In chapter 5.1, a comparison was made between the 
two most widely used methods of parathyroid imaging in the UK - 10MHz 
ultrasound (US) and 201-thallium/99m-technetium (Tl/Tc) subtraction scanning. 
These two techniques were compared prospectively in 25 patients with PHPT. 
Results showed poor sensitivities with both techniques (38-42%), though 
specificities were significantly better (89-97%). The low sensitivities of these 
techniques means that their routine preoperative use cannot be justified.
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An attempt was made to improve the sensitivity of Tl/Tc scanning in chapter 5.2 
by augmenting PTH secretion by infusing the calcium chelating agent, trisodium 
edetate. Six patients with PHPT and previous normal Tl/Tc scans were studied. 
In three instances the repeat Tl/Tc scan carried out after infusion of trisodium 
edetate was positive. Two of these patients went on to surgery and in each 
instance a parathyroid adenoma was found at the site corresponding to the scan 
abnormality.
With the introduction of the bisphosphonates into clinical practice considerable 
improvements have been seen in the management of many different conditions. 
The bisphosphonates are potent inhibitors of osteoclastic bone resorption and 
have been shown to be effective in the treatment of various types of 
hypercalcaemia - including that associated with cancer.
Pamidronate is the most potent of these drugs currently licensed for use in the 
UK. The optimum treatment schedule in cancer-associated hypercalcaemia is, 
however, not yet defined. Chapter 6.1 describes a comparison between a single 
intravenous infusion of high (90mg) and low (30mg) dose pamidronate. This 
study showed that, on average, there was no difference between these two 
regimens, though there was a suggestion that in those patients where there was 
evidence of tumour production of a PTH-like factor, the response to pamidronate 
was less good. This was explored further in chapter 6.2 where a retrospective 
analysis of results from 35 patients with cancer-associated hypercalcaemia 
treated with three different doses of pamidronate (30mg, 45mg and 90mg) were 
reviewed. Results showed that where NcAMP was elevated or TmP04 reduced 
prior to pamidronate therapy, the fall in serum calcium was less pronounced, 
with normocalcaemia unlikely to be achieved.
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Studies investigating therapies for cancer-associated hypercalcaemia usually use 
serum albumin adjusted calcium for monitoring purposes. Since other factors 
might potentially alter the usual close relationship between ionised and albumin 
adjusted calcium, both these parameters were measured prospectively in 8 
patients with cancer-associated hypercalcaemia treated with pamidronate 
(chapter 6.3). While there was some variation in the relationship between these 
two parameters, this was slight and unlikely to be of major clinical significance.
On the basis of the evidence presented in chapters 6.1 and 6.2, pamidronate 
might be expected to be particularly effective where PTH-like factors are not 
involved in the pathogenesis of hypercalcaemia. Chapter 6.4 describes the effect 
of intravenous pamidronate on 5 patients with immobilisation-related 
hypercalcaemia. As expected, since PTH-like factors are not involved in the 
pathogenesis of this condition, these patients respond particularly well even to 
very low doses of pamidronate.
Pamidronate is also effective in other conditions where bone resorption is 
frequently increased such as Paget's disease of bone and corticosteroid- 
associated osteoporosis. Definitive dose regimens with pamidronate in either of 
these settings, however, have yet to be established. A prospective study of 45 
patients with Paget's disease treated with either weekly or 3 monthly infusions of 
pamidronate is described in chapter 7.1. This showed that 3 monthly infusions, at 
equivalent total dose, are likely to be as effective as weekly treatment. 
Furthermore, it was apparent that patients with more severe disease required a 
higher total dose of pamidronate suggesting the existence of a dose/response 
effect.
Chapter 7.2 describes the effect of intermittent (3 monthly) infusions of 
pamidronate on corticosteroid-associated osteoporosis. This study showed
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significant increases in spinal L2-4 density (measured by DXA) and significant 
reduction in bone turnover as noted by a fall in serum ALP and urinary HP/Cr.
Altogether these studies illustrate how advances in the investigation and 
management of metabolic bone disease and disturbances of mineral metabolism 
have been effected in recent years.
CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW
28
1.1 D isorders of Bone and Calcium Metabolism
1.1.1 Introduction
Bone is a complex living tissue whose structural strengths rely upon the presence 
of a mineralised extracellular matrix. The presence of normal bone formation and 
resorption are crucial to normal bone physiology and disruption to these 
processes constitute the general descriptive heading of "metabolic bone disease".
Hypercalcaemia or hypocalcaemia may occur when alterations in calcium flux 
occur at the gastrointestinal tract, kidney or bone. Calcium continuously enters 
the extracellular fluid from gut and bone, however serum calcium concentrations 
are maintained within remarkably tight limits due largely to the effects of 
parathyroid hormone (PTH) and 1,25 dihydroxycholecalciferol 
(l,25(OH)2D3)(l,2).
1.1.2 Calcium homoeostasis - role of Gl tract
The net daily absorption of calcium from the gastrointestinal tract to the 
extracellular fluid is approximately 300mg (7.5mmoles). In order to be 
absorbable calcium must be both soluble and in ionised form (3). A variety of 
factors are known to affect the availability of calcium in the intestine. Phosphate, 
phytate and oxalate, for example will decrease calcium absorption (4) whereas 
carbohydrates such as lactose will lead to an increase (5). The availability of 
dietary calcium in itself is of importance as the efficiency of absorption is 
increased when dietary calcium is low (6). The main hormonal influence on 
dietary calcium absorption is the presence of vitamin D. The earliest evidence for 
this came from studies on rickets in both animals and man in the 1920s (7). In the 
1950s it was demonstrated that calcium was absorbed by an active transport
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mechanism across the gastrointestinal mucosal cells (8) and that this was under 
the control of vitamin D (9). It has more recently become apparent that vitamin 
D does not in itself have a direct effect on calcium absorption, but it must first be 
metabolised to l,25(OH)2D3 (10) which is the metabolite with the greatest 
efficacy in stimulating calcium absorption. In conditions where l,25(OH)2D3 
levels are low, for example due to chronic renal failure (11) or dietary 
deficiency, calcium malabsorption and hypocalcaemia may occur (12). Other 
calciotrophic hormones such as PTH and calcitonin do not appear to have any 
direct effects on the control of calcium absorption (13), though PTH may have an 
indirect effect by increasing l,25(OH)2D3 concentrations by stimulating the la -  
hydroxylase enzyme (14).
Drugs are also of considerable importance in calcium absorption. It has been 
demonstrated that calcium absorption is directly inhibited by corticosteroids (in 
spite of normal l,25(OH)2D3 levels) (15), neomycin (16), and bisphosphonates 
(17).
Subject age is also important as in man there is a progressive decrease in calcium 
absorption with advancing age as shown by balance studies and radiocalcium 
absorption (18). Part of this malabsorption, however, is probably due to vitamin 
D deficiency from poor dietary intake or reduced endogenous synthesis.
1.1.3 Calcium Homoeostasis - Role of the Kidney
Calcium excretion is regulated by a combination of glomerular filtration and 
tubular reabsorption, the calcium in the urine being the fraction of the filtered 
load which is not reabsorbed. Work by McLean and Hastings in the 1930s 
(19,20) showed that approximately 50% of calcium in serum is in ionised form, a 
further 10% is ultrafilterable but ligand bound with the remaining 40% being
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protein bound - mainly to albumin. Only 60%, therefore, of total serum calcium 
can be filtered and excreted by the kidney. In an average adult lOOOOmg calcium 
cross the glomerulus each day and 98% of this is reabsorbed in the renal 
tubules (21).
Glomerular filtration would appear mainly to depend on renal blood flow. When 
this is reduced as happens, for example, in hypercalcaemic states secondary to 
dehydration (22), calcium clearance is reduced.
The majority of calcium filtered by the glomerulus is reabsorbed by the tubules. 
Approximately 65% is reabsorbed in the proximal tubules and is not under 
hormonal regulation, 20-25% is reabsorbed in the ascending limb of the loop of 
Henle and 10% in the distal tubules (23). Calcium is reabsorbed by an active 
transport mechanism in the proximal tubule closely linked with sodium (24).
This association is of critical importance with respect to net serum calcium 
levels, as when dehydration occurs sodium is conserved by an increase in 
proximal tubular reabsorption. Since calcium reabsorption accompanies sodium 
reabsorption dehydration may potentiate hypercalcaemia. The mechanism of 
calcium reabsorption at the loop of Henle is unclear, though this is the site where 
thiazide diuretics act to promote calcium reabsorption (25). Calcium reabsorption 
is more closely controlled at the distal tubules where it is under the control of 
PTH (26) and possibly also vitamin D (27).
The kidney is also the principal site of synthesis of l,25(OH)2D3 (10) - the major 
active metabolite of vitamin D. Abnormalities of l,25(OH)2D3 metabolism are 
commonly found in association with chronic renal failure (28). In this situation 
circulating levels of l,25(OH)2D3 are generally low and secondary 
hyperparathyroidism is common (29). Oral l,25(OH)2D3 therapy has been 
successfully used to suppress this excess PTH secretion, but the doses required
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are generally associated with the development of hypercalcaemia (30). It has 
been noted, however, that more adequate PTH suppression can be achieved 
without this concomitant rise in serum calcium when l,25(OH)2D3 or la -  
hydroxycholecalciferol (alfacalcidol) is given intravenously rather than orally 
(31).
Calcium balance studies have shown that the kidney has considerable reserve in 
calcium excretion, as in order to increase serum calcium by O.lmmol/1, 5mmol of 
calcium would have to be released from bone. Measurement of calcium balance 
in normal individuals has shown that l-2mmol of calcium/day may be released 
from bone (32,33) which only rises to levels of 5-10mmol/day in conditions such 
as myeloma and metastatic breast cancer (34) - conditions commonly associated 
with hypercalcaemia. Thus, in the presence of normal renal function, increases in 
bone resorption of up to 10 fold would not be expected to cause hypercalcaemia. 
This is illustrated by the fact that hypercalcaemia is extremely rare in benign 
disorders associated with increased bone resorption (35).
Many different hormones are now known to influence the urinary excretion of 
calcium either directly or indirectly. Patients with primary hyperparathyroidism 
have been shown to have reduced clearance of calcium relative to that in normal 
subjects with similar serum calcium levels - due to increased tubular 
reabsorption of calcium (36). Corticosteroids are associated with increased 
urinary calcium losses as demonstrated both in Cushing's syndrome (37) and 
with administration of exogenous steroids (38) - probably due to inhibition of 
tubular calcium reabsorption (39). Oestrogen administration has also been shown 
to decrease urinary calcium losses though this is mainly due to inhibition of bone 
resorption leading to a subsequent decrease in the filtered load of calcium (40).
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Peacock and Nordin (2,36) have suggested that in steady state there is a 
curvilinear relationship between urinary calcium excretion (CaE) and serum 
calcium (figure 1.1) such that as gut calcium absorption and bone resorption 
increase changes in renal calcium excretion will determine the eventual serum 
calcium level reached. For any given level of serum calcium, if CaE lies to the 
left of the line defining the normal range this implies a decrease in renal tubular 
calcium reabsorption. This is seen, for example, in hypoparathyroidism. 
Conversely if CaE is to the right of the line defining the normal range this 
implies is an increase in calcium reabsorption. This is seen, for example, in 
hyperparathyroidism. Calcium kinetic studies using radioisotope tracers have 
measured gut absorption and bone calcium resorption and compared these to 
urinary calcium excretion (41). Assuming net gut calcium absorption in the 
fasting state is negligible, then under these circumstances calcium excretion - 
expressed as a ratio of urinary calcium to urinary creatinine - probably equals the 
net skeletal loss of calcium i.e. bone resorption.
1.1.4 Calcium Homoeostasis - Role of Bone
The prime role of bone in calcium homoeostasis is to act as a reservoir of 
calcium which may be used when gut absorbed calcium is insufficient to 
maintain serum calcium.
Parathyroid hormone has an important role in mobilising calcium from bone by 
stimulating osteoclastic bone resorption. The main target cell for PTH in bone is 
the osteoblast and increased resorption probably occurs by local paracrine 
signalling between the osteoblast and osteoclast (42). The effects of PTH on 
bone resorption may also depend, at least in part, on the presence of 
l,25(OH)2D3 (43). This bone remodelling system, though, is unlikely to be of 
major importance in calcium homoeostasis as long as bone formation and
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Figure 1.1
Relationship between urinary calcium excretion ((imol/litre glomerular filtrate) 
and serum calcium. Dotted lines indicated two standard deviations from the 
mean values obtained by Peacock et al.(36) in normal subjects during calcium 
infusions.
resorption remain coupled. When a pathological condition uncouples these 
processes, such as if bone resorption is increased in association with cancer 
or immobilisation (44), hypercalcaemia may then ensue.
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1.2 C ancer-associated  hypercalcaem ia
1.2.1 Differential Diagnosis
The most common cause of hypercalcaemia, certainly in hospital based studies, 
is that associated with the presence of cancer with an estimated incidence of 
approximately 150 new cases per million persons per year in the UK(45,46,47). 
The main differential diagnosis is from primary hyperparathyroidism with both 
this and cancer-associated hypercalcaemia making up approximately 90% of 
cases of hypercalcaemia (48). With the advent of highly sensitive and specific 2- 
site immunoradiometric assays for PTH, distinction between these two causes of 
hypercalcaemia has become easier with PTH low or undetectable in cancer- 
associated hypercalcaemia and elevated in primary hyperparathyroidism (49). 
Where PTH is low or undetectable other differential diagnoses to consider 
include: hyperthyroidism (50), immobilisation (51), sarcoidosis (52), vitamin D 
intoxication (53), milk-alkali syndrome (54), use of thiazide diuretics (55) and 
benign familial hypercalcaemia (56). Usually in these situations other clinical 
features alert one to the diagnosis with the possible exception of benign familial 
hypercalcaemia, where a high index of suspicion is required.
1.2.2 Pathogenetic Mechanisms
The mechanisms responsible for cancer-associated hypercalcaemia are 
heterogeneous and depend, to a significant extent, upon the type of malignancy 
present. In general terms two mechanisms are cited in the pathogenesis of this 
syndrome. Firstly, direct local invasion of bone by tumour cells leads to release 
of calcium into the blood at a rate exceeding the maximal rate of renal calcium 
excretion (35,57,58). Secondly, the tumour itself may produce a factor (or 
factors) which may act directly upon the bone to increase osteoclastic resorption
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and/or at the kidney to increase renal tubular calcium reabsorption (59,60) - this 
mechanism has become known as humoral hypercalcaemia. It has become clear, 
however, that both mechanisms are of importance, though to a greater or lesser 
extent, depending both upon the tumour type (61) and the clinical progression of 
the hypercalcaemia (62). Humoral hypercalcaemia is more common with solid 
tumours such as bronchial carcinoma (58) and hypercalcaemia due to direct 
invasion of bone more likely with haematological malignancies such as myeloma 
(58) and carcinoma of breast (58,63).
As described in section 1.1.3 the kidney has considerable reserve to increase 
urinary calcium excretion until bone resorption is greatly elevated. Histological 
evidence has suggested that there is "uncoupling" of bone resorption and 
formation in cancer-associated hypercalcaemia (62) leading to a net loss of 
skeletal calcium into the extracellular fluid. Furthermore renal impairment is 
more likely, as these patients are more prone to vomiting and decreased fluid 
intake both associated with the tumour itself, or if treatment with chemotherapy 
and/or radiotherapy is used (58).
It appears that in some cases of cancer-associated hypercalcaemia, there is a 
combination of dehydration and increased bone resorption, such that the release 
of calcium from bone exceeds the renal capacity for calcium excretion and serum 
calcium rises. PTH secretion is therefore suppressed, renal tubular calcium 
reabsorption falls (36) and release of skeletal calcium from bone surfaces is 
reduced (64). In addition l,25(OH)2D3 synthesis is reduced and intestinal 
calcium absorption is reduced (65). These homoeostatic mechanisms, however, 
may only partially compensate and hypercalcaemia ensues. Severe 
hypercalcaemia in itself is associated with a reduction in renal blood flow and 
GFR (22). Furthermore, tubular abnormalities occur leading to further loss of 
sodium and water (66) exacerbating the dehydration and a metabolic alkalosis
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may occur (67). A vicious circle then exists with worsening hypercalcaemia due 
to sodium linked calcium reabsorption at the proximal tubule (24) and further 
impairment in GFR.
1.2.3 Potential Humoral Mediators
In 1941 Albright suggested the possibility that cancer-associated hypercalcaemia 
may be attributed to ectopic PTH production when describing a patient with 
renal cancer, a raised serum calcium and low serum phosphate (68). Further 
evidence for this appeared in the 1960's when the first radioimmunoassays for 
PTH became available. Studies showed elevated levels of PTH in a group of 
patients with bronchial cancer (69) and in other non-parathyroid tumours (70). 
The presence of PTH was also demonstrated in tumour cells by 
immunohistochemical techniques (71). Lafferty, in 1966, (72) used the term 
pseudohyperparathyroidism to describe a series of 50 patients with these 
biochemical features. In this work he commented on the frequency of squamous 
and genitourinary cancers and the relative paucity of breast and haematological 
cancers in these patients. However, as the radioimmunoassays for PTH began to 
improve some doubt began to emerge about the involvement of PTH in cancer- 
associated hypercalcaemia. Powell et al.(73), in 1973, demonstrated that tumour 
extracts from several patients with humoral hypercalcaemia were capable of 
resorbing bone in vitro although serum PTH from these patients was consistently 
undetectable. It is now generally accepted that hypercalcaemia caused by ectopic 
PTH secretion by a tumour is exceedingly rare, and has only been convincingly 
described on two occasions (74,75).
The biochemical similarity of this syndrome to primary hyperparathyroidism, 
however, extended beyond an elevated plasma calcium and lowered plasma 
phosphate. Nephrogenous cyclic adenosine monophosphate (NcAMP) is that
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fraction of cyclic adenosine monophosphate generated and excreted by renal 
tubular cells and is produced almost exclusively in response to circulating PTH 
in normal man (76). NcAMP, therefore, provides an index of biologically active 
PTH or PTH-like peptides. Since cancer-associated hypercalcaemia is generally 
associated with low or undetectable PTH and NcAMP is often elevated in this 
syndrome, (77,78,79) this was further evidence for the existence of a factor 
which was not PTH but which had PTH-like activity. Other features normally 
found in association with excess PTH secretion were also described in 
association with hypercalcaemia of malignancy such as decreased renal tubular 
threshold for phosphate reabsorption (TmP04) and elevated threshold for renal 
tubular calcium reabsorption (TmCa) (80,81), though this latter index was shown 
to be highly dependent on renal sodium handling (82).
The presence of these features of PTH excess in the absence of detectable serum 
PTH led to the search for another factor which was not PTH but had PTH-like 
properties, was produced by a number of malignant tumours, would resorb bone 
and would cause hypercalcaemia. This search ended in 1987 with discovery of 
PTH-related protein (PTHrP) in a lung cancer (BEN) cell line. This protein has 
been isolated and its complementary DNA (cDNA) cloned and its gene mapped 
and isolated (83,84). The PTHrP gene is a complex transcriptional unit that by 
alternative splicing gives rise to messenger RNAs (mRNAs) encoding three 
related PTHrPs which differ only in their C-terminal regions. The initial peptide 
to be cloned was a 141 amino acid peptide in which 8 of the first 13 (N-terminal) 
amino acids were identical to PTH - this conserved sequence being common to 
all forms of PTHrP. After this N-terminus sequence, the homology with PTH is 
less striking with only 5 of the following 50 amino acids identical. Since this 
peptide was cloned, others which have been identified include 1-139 and 1-173 
amino acid peptides (85,86).
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PTHrP has been demonstrated to be of both similar (87) and increased potency 
(88) in terms of cAMP production compared to PTH in various in vitro systems. 
It is likely that differences in potency reflect both species differences and 
differences in the lengths of the peptides tested (89). PTHrP has now been found 
to be present both within the tumour cells (90) by immunocytochemistry and in 
the serum of patients with humoral hypercalcaemia (91,92). In addition to being 
produced by malignant tumours PTHrP has been found in normal keratinocytes 
(93), lactating mammary tissue (94), placenta (95), parathyroid glands (96) and 
central nervous system (97) - all of which would suggest that this protein has a 
physiological role.
Whether or not the presence of PTHrP by itself explains all the manifestations of 
humoral hypercalcaemia has been questioned. Certainly, compared with PTH, 
osteoclastic bone resorption is more marked, bone formation rates are lower, 
l,25(OH)2D3 levels are lower and the calcium lowering effect of 
bisphosphonates in such patients greater and more sustained than in primary 
hyperparathyroidism. Furthermore patients with humoral hypercalcaemia tend to 
be alkalotic rather than acidotic as is seen in primary hyperparathyroidism (67).
It is possible, therefore, that in malignancy the effects of PTHrP are modified by 
the presence of other factors such as tumour necrosis factor (TNF), interleukin-1 
(IL-1) or transforming growth factor (TGF) - all of which are more potent bone 
resorbing factors than PTH and are often produced by tumours (98,99,100).
There is also some evidence that tumours may produce another factor which 
interferes with renal 1-alpha hydroxylase activity and explains the low 
l,25(OH)2D3 levels often seen in patients with cancer-associated hypercalcaemia
(101). The differential effect on renal bicarbonate handling appears to be effected 
via an independent action of a component of PTHrP beyond amino acids 1-34
(102).
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Prostaglandins were first suggested as playing a role in the aetiology of this 
syndrome after the demonstration that they possessed potent bone resorbing 
activity in vitro (103). Raised levels of prostaglandin E2 and prostaglandin F 
were later found in tumour tissue from a patient with hypercalcaemia and renal 
adenocarcinoma (104) which seemed to respond to indomethacin therapy. Other 
workers, however have failed to confirm that prostaglandin synthetase inhibitors 
such as indomethacin have a significant calcium lowering effect in cancer- 
associated hypercalcaemia (105).
Cytokines such as interleukin-1 (IL-1) and tumour necrosis factor (TNF) have 
both been shown to increase bone resorption in vitro and may cause 
hypercalcaemia in animal models, however their role in human cancer-associated 
hypercalcaemia remains uncertain (106,107).
Abnormalities of l,25(OH)2D3 production have also been described in 
association with hypercalcaemia of malignancy. Generally serum levels of 
l,25(OH)2D3 are suppressed (65) with the exception of hypercalcaemia 
associated with lymphoma where levels may be elevated (108).
1.2.4 Management
Moderate hypercalcaemia (adjusted calcium 3.00-3.50mmol/l) is associated with 
a number of symptoms including polyuria, polydipsia, nausea, vomiting, lethargy 
and fatigue. CNS symptoms in the form of drowsiness, confusion and coma 
predominate in severe hypercalcaemia (calcium >3.50mmol/l), and may lead 
ultimately to death. In a recent review Ralston et al.(109) showed that efficient 
treatment of cancer-associated hypercalcaemia, with a reduction in serum 
calcium to below 2.80mmolA, was associated with a marked improvement in 
symptoms and, in addition, more of these patients were able to be discharged
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from hospital. The ideal treatment is that targeted specifically against the primary 
tumour i.e surgical resection or chemotherapy. Since this is not always feasible 
palliative, symptomatic treatment is often necessary.
As discussed in 1.1.3, patients with hypercalcaemia are usually dehydrated 
(22,66) and therefore rehydration is the first line in therapy. In most 
circumstances isotonic (0.9%) sodium chloride should be used since any measure 
that induces natriuresis will also induce calciuresis since tubular sodium and 
calcium reabsorption are linked (24). Detailed studies on the effects of 
rehydration have been carried out by Hosking et al.(l 10) who estimated an 
average sodium deficit of 500mmol in patients with cancer-associated 
hypercalcaemia. When this deficit was replaced with 4-8 litres of saline over 48 
hours a mean decrement in serum calcium of 0.4mmolA was seen.
The first effective pharmacological treatment for hypercalcaemia was inorganic 
phosphate which was first described in 1930 (111), and results of the effects of 
phosphate in a series of patients with cancer-associated hypercalcaemia was 
published in 1966 (112). Although this treatment was reasonably effective side- 
effects such as acute renal failure and extraskeletal calcification proved 
unacceptable (113,114), and phosphate, therefore, should be reserved solely for 
life-threatening episodes where standard therapies have failed.
Corticosteroids have been used for many years with variable success (115,116), 
however they cannot be recommended for routine use (117). It does appear, 
though, that some tumours are especially sensitive to corticosteroids such as 
haematological malignancies and tumours of the lymphoreticular system.
Mithramycin is a cytotoxic agent which has been shown to have a significant 
anti-hypercalcaemic effect (118). The main limitation in the use of mithramycin
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in this setting is the high incidence of serious side effects which include a 
coagulopathy, liver function upset - occasionally leading to massive hepatic 
necrosis and upset in renal function (119,120).
Calcitonin has been shown to be an effective agent in the treatment of cancer- 
associated hypercalcaemia (121,122). The mechanism of action of calcitonin is 
thought to be a combination of inhibition of osteoclastic bone resorption and the 
presence of a powerful natriuretic and calciuretic action (121,123). Although 
calcitonin may be an effective agent, a significant number of patients are either 
resistant or gain only transient benefit (121). The short duration of action of 
calcitonin has been ascribed to "down regulation" of the calcitonin receptors 
(124). By combining calcitonin with corticosteroids this "escape" phenomenon 
appears to be, at least partially, prevented (124,125).
A more recently employed agent in the management of cancer-associated 
hypercalcaemia is gallium nitrate. Like calcitonin, it acts primarily by inhibiting 
osteoclastic bone resorption. In a direct comparison, Warrell et al (126) have 
shown gallium to be more effective than calcitonin in the treatment of this 
condition. Problems have been described, however, with nephrotoxicity, the 
development of anaemia and, rarely, optic neuritis. Its present role in the 
management of cancer-associated hypercalcaemia remains uncertain.
The bisphosphonates are a family of compounds that were introduced into the 
treatment of metabolic bone disease in the 1970s. These drugs are synthetic 
analogues of pyrophosphate which are resistant to pyrophosphatases (127). They 
inhibit growth and dissolution of hydroxyapatite crystals in vitro and inhibit 
osteoclastic bone resorption in vivo (128,129). These properties led to this group 
of drugs being used in conditions where bone resorption is elevated such as in 
hypercalcaemia associated with malignancy (130), immobilisation (131) and
42
hyperthyroidism (132) and in Paget's disease of bone (133). In view of their 
efficacy and safety profile, these drugs have now probably become treatment of 
choice in the management of cancer-associated hypercalcaemia (134). In a recent 
study comparing the three intravenous bisphosphonates currently licensed for 
this indication in the United Kingdom, pamidronate (aminohydroxypropylidene 
bisphosphonate, APD) at a dose of 30mg was superior in terms of calcium 
lowering effect to 600mg clodronate (dichloromethylene bisphosphonate, 
C12MDP) and standard doses of etidronate (ethanehydroxy bisphosphonate, 
EHDP) (135). It is generally accepted, however, that clodronate can also be very 
effective though multiple infusions (over several days up to a total of 3000mg) 
are often required (136). As pamidronate is considerably more potent in terms of 
osteoclast inhibition than these other two drugs (see 1.5.5), lower doses (30- 
90mg) can be used effectively. This confers the added advantage of a single 
intravenous infusion generally being effective (137). Clodronate and etidronate 
are both also available as oral preparations which are often used in an attempt to 
maintain normocalcaemia. Results with these are variable and the benefit of 
prolonged oral treatment, often necessitating the ingestion of a large number of 
tablets per day, remains in doubt (138,139) - particularly when if relapse of 
hypercalcaemia does occur a further single infusion of pamidronate will usually 
have a calcium lowering effect similar to the initial treatment (140).
The optimum dose regimen for pamidronate remains uncertain. It is currently 
recommended that the dose of pamidronate be titrated against the prevailing 
serum calcium level, with larger doses of pamidronate given where the pre­
treatment serum calcium is highest. This is based on a single study by Thiebaud 
et al (141). Further evidence exists, however, that when doses of 15mg to 60mg 
pamidronate are used there is little difference in the calcium lowering effect, 
irrespective of the pre-treatment calcium level (140,142). A dose-response effect 
does appear to exist with pamidronate (like the other bisphosphonates), but only
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at doses below 0.05mg/kg (143). It is certain, however, that a number of patients 
fail to respond or only respond incompletely to pamidronate (144,145). The 
reasons for this are not clear, however it has been suggested that where there is 
evidence of tumour production of PTHrP, the calcium lowering effect is less 
good. This was suggested by Gurney et al.(146) who showed, in a small series, 
that TmP04 (a marker of PTH or PTH-like activity) was lower in patients with 
cancer-associated hypercalcaemia who responded less well to pamidronate.
Serum albumin is generally low in patients with cancer and it is important, 
therefore, that the total serum calcium be corrected for this low albumin. Failure 
to do so will mean that the incidence of hypercalcaemia will be significantly 
underestimated (147). It has been suggested, however, that the usual correction 
algorithms may not hold in critically ill patients (148) or in elderly hospital in­
patients (149). Furthermore the binding affinity of calcium for albumin is not 
constant at albumin concentrations below 30g/l (150). In addition to the above, 
measurement of ionised calcium depends to an extent on the prevailing serum 
albumin concentration with measured ionised calcium levels rising where serum 
albumin is higher (151). The experience at Glasgow Royal Infirmary in patients 
with cancer, is that a close correlation is present between ionised calcium and 
albumin corrected calcium (152) (see 2.1.1). However, it is not yet clear whether 
this close correlation is maintained when calcium is lowered with a 
bisphosphonate or whether the degree of metabolic upset present alters the usual 
close relationship between ionised and albumin adjusted calcium.
Although side-effects are thought to be uncommon with bisphosphonates, these 
drugs are all associated with impairment of bone mineralisation to a greater or 
lesser extent. This is seen especially with etidronate where even low dose oral 
therapy for Paget's disease may be associated with osteomalacia (153). Other
side effects include gastrointestinal intolerance with oral therapy, fever 
(following intravenous therapy) and rarely lymphopenia (154).
1.2a Vitamin D Metabolism and Hypercalcaemia
1.2a. 1 Introduction
The synthesis of vitamin D and, in particular, of its active metabolite, 1,25- 
dihydroxyvitmin D3 (l,25(OH)2D3) is of importance in both normal calcium 
homoeostasis and in the pathogenesis of cancer-associated hypercalcaemia 
(11,43). The principal site of l,25(OH)2D3 synthesis is the kidney (10,11). 
However, there is evidence that in certain situations extra-renal l,25(OH)2D3 
production is also of considerable importance (154a).
1.2a.2 Regulation of 1 .25-dihvdroxyvitamin D3
The conventional view is that l,25(OH)2D3 is synthesised in accordance with the 
physiological demand of the body for calcium and phosphate. The main site of 
this regulation is at the level of the la-hydroxylase enzyme which controls the 
production of l,25(OH)2D3 from 25-hydroxy vitamin D3 (25(OH)D3). Activity 
of this enzyme is controlled by changes in serum calcium, phosphate, parathyroid 
hormone (PTH), calcitonin and other vitamin D metabolites (154b). The primary 
stimuli of the renal la-hydroxylase are PTH, low serum calcium and low serum 
phosphate. The resultant increase in serum l,25(OH)2D3 concentrations observed 
following stimulation of la-hydroxylase then act to mobilise calcium from bone 
(by stimulation of osteoclastic resorption) and to increase intestinal calcium 
absorption. It also appears that l,25(OH)2D3 can regulate its own biosynthesis by 
acting as a feedback regulator on either the parathyroid gland or the kidney or 
both. Furthermore, l,25(OH)2D3 may stimulate the formation of renal 24- 
hydroxylase which metabolises excess 25(OH)D3 to the relatively inactive 
metabolite, 24,25-dihydroxyvitamin D3 (154c).
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1.2a.3 Extra-renal Synthesis of 1,25-dihvdroxwitamin D3
Although the principal site of l,25(OH)2D3 production is the kidney (10,11), it is 
now recognised that extra-renal l,25(OH)2D3 production can be of importance in 
some situations. This is seen, for example, in pregnancy where l,25(OH)2D3 is 
produced by the placenta (408).
Barbour et al.(154a) reported the finding of a high serum l,25(OH)2D3 
concentration in an anephric patient with sarcoidosis. Since then it has been 
shown that the elevated serum concentrations of l,25(OH)2D3 seen in patients 
with sarcoidosis result from increased production of l,25(OH)2D3 by the 
macrophage (a prominent constituent of the sarcoid granuloma) (154d).
Although similar to renal la-hydroxylase, macrophage la-hydroxylase is 
immune to the stimulatory effects of PTH, is very sensitive to stimulation by 
interferon-gamma - a lymphokine produced by activated lymphocytes, is very 
sensitive to inhibition by glucocorticoid but is refractory to inhibition by 
l,25(OH)2D3 (154e). The renal enzyme, on the contrary, is relatively insensitive 
to inhibition by glucocorticoid but is down-regulated by l,25(OH)2D3.
From the above it might be expected that in patients with cancer-associated 
hypercalcaemia, serum concentrations of l,25(OH)2D3 would be low since serum 
calcium is elevated and PTH suppressed. While this may generally be the case, a 
significant proportion of patients with cancer-associated hypercalcaemia have 
either normal or elevated serum concentrations of l,25(OH)2D3. This appears to 
be the case both for lymphoreticular malignancies, (where l,25(OH)2D3 appears 
to be synthesised within the tumour) (108) and for squamous cancer (65). The 
significance of this latter finding remains unclear as it would appear that those 
patients who have cancer-associated hypercalcaemia and normal or elevated 
serum concentrations of l,25(OH)2D3, do not exhibit the expected increase in
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intestinal calcium absorption (154f). In this situation (where PTH is suppressed) 
it has been suggested that the increased serum concentrations of l,25(OH)2D3 
observed may be due to the stimulation of la-hydroxylase by a parathyroid 
hormone-like peptide - presumably parathyroid hormone-related protein (PTHrP) 
(85). However, it remains a possibility that the elevated concentrations of 
l,25(OH)2D3 found in these patients may derive from tissues other than kidney 
(65).
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1.3 Primary Hyperparathyroidism
1.3.1 Introduction
Primary hyperparathyroidism (PHPT) is a common condition associated with 
excess and inappropriate production of parathyroid hormone (PTH) and 
characterised by the presence of hypercalcaemia. One of the earliest and most 
famous descriptions of PHPT was that of Captain Charles Martell who developed 
progressive crippling disease (osteitis fibrosa cystica) associated with recurrent 
renal stones (155). In modem clinical practice approximately 250 new cases of 
primary hyperparathyroidism per million population are seen per year (46) and 
the prevalence of this condition, based on a study measuring serum calcium in 
26,000 consecutive samples, is about 1 in 1000 (156). As stated in 1.2.1 the main 
differential diagnosis is from cancer-associated hypercalcaemia where, certainly 
with the new assays for measuring the intact peptide, PTH is generally, though 
not always, undetectable (49).
PHPT may be due to the presence of a solitary parathyroid adenoma, hyperplasia 
of the parathyroid glands or, very rarely, a parathyroid carcinoma. In 85-90% of 
cases a parathyroid adenoma is the cause of this condition.
1.3.2 Clinical Features
Most clinical features such as thirst, polyuria, dyspepsia, lethargy and nausea are 
likely to be directly due to the effect of hypercalcaemia, as are complications 
such as renal stones and pancreatitis (157). The bone changes such as, in the 
most extreme cases, osteitis fibrosa cystica and increased bone resorption and 
osteoporosis (158) are more likely to be due to the direct action of PTH on the 
osteoblast (42). The hypercalcaemia of PHPT is remarkably constant with only
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very small changes taking place with time. This is in contrast with cancer- 
associated hypercalcaemia where serum calcium rises progressively (35).
There has been considerable interest in recent years in the control of PTH 
secretion. A considerable weight of evidence now exists to show that the 
abnormal (adenomatous or hyperplastic) parathyroid gland(s) is not completely 
autonomous. Gardin et al (159) showed by using infusions of ethylenediamine 
tetra-acetate (EDTA) that the set point of parathyroid cells for calcium is 
elevated in PHPT - which explains why the elevation of serum calcium which 
occurs in this condition does not lead to PTH suppression as would be expected. 
It is possible, therefore, to augment PTH secretion still further in PHPT by 
lowering the serum calcium, even though absolute hypercalcaemia still persists 
(159,160). Grant et al.(161), in a study using intravenous citrate to create relative 
hypocalcaemia, however showed that the rise in PTH is dependent not only on 
the absolute fall in serum calcium but also upon the rate of change of calcium. 
Similarly, causing a further elevation in serum calcium by using an oral calcium 
load test may lead to at least partial suppression of PTH secretion (162,163).
1.3.3 Management
Parathyroidectomy is generally highly successful, usually being curative, 
especially when carried out by an experienced surgeon (164). The indications for 
surgery, particularly in asymptomatic subjects, remain controversial. This area 
has been reviewed recently by the National Institutes of Health in the United 
States who have issued a "Consensus Statement" listing suggested indications for 
undertaking parathyroid surgery (165) which include:
1.Markedly elevated serum calcium or previous life-threatening hypercalcaemia.
2.Reduced creatinine clearance.
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3.The presence of a kidney stone or stones.
4.Markedly elevated 24 hour urinary calcium excretion.
5.Substantially reduced bone mass.
The risks of surgery in some instances, therefore, may outweigh the potential 
benefits. Furthermore the role of parathyroid surgery in the tertiary 
hyperparathyroidism which may follow successful renal transplantation is also 
controversial (166). For these reasons there has been continued interest in the 
non-surgical management of hyperparathyroidism.
Choice for medical therapy for primary hyperparathyroidism is limited (167). 
Treatments which have been used include oral phosphates (112), though some 
patients respond poorly to this regime and unacceptable diarrhoea is often a 
problem. Bisphosphonates have been used in the treatment of PHPT. Oral 
etidronate is of no real benefit, however intravenous clodronate has been used 
with some success, though the calcium lowering effect is often incomplete and 
short lived (168,169). Oestrogens or progestagens are useful in postmenopausal 
women (170,171) and may maintain serum calcium within the normal range for a 
number of years. Their mechanism of action is unknown, however they appear to 
act independently of changes in PTH secretion. Other agents which have been 
used include H2 blockers (172), the calcium channel blocker, diltiazem (173) 
and the betablocker, propranolol (174) - none of these agents, however, appear to 
be of any major, long-term, clinical value.
From the above it can be seen that at the present time, where active intervention 
is indicated, the treatment of choice is surgery. In an attempt to lessen operation 
time and improve the chances of finding an adenoma some form of parathyroid 
imaging is often carried out preoperatively (175) and evidence exists that the use
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of pre-operative imaging may both reduce operating time and result in an 
increased number of successful operations (176).
Many different methods have been used to this end with variable degrees of 
success. Clinical examination is unsatisfactory as the abnormal gland is usually 
small and soft in consistency. Overall, less than 1% of parathyroid adenomas are 
palpable (177). However, several different parathyroid imaging techniques have 
been developed - these include 201-thallium/99m-technetium (Tl/Tc) subtraction 
scanning (178,179), high resolution (10MHz) ultrasound (US) (180), computed 
tomography (CT) (181) and magnetic resonance imaging (MRI) (182). The most 
widely available of these techniques in the UK are ultrasound (US) and Tl/Tc 
scanning. Tl/Tc scanning was first described by two groups in 1983 (178,179). 
This technique involves the use of thallium-201 (201T1), a potassium analogue 
which is taken up by metabolically active tissue throughout the body. Thallium- 
201 appears to substitute for potassium in the ATP-ase dependent 
sodium/potassium pump (175). In a normal individual neck images obtained after 
201T1 show thyroid activity but separate parathyroid activity is not discernible. 
Even when a large parathyroid adenoma is present it is often difficult to 
determine whether any extra-thyroidal activity is present. As Technetium-99m is 
taken up by the thyroid via the iodide trap but does not accumulate in the 
parathyroids, subtraction of a 99mTc image from a 201T1 image should remove 
thyroidal activity rendering residual activity in the parathyroid visible. Reported 
accuracy of localisation of these techniques varies from 65% to over 90% 
(178,179,183).
Krubsack et al.(184) prospectively compared US, Tl/Tc, CT and MRI scanning. 
Specificities of all four of these techniques were generally high (87-95%), 
however sensitivities were lower, with Tl/Tc scanning best at 73% and US 
poorest at 55%. Direct comparison between US and Tl/Tc scanning shows both
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techniques are comparable with specificities very high and sensitivities in the 
range 74-80% (185,186).
Selective venous catheterisation with measurement of PTH levels throughout the 
neck has been shown to be useful in localising parathyroid adenomas (187,188), 
with an accuracy of around 80% (188). This technique, however, requires 
considerable skill, is time consuming and costly and is associated with a small, 
but definite, morbidity and therefore should probably be reserved for instances 
where there has been a previous unsuccessful neck exploration (188).
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1.4 Immobilisation-Related Hypercalcaem ia
1.4.1 Diagnosis and clinical features
Immobilisation-related hypercalcaemia was first described by Albright in 1941 
(189). Although it is not often appreciated as a clinical problem, hypercalciuria is 
commonly associated with immobilisation - leading to a negative calcium 
balance and osteoporosis (190). Generally immobilisation-related 
hypercalcaemia is associated with conditions where bone turnover is already 
high such as in children, adolescents (191) and in patients with Paget's disease of 
bone (192). This syndrome was initially thought to be exceedingly rare. More 
recently this view has been challenged as work by Maynard et al.(193) showed 
hypercalcaemia to affect 11% of tetraplegic patients under the age of 21. In 
addition, measurement of ionised calcium may also identify milder examples of 
this condition (194). Immobilisation-related hypercalcaemia is characterised by 
increased bone resorption, with radiological evidence of osteopenia (195), 
increased osteoclastic activity on bone biopsy (196) and elevated urinary 
hydroxyproline excretion (197). In addition when tetracycline uptake into 
mineralising bone is studied it is apparent that bone formation rates may also be 
reduced (44). Parathyroid hormone levels have been reported as high, normal or 
low in this condition (195) and parathyroidectomy is ineffective. Serum levels of 
l,25(OH)2D3 are generally low (195).
1.4.2 Management
Optimal therapy for immobilisation-related hypercalcaemia is not well defined, 
though physiotherapy and re-mobilisation are important components. Dietary 
calcium restriction is irrational where intestinal calcium absorption is low (due to 
low l,25(OH)2D3 levels) and a negative calcium balance exists (198). Calcitonin
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therapy may be effective but as with cancer-associated hypercalcaemia problems 
of "escape" may occur (124,197). Corticosteroids have also been shown to be of 
some value. However, their concomitant reduction of intestinal calcium 
absorption (199) and reduction in bone formation (200) make them far from ideal 
agents. Given that increased bone resorption is the principal abnormality that 
predisposes these patients to hypercalcaemia, the bisphosphonates are likely to 
be of value in the management of this condition. Preliminary evidence suggests 
this indeed is the case. A report by Haag et al (131) has demonstrated successful 
treatment with etidronate and Yates et al.(201) have similarly shown 2 patients 
responding successfully to clodronate. More recently a report by McIntyre et 
al.(202) has described a 16 year old male successfully rendered normocalcaemic 
with 30mg pamidronate. As is the case with cancer-associated hypercalcaemia it 
is likely these drugs will become the agents of choice in the treatment of this 
condition.
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1.5 P age t's  D isease of Bone
1.5.1 Introduction
Paget's disease is a focal disorder characterised by increased and disorganised 
formation and resorption of bone. This results in a dramatic increase in bone 
turnover (203). As a result of this increased metabolic activity, changes in bone 
shape may occur, which in turn has implications for the quality and competence 
of bone formed.
1.5.2 Epidemiology
The prevalence of Paget's disease is approximately 3-4% around the age of 40 
and rises exponentially with age to around 10% or higher after age 90 years 
(204). There have been no studies reported examining the incidence of the 
disorder, but its prevalence might suggest a rising incidence with age, with an 
average of 0.3% per annum in the population over 55 (205). Paget's disease 
appears to be more prevalent in men with a male to female sex ratio of 1.4 to 
1.9:1 (204,206).
Paget's disease would appear to be more common in Europe, North America and 
Australasia (207). A survey of 31 British towns showed the highest prevalence to 
be in Lancashire, with prevalences elsewhere in the UK being significantly lower 
(206). These features have lead to the search for a possible environmental 
"trigger".
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1.5.3 Aetiology
The aetiology of Paget's disease is unknown however a "slow virus" infection 
has been considered likely. This is on the basis that characteristic inclusion 
bodies resembling paramyxovirus nucleocapsids are almost invariably present in 
pagetic osteoclasts (208). The identity of this proposed virus remains uncertain, 
though positive immunohistochemical staining has been described for both 
measles virus (209) and respiratory syncytial virus (210) antigens in pagetic 
osteoclasts. Measles virus RNA sequences have also been reported to be present 
in these cells by in situ hybridisation (211). More recently canine distemper virus 
(CDV) has been suggested as the putative agent on the basis of the apparent 
association of Paget's disease with dog ownership (212) and positive in situ 
hybridisation for CDV in pagetic bone (213). More recently some doubt has been 
cast on this hypothesis as, Ralston et al.(214) using the highly sensitive technique 
of the polymerase chain reaction (PCR), failed to detect viral sequences for a 
number of paramyxoviruses including measles, canine distemper virus, 
parainfluenza virus 3 and respiratory syncytial virus in pagetic bone.
1.5.5 Clinical Features
The proportion of the pagetic population with symptoms is difficult to establish. 
A widely quoted figure is 5%, though figures of up to 30% are described 
(215,216). Pain is the most common presenting feature accounting for around 
50% of hospital referrals (217). The mechanism of the pagetic pain is not clear, 
however it has been suggested that it is due to increased vascularity or periosteal 
stretching. In addition, microfractures - which are a not uncommon 
accompaniment - are often painful and there is a high incidence of joint disease 
associated with Paget's (217).
54
Fractures, generally of long bones, are not uncommon. In up to 90% of cases 
these occur in the femur, tibia or forearm (218). They generally follow trivial 
injury, though in around half the patients with fracture no history of trauma is 
obtained. Non-union is a significant problem in the management of these 
fractures with Dove (219) describing an incidence of 40% in patients with 
femoral fractures.
Neurological complications are common. They generally arise from Paget's 
disease affecting the skull or spinal column, though bone enlargement may cause 
compression of peripheral nerves (220).
Rarely cardiac output may be increased in patients with Paget's disease 
associated with an increase in the capillary bed (221). This may in turn give rise 
to high output cardiac failure especially in those patients with more extensive 
disease (222).
Even more rarely, sarcomatous change may complicate Paget's disease. The true 
incidence of this is unknown, though likely to be less than 0.15% (223).
1.5.6 Management
A wide variety of agents have been used in the treatment of Paget's disease.
Major interest has focussed on the use of calcitonin and the bisphosphonates 
which are now generally regarded as the agents of choice. Many other drugs 
have been tried including fluoride, mithramycin, actinomycin D, glucocorticoids, 
colchicine and glucagon and generally these agents are either ineffective, toxic or 
both (224).
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Calcitonin is a 32 amino acid peptide secreted by the C cells of the thyroid (225). 
The major stimulus to its endogenous secretion is an increase in serum calcium
(226), however it is also affected by gastrin, B-adrenergic stimulation and alcohol
(227). The main physiological action of calcitonin is thought to be lowering of 
serum calcium (228) which is effected via inhibition of skeletal mobilisation of 
calcium by suppression of bone resorption (229). In addition to these features, 
calcitonin has been claimed to possess potent analgesic properties (230), which 
may have some relevance to its use in Paget's disease. The mechanism of this 
action is not clear, though it may be via an increase in endogenous opiate 
secretion (230).
Administration of a single dose of calcitonin to patients with Paget's disease 
causes a decline in urinary hydroxyproline excretion within 2 hours (231) 
followed by a later decline in serum alkaline phosphatase (232). With long-term 
calcitonin therapy (up to 27 months), these biochemical parameters may fall by 
up to 65% of their pre-treatment levels (233) though rarely return to normal 
(234). Rebound in these biochemical parameters towards their pre-treatment 
values is commonly seen on cessation of therapy (235). Often serum alkaline 
phosphatase levels cannot be lowered below a certain level in spite of increasing 
the dose of administered calcitonin (233) - a feature known as the "plateau 
phenomenon".
Side effects are common soon after administration of calcitonin. Most common 
are nausea, flushing, sweating and diarrhoea - these features appear to be dose 
related (236). Furthermore calcitonin has to be given by subcutaneous or 
intramuscular injection (though nasal preparations are currently being 
developed). These features are all major drawbacks in the use of calcitonin in 
treating Paget's disease.
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As discussed in 1.2.4 the bisphosphonates are potent inhibitors of osteoclastic 
bone resorption and are, therefore likely to be of value in the treatment of Paget's 
disease. As in cancer-associated hypercalcaemia, the bisphosphonates most 
commonly used in the treatment of Paget's disease are etidronate, clodronate and 
pamidronate - although third generation derivatives such as alendronate, 
tiludronate and risedronate are now on trial.
Etidronate was the drug first studied in the management of Paget's disease (133). 
There are several disadvantages in using etidronate in this setting. Firstly it has 
generally only been used in oral form, and as these drugs are highly water 
soluble their bioavailability is very low. Recker and Saville (237) have studied 
the bioavailability of 14C-labelled etidronate and found bioavailability ranged 
between 1% and 10% - even on an empty stomach. Secondly, of all the 
bisphosphonates, etidronate has been shown to have the greatest inhibitory effect 
on bone mineralisation (129) and even at recommended therapeutic doses has 
been associated with significant osteomalacic change (154). Furthermore, with 
respect to inhibition of bone resorption, etidronate is significantly less potent 
than the other bisphosphonates and therefore higher doses need to be used in an 
attempt to obtain an adequate therapeutic response (238,239).
In spite of these apparent disadvantages, etidronate has been used with some 
success in the treatment of Paget's disease (240,241,242,243). Etidronate is 
generally given at a dose of 5mg/kg/day for 6 months or 20mg/kg/day for 1 
month (244), with the latter dose being said to cause more effective suppression 
of biochemical markers of disease (245). While inhibition of bone resorption, as 
measured by suppression of urinary hydroxyproline excretion, occurs early after 
the administration of oral etidronate, suppression of urinary calcium excretion 
does not occur (246). This probably represents the mineralisation impairment 
associated with this therapy. Interestingly, this is not seen with intravenous
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etidronate where urinary calcium excretion rises in spite of apparent inhibition of 
bone resorption (247).
Clodronate, which is a "second generation" bisphosphonate, is a potent inhibitor 
of bone resorption which has a less marked effect on inhibition of mineralisation 
than etidronate (128). Clodronate is highly effective as both oral (248) and 
intravenous (249) preparations and as with all bisphosphonates the treatment 
effect lasts for several months or years after cessation of therapy (250,251). 
Clodronate is significantly more effective than calcitonin and if clodronate is 
added to the therapeutic calcitonin regime when the "plateau" phase is reached 
further disease suppression can be achieved (250).
Pamidronate is also a potent inhibitor of bone resorption which like clodronate is 
said not to inhibit mineralisation. Pamidronate is 100 times more potent than 
etidronate (239) and 10 times more potent than clodronate (252). Like 
clodronate, pamidronate has been shown to be effective in both oral (251,253) 
and intravenous forms (254,255). There is, as yet, no consensus regarding the 
treatment regime to be recommended: most workers have used short courses of 
daily or weekly treatment (251,256) with good effect. Thiebaud et al.(257) 
suggested that a single intravenous infusion of 60mg is sufficient to achieve 
disease suppression lasting for 1 year. This study however, generally followed 
patients with mild Paget's disease and the one patient who had extensive disease 
did not respond to this regime. Similarly Vega et al.(255) found a regime of 
25mg pamidronate per day for 7 days produced only a very transient response, 
with relapse occurring in 2-3 months. Most patients in this study, though, had 
very severe Paget's disease with pre-treatment alkaline phosphatase levels of up 
to 6-8 times the upper limit of normal. Harinck et al.(253) compared oral 
pamidronate, 600mg given daily until urinary hydroxyproline excretion returned 
to normal, with a 10 day course of intravenous pamidronate (20mg daily).
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Studies on duration of remission in these patients showed this to be around 2 
years in 50% and 4.5 years in 25%. In a further study (251) comparing two 
different groups, 1 treated solely with oral pamidronate and 1 with a combination 
of oral and intravenous pamidronate, the same authors concluded that 
intravenous therapy was more effective but that a 10 day course of 20mg per day 
was not enough to achieve remission in all patients.
Disease suppression after intravenous pamidronate is generally associated with 
decreased radioisotope uptake on bone scanning (258). Vallenga et al (258) 
reported that radionuclide uptake on bone scans drops by approximately 85% of 
pre-treatment value after 1 year with pamidronate therapy. Patel et al.(259) found 
that some lesions may show increased uptake and others decreased uptake in the 
same patient, even when biochemical evidence of disease suppression exists. 
Along with disease suppression, bone remodelling occurs which may be 
associated with dramatic radiographic improvement (260).
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1.6 Primary O steoporosis
1.6.1 Introduction
Osteoporosis is characterised by low bone mass, leading to an increased risk of 
fragility fractures (261). It can be thought of in terms of a disorder of 
remodelling (262) which involves not only thinning of trabecular and cortical 
bone but also, in many cases, destruction of the bone trabeculae themselves 
(262,263). Osteoporosis has been recognised to have become one of the major 
public health problems of the latter part of the twentieth century. It is thought to 
be responsible for at least 1.2 million fractures each year in the United States 
(264) where the direct and indirect costs were estimated at $6.1 billion annually 
in 1984 (265). In the United Kingdom in 1987/8 it was estimated that the direct 
costs of hip fracture alone was £160 million per year (266).
Involutional (or primary) osteoporosis generally begins in middle life and 
becomes progressively more frequent with advancing age. Riggs and Melton 
have suggested that this condition can be divided into two distinct syndromes, 
type I (postmenopausal) osteoporosis and type II (age-related/senile) 
osteoporosis (267,268).
Type I osteoporosis typically affects women within 15-20 years after the 
menopause. It is characterised by fractures at sites rich in trabecular bone such as 
vertebrae and Colles' fracture of the distal forearm. Type II osteoporosis affects 
both men and women usually over the age of 70 years, though is twice as 
common in women. It is characterised by fractures at sites which, in the young 
adult, contain substantial amounts of both cortical and trabecular bone. This is 
usually manifested by fractures of the hip and vertebrae.
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These fractures, however, are not specific to osteoporosis, and to make this 
diagnosis with certainty, therefore, requires demonstration of decreased bone 
density (269). Many different techniques are now available to do this (270), 
some of which are discussed in more detail below.
1.6.2 Diagnosis
If measurements of bone mass are to be clinically useful, they must be safe, 
precise, accurate and of reasonable cost. Generally four methods are in common 
usage:
1.Single-photon absorptiometry (SPA).
2.Dual-energy photon absorptiometry (DPA).
3.Dual-energy X-ray absorptiometry (DXA).
4.Quantitative computed tomography (QCT).
Single-energy absorptiometry employing radionuclides has been available for 
nearly 30 years and is commonly used to measure appendicular bone mass 
(usually radius and ulna) (271). Dual-energy methods were developed later to 
permit correction for soft tissue and are used in order to measure bone density at 
axial sites such as the spine and hip. Until recently radionuclides, usually 153- 
Gadolinium or 125-Iodine, were the source of photons, however low energy X- 
rays are now being used because the higher photon flux permits greater precision 
and shorter scan speeds despite lower exposure to radioactivity (272,273). By 
replacing the 153-Gadolinium source with a dual-energy X-ray source, the 
precision error of measurements in vivo can be halved, while at the same time 
scans are rapid (5 versus 20 minutes for regional areas) and have better spatial 
resolution (2mm versus 4mm) (274). The results of these various techniques are 
expressed in units of mass (gm mineral) or units of mass corrected for area
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(g/cm2). This is usually what is referred to as bone density however, as QCT 
allows measurement of volume of bone, results with this technique can be 
expressed as a true density (ie g/cm3) (275).
In order to be clinically useful these measurements must be able to predict the 
likelihood of fracture. While this is still debated a number of prospective studies 
have shown this to be true. Measurement of radial bone mass predicted the risk 
of fracture in 366 Swedish women followed for 15 years (276) and measurement 
of density at radius and spine predicted fractures at all sites in 1237 Japanese 
American women followed for more than 4 years (277). In general terms a 
decrease of 1 standard deviation in bone mass is associated with an increased risk 
of fracture of the order of 50-100% (278).
1.6.3 Postmenopausal osteoporosis - pathogenesis
Postmenopausal osteoporosis (type I) is often associated with Colies' fracture of 
the forearm and/or vertebral compression fractures. Women with this type of 
osteoporosis have rates of trabecular bone loss of up to three times normal, 
though cortical bone loss is only slightly increased (279,280). Riggs et al.(264) 
have suggested that this is due to the following sequence of events: oestrogen 
withdrawal at the menopause leads to increased bone loss with increased bone 
resorption. This is associated with a slight but significant rise in serum calcium 
which in turn leads to decreased secretion of PTH (281) and increased secretion 
of calcitonin (282). Renal 1-alpha hydroxylase is suppressed, which results in 
decreased l,25(OH)2D3 levels which in turn is associated with decreased calcium 
absorption (283). This leads to a negative calcium balance which further 
exacerbates bone loss (284). While this theory is attractive, serum levels of sex 
steroids are similar in postmenopausal women with and without type I 
osteoporosis (285). Other factors - perhaps peak bone mass in the individual -
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must be involved, therefore, to determine individual susceptibility to this 
condition.
1.6.4 Postmenopausal Osteoporosis - Management
Management of postmenopausal osteoporosis can be considered both in terms of 
prevention and treatment of established disease. Dietary calcium, if low, should 
be increased at least to the recommended minimum daily allowance of 800mg 
per day (264). The National Institutes of Health Consensus Conference on 
Osteoporosis in the United states recommended a calcium intake of lOOOmg to 
1500mg per day for all postmenopausal women (286), although the evidence to 
support these figures is uncertain. As it is logistically impossible to investigate 
and treat the entire population at risk of osteoporosis, it will be necessary to 
develop criteria to identify those at risk. At the present time it is not clear how 
this should be done, although it seems likely that an assessment of osteoporosis 
risk factors, such as early menopause, small body build, family history excess 
alcohol etc, should be made and on the basis of this densitometry carried out on 
those apparently at greatest risk (264).
Treatment of postmenopausal osteoporosis can be divided into treatment with 
antiresorptive agents such as calcium, oestrogen, calcitonin and bisphosphonates 
and agents which stimulate bone formation such as fluoride and parathyroid 
hormone.
The role of calcium in the treatment of osteoporosis remains controversial. 
Several studies have shown that calcium supplementation will reduce bone loss 
from both cortical and trabecular bone (287,288) and suppress indices of 
increased bone turnover (289). On the basis of this, therefore, it would seem 
reasonable to use calcium, at least as an adjunct to other therapies.
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Oestrogen therapy in postmenopausal osteoporosis is associated with a dose- 
dependent reduction in both bone loss (290) and fracture risk (291). To be 
effective in preventing fractures it probably has to be taken for at least 10 years 
after the menopause (292), which may cause problems with compliance which 
may be as low as 30% (293). Oestrogen therapy is usually combined with a 
progestogen to decrease the risk of endometrial carcinoma (294), though this is 
not necessary in those women who have had a hysterectomy. Regular menstrual 
bleeding is a major disincentive to compliance with hormone replacement 
therapy (295), though this may be improved by the use of continuous oestrogens 
and progestogens which generally are not associated with a withdrawal bleed 
(296).
As described previously calcitonin is a potent inhibitor of bone resorption (see
1.2.4 and 1.5.5) (229) and has been used with variable success in the 
management of cancer-associated hypercalcaemia and Paget's disease of bone 
(229,232,233). Parenteral calcitonin has been shown in a number of studies to 
increase bone mass (297,298), though data on long-term fracture rates is lacking. 
With the development of intranasal calcitonin long term therapy has become 
more convenient with recent studies suggesting salmon calcitonin may have a 
role in both prevention (299) and treatment of osteoporosis (300).
In recent years there has been considerable interest in the use of bisphosphonates 
in the prevention and treatment of postmenopausal osteoporosis. Initial work in 
this area was carried out in 1976 when Heaney and Saville (301) demonstrated 
that continuous treatment of osteoporosis with etidronate at a dose of 20mg/kg 
body weight resulted in a 50% reduction in bone resorption and a slight but 
significant increase in total body calcium. In 1984 Anderson et al.(302) reported 
results on a form of "coherence therapy" using etidronate and phosphate. The 
theory underlying "coherence therapy" is that sequential stimulation and
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suppression of osteoclastic activity will induce synchronisation of bone 
formation and resorption throughout the skeleton. In Anderson's study phosphate 
was used to activate osteoclastic bone resorption then etidronate was given 
depress osteoclastic activity. Treatment was then stopped for a period to allow 
unopposed osteoblastic (bone formative) activity. In this study a marked 
improvement in bone mass was noted on bone histomorphometry. In 1990 Storm 
et al.(303) published results of a three year placebo controlled study on the use of 
oral etidronate given at a dose of 400mg per day for 2 weeks followed by 
calcium supplementation for 11 weeks to 66 women. Bone density at the spine 
was measured by dual-photon absorptiometry and showed a mean increase of 
5.3% at three years. Importantly a significant reduction in fresh, radiologically 
apparent, vertebral fractures was noted from weeks 60 to 150 in this study. Later 
the same year Watts et al.(304) reported results of a larger 2 year double-blind 
placebo controlled study looking at a total of 429 women. This study included a 
group given phosphate in an attempt to activate osteoclastic activity prior to 
etidronate administration as described by Anderson et al.(302). This study used 
the more precise technique of dual-energy X-ray absorptiometry to measure bone 
density. After 2 years the etidronate treated patients showed an average increase 
in their spinal bone density of the order of 5%. Furthermore, this was not 
achieved at the expense of losing bone from the hip as neck of femur density was 
unchanged. As in the study of Storm et al.(303) the incidence of new vertebral 
fractures was reduced by half. Cyclical etidronate is therefore a highly promising 
treatment however many questions remain unanswered. Firstly the long term 
effect is not known, although early results suggest a plateau in bone density gain 
of around 7% is reached (305). Secondly it appears that those patients with the 
lowest bone densities respond best which raises some doubt about the 
preventative value of this treatment. Thirdly, and perhaps most importantly, 
questions have been raised about the quality of new bone formed. As bone
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turnover is reduced a progressively greater proportion of the skeleton will be 
comprised of older bone which may be more liable to fracture (306).
Most studies to date with bisphosphonates have concentrated on oral therapy. In 
view of the very low oral bioavailability of these drugs, intravenous 
administration is likely to be of some advantage. There is little information 
available on the use of intravenous bisphosphonates in the treatment of 
postmenopausal osteoporosis. A recent study from Italy (307) using 
aminohydroxybutylidene bisphosphonate (AHBuBP) by intermittent intravenous 
infusions showed an average increase in spinal density of 9% in 1 year. The 
authors suggested that this result was better than with oral etidronate at least in 
part because of the greater bioavailability achieved by using this route of 
administration.
The alternative to using inhibitors of bone resorption to treat osteoporosis is to 
stimulate bone formation. Perhaps the best known agent in this class of drugs is 
sodium fluoride.
Fluoride is thought to act by direct osteoblastic stimulation leading to increased 
bone formation rates (308). Results of the long-term effects of fluoride therapy 
are conflicting. Results from France (309) using 50mg per day sodium fluoride in 
enteric coated capsules has shown that the probability of sustaining a new 
fracture was significantly lower compared to a group on placebo. More worrying 
are results from Riggs et al.(310) where women were treated with an average of 
75mg per day of sodium fluoride for 4 years. In this study in spite of a 35% 
increase in bone density at the lumbar spine, the overall rate of vertebral 
fractures did not decrease suggesting that the new bone formed may be 
structurally unsound (311). Furthermore an increase (not statistically significant) 
in hip fractures was seen. This increased frequency of peripheral fractures has
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also been described by another group (312) and until this controversy is sorted 
out the clinical role of sodium fluoride will remain in doubt.
If the role of sodium fluoride is in some doubt, the value of parathyroid hormone 
as a treatment for osteoporosis is even less clear. In a multicentre study Reeve et 
al.(313) using a 1-34 amino acid fragment of PTH, treated 16 patients with daily 
subcutaneous injection for 6 months. There was an increase in new bone 
formation histologically, but there was no improvement in either calcium balance 
or cortical bone density. This might suggest that any increase in trabecular bone 
is at the expense of cortical bone.
1.6.5 Senile osteoporosis - pathogenesis and management
As described above senile osteoporosis (or type II osteoporosis) is more common 
in men and women over the age of 70 years. This condition is manifest not only 
by vertebral and Colies' fractures, but also by a marked increase in femoral neck 
fractures - whose incidence increases exponentially with increasing age.
In type II osteoporosis bone density values for the femoral neck and vertebrae are 
generally in the lower part of the normal range, adjusted for age and sex (314). 
This implies a proportionate loss of trabecular and cortical bone has occurred.
The two most important aetiological features in the pathogenesis of type II 
osteoporosis are decreased osteoblast function and impaired production of 
l,25(OH)2D3 (264,315). Impaired production of l,25(OH)2D3 is, in turn, 
associated with decreased calcium absorption and secondary 
hyperparathyroidism.
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Generally the pharmacological treatment of type II osteoporosis is similar to type 
I, though most clinical studies have failed to distinguish between these two types 
of osteoporosis to any significant degree.
Some differences do, however, exist with respect to managing the patient with 
type II osteoporosis. Oestrogen replacement therapy acts mainly by suppressing 
the normal postmenopausal increase in bone turnover. For maximum effect, 
therefore, it should be commenced as soon as possible after the menopause as it 
has been disputed whether oestrogens have any effect in elderly postmenopausal 
women (292). Clear evidence does exist, though, that oestrogens prevent bone 
loss in all stages of postmenopausal life, at least up to the age of 70 years 
(316,317).
Given that decreased l,25(OH)2D3 production is associated with type II 
osteoporosis (315) and this may result in intestinal calcium malabsorption (199), 
vitamin D supplementation, with active metabolites of vitamin D, may be 
indicated. Grimo et al.(318) found that administration of lug 1-alpha vitamin D3 
to elderly patients with senile osteoporosis resulted in a significant reduction in 
vertebral crush fractures over a 2 year period. This study was in a relatively small 
number of patients and further studies in this area are awaited with interest.
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1.7 Secondary osteoporosis
Secondary osteoporosis is usually considered to include endocrine causes of 
generalised osteoporosis such as hyperthyroidism (319), hypogonadism (320) 
and Cushing's syndrome (321). There has also been a suggested association with 
diabetes mellitus (322), and osteoporosis has rarely been described during or just 
after pregnancy (323). The most common cause of secondary osteoporosis is 
probably that associated with use of therapeutic doses of corticosteroids.
1.7.1 Corticosteroid-associated osteoporosis - pathogenesis
Soon after the introduction of corticosteroid drugs, it became apparent that 
patients on prolonged therapy developed vertebral fractures (324). The true 
incidence of osteoporosis in patients receiving corticosteroids is unknown. 
Available data suggests a 30-50% incidence of atraumatic fractures (325,326).
Corticosteroid-associated osteoporosis is a result of a number of factors that 
adversely affect calcium homoeostasis. Gonadal dysfunction is a common long 
term consequence of corticosteroid therapy. This is due to a combination of 
inhibition of pituitary gonadotrophin secretion (327) and a direct suppressive 
effect on the ovary or testis (328).
It is generally accepted that corticosteroids decrease intestinal calcium 
absorption in man (199). This appears to be due to a combination of a direct 
action on the intestinal mucosa decreasing active calcium transport (329) and 
decreased vitamin D activity (330).
Hypercalciuria with a resultant negative calcium balance is a common 
association with prolonged corticosteroid usage (331) and this probably plays an
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important role in the development of secondary hyperparathyroidism which is 
also commonly present (332).
The most important actions of corticosteroids, however, in the pathogenesis of 
osteoporosis is their direct effect on bone. Histomorphometric studies have 
suggested that bone resorption is increased (332). This increased bone resorption 
may be, at least in part, due to the presence of secondary hyperparathyroidism 
and also to a direct effect in stimulating osteoclastic bone resorption (333). As 
well as increasing bone resorption corticosteroids also decrease bone formation. 
Histomorphometric studies show a marked decrease in the number of osteoid 
seams present (334) and, furthermore, the total amount of bone replaced each 
remodelling cycle has been shown to be reduced (335). Osteoblast-like cells have 
corticosteroid receptors and corticosteroids appear to have a direct inhibitory 
effect on osteoblast replication and differentiation (336).
1.7.2 Corticosteroid-associated osteoporosis - diagnosis
Not all patients on long term corticosteroid therapy develop osteoporosis, with 
premenopausal women in particular, apparently relatively protected (337). For 
this reason, it is important to identify persons at risk for closer follow up or 
treatment. Exactly how this should be done is not clear. Densitometry is likely to 
be helpful, though a recent study using dual-photon densitometry suggested that 
this technique was not sufficient to identify at risk patients as fractures appeared 
to occur at higher bone densities than is generally the case in involutional 
osteoporosis (338). This study is yet to be confirmed with dual-energy X-ray 
densitometry (DXA).
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1.7.3 Corticosteroid-associated osteoporosis - management
In contrast to postmenopausal osteoporosis there is dearth of information of the 
prevention and treatment of corticosteroid-associated osteoporosis (339).
The most obvious way of attempting to lessen the effects of corticosteroids on 
bone is to try and reduce the dose of corticosteroid used. One way of doing this 
appears to be by using an alternate day dosing regime. This has been shown to 
result in less marked inhibition of intestinal calcium absorption and, at least in 
animals, reduces the incidence of osteoporosis (340). However, Gluck et al.(341) 
measured forearm bone density in a cohort of patients receiving either alternate 
day or daily corticosteroids and found no difference in the rate of bone loss. 
There is, therefore, little support for using alternate day dosing regimes to limit 
osteoporosis.
Since intestinal calcium malabsorption is thought to be one of the major factors 
involved in the pathogenesis of this condition (199), vitamin D and its active 
metabolites may be expected to be of some benefit. Hahn et al.(342) in 1979 
showed that administration of vitamin D was associated with an increase of 46% 
in intestinal radiocalcium absorption and a decrease of 54% in PTH. This was 
associated with a reduction in the number of osteoclasts seen on bone histology. 
Two other studies have reported benefit in using 1-alpha hydroxyvitamin D on 
the bone mass of steroid-dependent patients (343,344), however these were both 
short term studies and the long term use of vitamin D and its metabolites in 
corticosteroid-associated osteoporosis remains uncertain.
Fluoride is a potent stimulator of bone formation (see 1.6.4). Since bone 
formation rates are low in corticosteroid-associated osteoporosis, fluoride might 
be expected to be effective. Little data on this is available. Rickers et al.(345)
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randomly allocated patients commencing steroid therapy to fluoride and calcium, 
vitamin D, or placebo. Bone mineral content at the forearm declined 2.5% in all 
groups in the first 6 months and the authors concluded that fluoride was without 
benefit at least in the prevention of corticosteroid-associated osteoporosis.
Similarly, despite considerable interest in the use of calcitonin for the treatment 
of postmenopausal osteoporosis, little attention has'beenpaid to its role in 
corticosteroid-associated osteoporosis. The only major study published to date is 
that of Ringe et al.(346) who demonstrated a beneficial effect with calcitonin in a 
six month prospective study.
The increased bone resorption normally seen with this condition implies that the 
bisphosphonates may also be effective. As is the case with the other agents 
described above, little information is available here. Reid at al.(347) in 1988, 
treated 16 patients on oral corticosteroids with oral pamidronate for one year. 
These 16 patients had a mean increase in spinal bone density of 19% (as 
measured by quantitative computed tomography) whereas bone density in 
controls was unchanged. Five of these pamidronate treated patients were 
followed for a further year and the initial gain in bone mass appeared to have 
been maintained (348). While this agent would appear to be promising further 
studies are awaited.
1.7.4 Diabetes mellitus associated osteoporosis
An association between diabetes mellitus and osteoporosis was first described by 
Albright and Reifenstein in 1948 (349). In the description of diabetic bone 
disease, a distinction must be drawn between insulin dependent diabetes mellitus 
(IDDM) and non-insulin-dependent diabetes mellitus (NIDDM).
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In IDDM, a decreased bone mass has been frequently observed when measured 
by X-ray (350), single photon absorptiometry (351,352) and dual photon 
absorptiometry (353). The situation in NIDDM is less clear with both decreased 
(350) and increased bone mass (354) being described. As NIDDM is often 
associated with obesity, and obesity is associated with a reduced incidence of 
osteoporosis (355), an appropriate control group is necessary. Whether or not 
osteopenia is correlated with diabetic control is not clear as this information is 
lacking from many studies. In IDDMs, where osteopenia is present, diabetic 
control has generally been poor with glycated haemoglobin concentrations of 
greater than 10% (356,357). Similarly the extent of bone loss has been shown to 
be correlated with both the extent of glycosuria and fasting blood glucose 
concentration (321,358).
In addition to a suggested low bone mass, diabetic patients appear to have an 
increased risk of sustaining a fracture (359,360). When the various studies which 
have investigated this are pooled, the estimated increased risk of fracture in 
diabetes is approximately twofold (361). Against this a case-controlled study 
from the Mayo clinic failed to show any excess of fracture in diabetic patients 
(362). This study, though, has been criticised as, being retrospective some 
fractures may have been missed. Furthermore, it is likely that a number of 
undiagnosed diabetics were present in the control group; if this is the case the 
validity of the results from this study are open to question. It is possible, 
however, that fracture rates are increased in diabetics, not because of alterations 
to bone mass, but because of an increased incidence of falls, for example 
secondary to the presence of neuropathy. Indeed, Nabarro attributed the 
incidence of vertebral fractures in diabetics to hypoglycaemic seizures (363).
The mechanism of bone loss associated with diabetes has been investigated by 
histological and biochemical studies. It would appear that diabetes is associated
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with a low bone turnover state with decreased bone formation and resorption 
(361). This would be compatible with the view that insulin is required for normal 
bone formation (364). One histomorphometric study has suggested that the initial 
problem in diabetic bone disease is increased bone resorption with the low 
turnover state a late finding (365). Further biochemical evidence has suggested 
this to be true with hypercalciuria frequently found (321,366), implying 
increased bone resorption (see 1.1.3). Hypercalciuria, however, in the setting of 
diabetes mellitus, may not be simply due to increased bone resorption. The 
osmotic diuresis associated with glycosuria may be associated with calciuresis 
(366) and changes in plasma glucose and insulin have been shown to alter renal 
tubular calcium handling (367,368). Studies are, therefore required looking at 
more specific markers of bone resorption such as hydroxyproline or collagen 
cross-link excretion.
The presence of secondary hyperparathyroidism has been suggested as a cause of 
the hypercalciuria of diabetes (366) and this certainly could contribute to 
increased bone resorption. The literature is once again conflicting on this issue 
with there also being studies suggesting the presence of relative 
hypoparathyroidism (369) and normal parathyroid function (370).
As can be seen from the above considerable uncertainty exists over the extent 
and pathogenesis of osteopenia in diabetic patients with further studies using 
today's more sensitive technologies required.
CHAPTER 2 
TECHNICAL METHODS
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2.1 Biochemical Technical M ethods
2.1.1 Routine analyses
Seram calcium, phosphate, creatinine, electrolytes, gamma glutamyl transferase 
CyGT) and alkaline phosphatase and urinary calcium, phosphate, sodium and 
creatinine were measured by standard autoanalyser techniques (Technicon, 
Tarrytown, USA). Seram total calcium was adjusted for albumin using the 
algorithm: calcium (adjusted) = total measured calcium ± [47 - measured 
albumin (g/1) x 0.019]. This method has been previously shown to correlate 
closely with ionised calcium (152).
Reference ranges for our laboratory were:-
seram adjusted calcium: 2.20-2.60mmol/l 
serum phosphate: 0.70-1.40mmolA 
serum creatinine: 40-130umol/l 
gamma glutamyl transferase: <36UA 
alkaline phosphatase: 80-280U/1 
urine calcium/creatinine: <0.50mmol/mmol
2.1.2 Parathyroid hormone (PTH)
Seram intact PTH(l-84) was measured in a two-site immunoradiometric assay, 
using two monoclonal antibodies. PTH(l-34) is labelled with the rat/mouse 
monoclonal antibody 3B3 which is radiolabelled. The C-terminus 74-84 amino 
acids are labelled with the mouse monoclonal ESQ-1 (on solid phase). The assay 
has a minimum detection limit of 0.5pmol/l and a range of 1.5-250pmol/l with an 
intra-assay co-efficient of variation (cv) of less than 10%. Studies on clinical 
samples indicate excellent discrimination with this assay between normal
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subjects (mean 2.21; range 1.0-5.0pmol/l) and patients with primary 
hyperparathyroidism (mean 21.0; range 5.8-100pmol/l) who in turn are well 
separated from patients with cancer-associated hypercalcaemia (14/18 
<0.5pmol/l) (371). In one study (3.1) PTH in the first seven hypercalcaemic 
patients was measured in a N-terminal specific radioimmunoassay (372). This 
assay used highly purified bovine PTH as standard and for radioiodination and a 
guinea pig anti-bovine PTH serum which would recognise both ends of the intact 
PTH molecule. The mean intra-assay cv for this assay was 7% and the normal 
range was from the limit of detection (150ng/l) to 600ng/L
2.1.3 Parathyroid hormone-related protein (PTHrP)
Serum PTHrP concentration was measured in a two-site immunoradiometric 
assay (Nichols Institute, California, USA). In this assay affinity-purified anti- 
PTHrP(37-74) bound to a solid phase is used as the capture antibody and 
radiolabelled anti PTHrP(l-36) used as the signal antibody. The sensitivity of 
this assay is 0.7 pmol/1. Human PTH(l-34), PTH(l-84), PTHrP(l-34) and 
PTHrP(36-76) have less than 0.1% cross-reactivity. All samples were collected 
into specific collection tubes, containing proteinase inhibitors, on ice and were 
centrifuged immediately. This assay has a cv <10% in the PTHrP concentration 
range 2-50pmol/l. A normal reference range has been established of <0.7- 
2.6pmol/l (373)
2.1.4 Vitamin D metabolites
25-hydroxycholecalciferol (25(OH)D3) and 1,25 dihydroxycholecalciferol 
(l,25(OH)2D3) were measured using a modification of the method used by 
Reinhardt et al.(374). The vitamin D metabolites were extracted from serum and 
separated from other vitamin D metabolites by reverse phase high performance
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liquid chromatography (HPLC). The purified 25(OH)D3 and l,25(OH)2D3 were 
then quantitated using competitive protein binding assays with charcoal 
separation. The mean between assay cv for 25(OH)D3 was 10% and normal 
range 15-100nmol/l. The sensitivity of the assay was typically 5nmol/l. For 
l,25(OH)2D3, between assay cv was 20% and sensitivity typically 15pmol/l. The 
normal range for our laboratory was 20-120pmol/l.
2.1.5 Osteocalcin
Serum osteocalcin was measured in a commercially available radioimmunoassay 
(Incstar, Minnesota, USA). This utilises anti-bovine osteocalcin antibody and 
1251 bovine osteocalcin. Within and between assay cv's were 10% and 15% 
respectively. The normal range was 1.8-6.6ng/ml. Typical sensitivity of this 
assay was 0.6ng/ml.
2.1.6 Ionised calcium
Serum ionised calcium was measured in a Radiometer ICA 1 and results were 
adjusted to pH 7.40 in order to minimise the effect of carbon dioxide loss from 
the sample (375). Samples were collected anaerobically into vacutainers without 
preservative and analysed within 1 hour. Normal range for our laboratory is 1.10- 
1.28mmol/l with a between assay cv of <2% and within assay cv of <1%.
2.1.7 Testosterone, sex hormone binding globulin and gonadotrophins
Testosterone was measured by radioimmunoassay using double antibody 
separation. This assay has an interassay cv of <10% and intra-assay cv of <8%. 
SHBG was measured using a "Delfia SHBG" kit (Pharmacia Wallac, Milton 
Keynes, UK). This assay is a solid phase two-site fluroimmunometric assay in
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which polyclonal anti-SHBG antibodies (derived from rabbit) and monoclonal 
antibodies (derived from mice) directed against the SHBG molecule are used. 
Typical intra-assay cv is 8% and typical interassay cv is 6%. A measure of free 
androgen index (FAI) was derived using the formula - testosterone/SHBG xlOO. 
Leutinising hormone (LH) was measured using a commercially available 
microparticle enzyme immunoassay (Abbot Laboratories, Illinois, USA). This 
assay has a typical sensitivity of 0.5mUA, interassay cv of 5.5% and intra-assay 
cv of 6.7%. Follicle stimulating hormone (FSH) was also measured using a 
microparticle enzyme immunoassay (Abbot Laboratories, Illinois, USA). This 
assay has a typical sensitivity of 0.2mUA, interassay cv of 7.0% and intra-assay 
cv of 3.8%.
2.1.8 Cyclic adenosine 3' 51 monophosphate (cAMP")
Plasma cyclic adenosine monophosphate (PcAMP) was measured by a 
commercially available radioimmunoassay (Amersham, Aylesbury, UK). Urine 
cyclic adenosine monophosphate was measured, after appropriate dilution, by an 
"in-house" radioimmunoassay as described by O’Reilly et al.(376). The between 
assay cv was less than 10% and the limit of detection 2.6nmol/l. Urinary cyclic 
AMP excretion (UcAMP) was expressed as a function of glomerular filtrate 
(UcAMP = urine cAMP divided by urine creatinine multiplied by serum 
creatinine) and the normal range was 22-66nmol/l GF.
The nephrogenous component (NcAMP) of UcAMP was calculated as UcAMP 
minus PcAMP (normal range 5-27nmol/l GF) (76).
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2.1.9 Hvdroxvproline
Hydroxyproline (HP), an index of total bone resorptive activity (377), was 
measured in true fasting (second voided) morning urine specimens using a 
colourimetric technique similar to that described by Goverde et al.(378), 
followed by autoanalyser quantitation. Urinary HP was expressed as a molar 
ratio relative to urinary creatinine (Cr) excretion (mmol/mmol). The mean 
between assay cv was 8% and typical sensitivity 0.005mmol/l. The reference 
range for HP/Cr in our laboratory was 0.005-0.033 mmol/mmol.
2.1.10 Renal tubular reabsorption of phosphate
The notional threshold for renal tubular phosphate reabsorption (TmP04) was 
derived from a nomogram (379) after measurement of urinary phosphate and 
creatinine and serum phosphate and creatinine. The normal range lay between 
0.70-1.35 mmol/1 GF.
2.1.11 Urinary calcium excretion
Urinary excretion of calcium was expressed as a molar ratio relative to urinary 
creatinine (Ca/Cr, mmol/mmol), with the normal range being up to 0.50. A value 
for calcium excretion (CaE) was also obtained by the equation (urine 
calcium/urine creatinine) x serum creatinine. Results were expressed as umol/l 
GF and the reference range for normocalcaemic subjects 7.5-37.5umol/l GF.
Renal tubular reabsorption of calcium was assessed by comparing CaE and the 
simultaneous serum calcium measurement with a normal range obtained by 
calcium infusion studies in healthy subjects (36) (figure 1.1). A value for the 
renal tubular threshold for calcium absorption (TmCa) was obtained from a
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computer program produced by Rorer Pharmaceuticals Ltd and based on a 
nomogram (380) (normal range 1.98-2.61 mmol/1 GF).
2.1.12 Urinary sodium excretion
Urinary sodium excretion (NaE) was derived by the following equation: (urinary 
sodium/urinary creatinine) x serum creatinine. Results were expressed in mmol/l 
GF and the reference range in healthy normocalcaemic subjects 0.10-1.30mmol/l 
GF.
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2.2 Radionuclide Bone Scans
Radionuclide bone scans were performed using standard techniques, three hours 
after the intravenous injection of 600 Megabequerels (MBq) of 99m-labelled 
methylene bisphosphonate.
2.3 Whole Body Retention of Radiolabelled Bisphosphonate
Whole body retention of radiolabelled bisphosphonate (WBR) was carried out as 
a further measure of bone turnover in patients with Paget's disease. A single 
intravenous injection of 2 MBq 99m-methylene bisphosphonate was given then 
24 hours later the patient passed through a whole body counter. The normal 
range was 19-37%. Typical precision of this technique was <1%.
2.4 Dual-Energv X-Rav Absorptiometry (DXA)
Measurement of bone density was carried out at the lumbar spine (L2-4) and the 
neck of femur by the technique of dual-energy X-ray absorptiometry (DXA) on a 
Lunar DPX. All scans were carried out on the same machine by the same 
operator, using the same analysis software and results expressed as areal 
densities (g/cm2). Precision at L2-4 for 17 normal subjects scanned 6 times was 
0.5% and at neck of femur was 1.05%.
2.5 Parathyroid Thallium/Technetium Subtraction Scans
A standard 201-Thallium(Tl)/99m-Technetium(Tc) parathyroid subtraction scan 
was carried out as described by Fogelman et al.(381). Images were acquired in 1 
minute segments for 20 minutes after the intravenous administration of 80 MBq 
201T1 then for 10 minutes after the administration of 180MBq 99mTc. Images
were stored in a computer interfaced to the gamma camera and a "subtraction" 
scan then obtained.
EXPERIMENTAL WORK
CHAPTER 3
CLINICAL APPLICATION OF CURRENTLY AVAILABLE 
BIOCHEMICAL TECHNIQUES
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3.1 An a sse ssm e n t of the pathogenesis of b reast cancer-associa ted  
hypercalcaem ia
3.1.1 Introduction
Biochemical measurements can provide significant insight into the pathogenesis 
of many disorders of bone and calcium metabolism. This is particularly well 
illustrated by cancer-associated hypercalcaemia where, as a result of careful 
biochemical evaluation, it was well recognised that a substance with PTH-like 
activity was present in the circulation (68-73,77-81). This fact was appreciated 
for many years before the discovery of parathyroid hormone-related protein 
(PTHrP). It is now accepted that such humoral hypercalcaemia is more common 
with solid tumours (91,92) whereas hypercalcaemia due to local osteolysis by 
bone metastases is more common in haematological malignancy such as 
myeloma (91,92). The position with breast cancer-associated hypercalcaemia is 
somewhat less clear. Traditionally, it has been thought that breast cancer- 
associated hypercalcaemia occurred predominantly as the result of increased 
osteoclastic bone resorption due to extensive bone metastases (58,63). Recent 
evidence, however, has suggested that humoral factors may also play a 
significant role in the pathogenesis of this condition (382,383).
In this study, by using a combination of biochemical markers and radionuclide 
bone scans, an assessment was made of the relative contribution of humoral and 
local osteolytic mechanisms to the pathogenesis of hypercalcaemia in 20 patients 
with breast cancer.
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3.1.2 Patients and methods
The study group consisted of 20 consecutive patients who presented with 
hypercalcaemia associated with breast cancer. Nine normocalcaemic patients 
with breast cancer and bone metastases, who also presented consecutively, 
served as disease controls. Hypercalcaemia, in this study, was defined as a serum 
total calcium adjusted for albumin of greater than 2.80mmol/l. All 
hypercalcaemic patients had been sodium repleted for 48 hours prior to study 
with a minimum of 6 litres 0.9% sodium chloride solution. At the time of study 
two hypercalcaemic patients were receiving tamoxifen and two megestrol, 
though both these treatments had been commenced at least 6 months previously. 
None of the patients included in this study received corticosteroids or any other 
cytotoxic chemotherapy around the time of these investigations.
Bone metastases were assessed by review of standard radionuclide bone scan 
films. Patients with less than six "hot spots" were considered as having a light 
tumour load and those with six or more "hot spots", a heavy tumour load - as 
previously described (384).
Tissue diagnoses were taken from histopathological reports of breast biopsies.
Statistical methods used were the Mann-Whitney U-test and Spearman rank 
correlations where appropriate.
3.1.3 Results
Hypercalcaemic patients were divided into two groups by the levels of urinary 
cyclic adenosine monophosphate (UcAMP); those where values fell within the 
reference range of 22-66nmol/l GF and those where UcAMP was greater than
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66nmol/l GF (figure 3.1). UcAMP levels were within the reference range in all 9 
normocalcaemic patients. While results of nephrogenous cAMP (NcAMP) were 
available in only 9 hypercalcaemic patients, there was a close correlation 
between NcAMP and UcAMP (r=0.90, p=0.01) and, for the purposes of this 
study UcAMP was considered to be a reasonably accurate reflection of NcAMP.
Calcium excretion (CaE) when expressed against the prevailing serum calcium 
(figure 3.2), was deviated to the right of the line defining their normal 
relationship in 9 cases in the hypercalcaemic group - indicating that renal tubular 
reabsorption of calcium (TmCa) was raised. Interestingly, these patients were not 
necessarily the same as those who exhibited elevated UcAMP levels. This 
relationship between CaE and serum calcium was generally normal in the 
normocalcaemic group, though in one instance TmCa may have been marginally 
increased.
In the hypercalcaemic group, UcAMP excretion tended to be higher in patients 
with a light tumour load, though some patients with a heavy tumour load also 
exhibited raised UcAMP levels. UcAMP values were (median, range) 70nmol/l 
GF (33-131) in patients with a light tumour load and 38nmol/l GF (22-112) in 
those with a heavy tumour load (p=0.07) (figure 3.3). Tumour load was 
considered to be light in 7/9 patients in the normocalcaemic group; however, 
UcAMP excretion was within the normal range in all patients in this group.
Other results are shown in table 3.1. Serum calcium, creatinine and urinary 
calcium/creatinine ratio were similar in both the "normal" UcAMP and "high" 
UcAMP hypercalcaemic groups. Urinary calcium/creatinine ratio (Ca/Cr) was 
significantly lower in the normocalcaemic group, though it was still above the 
upper limit of the reference range of 0.50 implying increased bone resorption in 
these patients. Similarly, CaE was significantly lower in the normocalcaemic
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group. Sodium excretion (NaE) was significantly higher in the hypercalcaemic 
"normal" UcAMP group. The reason for this is not clear, though the data is 
skewed by one patient where NaE was very high (10.4mmol/l GF). Values for 
the renal tubular threshold for phosphate reabsorption (TmP04) were decreased 
in 12 of the hypercalcaemic patients and both TmP04 and serum phosphate were 
significantly lower in patients with raised UcAMP. There was a significant 
negative correlation between individual TmP04 values and UcAMP levels (r= - 
0.54, p=0.02), but no significant correlation was found between UcAMP and 
serum calcium, serum creatinine, urinary Ca/Cr, CaE or NaE. In the 
normocalcaemic group 8/9 TmP04 values were normal. In one patient it was low 
at 0.58mmol/l GF, though UcAMP excretion in this patient was normal at 
55.5nmol/l GF.
Parathyroid hormone (PTH) levels in the hypercalcaemic patients were 
undetectable in 15 cases and just detectable at the lower limit of the reference 
range in 3. PTH was not measured in the remaining 2 cases in this group. In the 
normocalcaemic patients, PTH was within the reference range in 8/9 instances.
In the abnormal case it was just above the upper limit of the reference range.
PTH was undetectable in 1 patient in this group whose serum calcium was 
2.60mmol/L
The majority of tumours were invasive ductal carcinomas. There was no obvious 
association between the tissue type and level of UcAMP.
3.1.4 Discussion
In clinical practice, PTHrP mediated hypercalcaemia may be suspected by the 
finding of biochemical abnormalities suggestive of primary hyperparathyroidism 
in the absence of detectable PTH levels (58,59,60,73,77,78). While breast cancer
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has traditionally been considered to be due to local osteolysis as the result of 
increased bone resorption from skeletal metastases (63), PTH-like biochemical 
abnormalities have also been observed in this situation and, furthermore, PTHrP 
has been extracted from the tumour of a patient with humoral hypercalcaemia 
associated with breast cancer (385). Hypophosphataemia and depressed renal 
tubular phosphate reabsorption have long been recognised to occur in 
hypercalcaemic breast cancer patients (386,387), but previous workers have 
attributed these findings to the effect of hypercalcaemia on the renal tubule per 
se (386). More recently, elevated levels of NcAMP have been found in between 
35%-39% of patients with breast cancer and hypercalcaemia (79,382), as have 
increased levels of renal tubular reabsorption of calcium (383) - all features 
which would be consistent with the renal tubular effects of PTHrP (84,98).
NcAMP data was not available in all of the hypercalcaemic patients in this study, 
but in the presence of normal renal function UcAMP is thought to be a reliable 
indicator of NcAMP (388). This is borne out in this work by the close correlation 
found between UcAMP and NcAMP in those patients where full data were 
available.
In this study elevated UcAMP values were found in 45% of cases where 
hypercalcaemia was present, a slightly higher proportion than that which was 
noted by Isales et al.(382) and Rude et al.(79). It was not possible in this present 
study to define "high cAMP" and "low cAMP" groups of hypercalcaemic 
patients as originally described by Stewart et al.(77) because the UcAMP values 
followed a continuous distribution, with even the lowest values being clearly 
detectable within the normal range. Since the majority of hypercalcaemic 
patients had undetectable PTH levels, the abnormalities of renal tubular calcium 
and phosphate handling and UcAMP excretion may be explained by the action of
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PTHrP. If this is the case, a higher percentage of patients with breast cancers 
may be expressing PTHrP than has generally been accepted.
The interpretation of the "normal" UcAMP values in the hypercalcaemic cancer 
patients is more difficult. However, continued UcAMP excretion in the presence 
of low PTH values may also have been due to the action of PTHrP. While levels 
of UcAMP excretion were also within the normal range in the normocalcaemic 
patients, this could have been explained by the effects of endogenous PTH. 
However, in one normocalcaemic patient PTH was undetectable and UcAMP at 
the upper limit of the reference range at 64.6nmol/l GF. It is possible, therefore, 
that this patient may also be expressing PTHrP and, one may speculate, might 
become hypercalcaemic in the future.
While TmP04 and serum phosphate values were significantly lower in the 
hypercalcaemic patients with high UcAMP excretion, elevations in renal tubular 
calcium reabsorption were not confined to patients with elevated UcAMP levels. 
Thus, while 5/9 (56%) patients with high UcAMP had elevated renal tubular 
calcium absorption, 4/11 (36%) with normal UcAMP exhibited similar increases 
in renal tubular reabsorption of calcium. Furthermore, although most 
hypercalcaemic patients with a light tumour load had elevated UcAMP levels, 
raised UcAMP was also seen in patients with a heavy tumour load.
These data, in keeping with previous observations (389), indicate that some 
manifestations of PTH-like activity may be seen in the absence of others in 
patients with cancer-associated hypercalcaemia. Although the reasons for this are 
unclear, it has been suggested that some tumours associated with humoral 
hypercalcaemia release other factors which may interfere with PTHrP binding to 
the PTH receptor (101). An alternative possibility, and one which may be 
relevant to the renal calcium handling data, would be the presence of variations
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in sodium excretion, which have been shown to interfere with the clinical 
assessment of renal tubular calcium reabsorption (24,82).
Acute extracellular fluid expansion with 0.9% saline at a rate of llitre/hour can 
increase UcAMP excretion in normal subjects by causing a dilutional fall in 
serum calcium and subsequent rise in PTH. However, when hypoparathyroid or 
hypercalcaemic subjects are studied no rise in UcAMP is observed (390) 
suggesting that natriuresis does not control UcAMP production. Since a rise in 
serum PTH at the time these patients were studied was not observed, it is 
unlikely that the fluid replacement regime used is the cause of the increased 
UcAMP seen in these hypercalcaemic patients.
These results indicate that biochemical markers of a PTHrP-mediated 
mechanism of hypercalcaemia may be observed in 45%-60% of patients with 
breast cancer depending upon whether TmP04, UcAMP or renal tubular calcium 
reabsorption is assessed. Whether such a mechanism of hypercalcaemia is also 
operative in patients with normal but "inappropriately detectable" UcAMP levels 
will probably be defined in the future by the availability of immunoassays for the 
direct measurement of PTHrP.
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3.2 C hanges in serum  parathyroid horm one-related protein (PTHrP) 
concentra tions in normal pregnancy
3.2.1 Introduction
The previous study illustrated the value of measuring indirect biochemical 
markers for parathyroid hormone-related protein (PTHrP). However, in the 
setting of humoral hypercalcaemia of malignancy, PTHrP plasma concentrations 
are likely to be significantly elevated (91,92) which in turn leads to elevation of 
nephrogenous cyclic adenosine monophosphate (NcAMP) (77,78,79) and 
depression of the renal tubular threshold for phosphate reabsorption (TmP04) 
(80,81). In physiological situations (where PTHrP concentrations are not 
elevated) it is likely that direct measurement of PTHrP is required rather than the 
use of these indirect markers of PTH-like activity.
Following the discovery of PTHrP as the likely principal mediator of humoral 
hypercalcaemia of malignancy (83,84,85), subsequent studies suggested the 
possibility of a physiological endocrine or paracrine role for this peptide. PTHrP 
itself and its messenger RNA (mRNA) have been found in a number of normal 
tissues including skin, thyroid, parathyroid, pituitary, adrenal and stomach 
(96,391). In addition, it is likely that PTHrP plays a role in the maintenance of 
normal pregnancy and lactation. Very high levels of PTHrP have been found in 
human and other mammalian milk (94,392) and evidence now exists to suggest 
that PTHrP is the principal factor involved in the transfer of calcium from the 
breast into milk (393). PTHrP has also been shown to have a physiological role 
in controlling maternal/fetal placental calcium transport in sheep (95,394).
In this study a new two-site immunoradiometric assay was used to measure 
changes in plasma concentrations of PTHrP during normal pregnancy.
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Concentrations of PTHrP found were compared with other indices of calcium 
homoeostasis.
3.2.2 Patients and Methods
10 women (mean age 26.9 years, range 17-32) were studied at presentation to the 
antenatal clinic (range 9-11 weeks gestation, mean 9.9 weeks), at 2nd trimester 
(20-24 weeks, mean 22.2 weeks), 3rd trimester (33-34 weeks, mean 33.4 weeks), 
term (36-40 weeks, mean 38.1 weeks) and 6 weeks post-delivery. Gestational 
dates were confirmed by ultrasound. At each visit measurement was made of 
plasma PTHrP, PTH, cyclic adenosine monophosphate (PcAMP), osteocalcin , 
calcium, albumin and total alkaline phosphatase (ALP). Calcium was adjusted 
for the prevailing serum albumin as described in section 2.1.1. In addition, at 
each visit a true fasting (second voided) urine sample was obtained for 
measurement of cyclic adenosine monophosphate and urinary calcium and 
creatinine. Urinary calcium excretion was expressed as a ratio of urinary 
creatinine (mmol/mmol) (Ca/Cr) and a figure for nephrogenous cAMP (NcAMP) 
was derived as described in section 2.1.8.
No patient suffered from any other condition thought likely to interfere with their 
calcium homoeostasis and no patients were on any medication other than 
supplemental iron and folic acid. None of the patients studied developed pre- 
eclampsia or pregnancy-associated hypertension and each had an uneventful 
pregnancy. Onset of labour was spontaneous in 9 instances and in the remaining 
case an elective Caesarian section was performed on account of cephalo-pelvic 
disproportion. In each case a normal live child was delivered. After delivery only 
1 mother elected to breast feed her child.
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Statistical analyses of the above parameters was carried out using Scheffe's test 
for multiple simultaneous comparisons. Results are presented as means ± SEM.
3.2.3 Results
Changes in plasma PTHrP concentrations are shown in figures 3.4 and 3.5. 
PTHrP was undetectable (<0.7pmol/l) in 2 instances in 1st trimester, 1 instance 
in 2nd trimester and 1 instance at term. PTHrP rose gradually from 0.8pmol/l ± 
0.2 (1st trimester) to 2.7pmol/l ± 0.2 (post natal) (p<0.00001). Serum alkaline 
phosphatase (figure 3.5) rose from nadir at 1st trimester of 94U/1 ± 8 to a peak of 
347 ± 25U/1 at term (p<0.00001), thereafter levels fell to 184 ± 19UA (p=0.04 vs 
term) at post natal assessment. ALP and PTHrP were significantly correlated up 
to term (r=0.44, p=0.005). Plasma PTH (figure 3.6) tended to fall slightly 
through pregnancy to a nadir of 1.5 ± 0.1pmol/l in the 3rd trimester (p=NS), 
though rose significantly at the post natal assessment from 1.8pmol/l ± 0.2 (1st 
trimester) to 3.1pmol/l ± 0.5 (p<0.01). NcAMP (figure 3.4) was unchanged 
during pregnancy, however showed a tendency to rise in parallel with PTH and 
PTHrP post natally. 1st trimester NcAMP was 15.8nmol/l GF ±2.3 and was 
21.3nmolA GF ± 3.4 at the post natal visit (p=NS). Neither PTH nor PTHrP alone 
was significantly correlated with NcAMP. Osteocalcin (figure 3.6), though 
initially lower than normal pre-pregnancy levels, rose through pregnancy from a 
nadir of 1.2ng/ml ± 0.2 to a peak of 2.4ng/ml ± 0.3 (post natal) (p<0.05). While 
the pattern of change of PTH and osteocalcin through pregnancy was similar, no 
significant correlation was evident between these two parameters. Adjusted 
serum calcium showed no significant change through pregnancy or the 
puerperium (figure 3.7). Mean concentration at 1st trimester was 2.36 ± 
0.02mmolA, at term was 2.42 ± 0.02mmolA and post partum was 2.35 ± 
0.03mmolA (p=NS). Changes in urinary Ca/Cr are shown in figure 3.8. Values
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fell through pregnancy from a peak of 0.70 ± 0.11 at 1st trimester to a nadir of 
0.19 ± 0.04 at post natal assessment (p<0.02).
3.2.4 Discussion
Results from this study show that plasma concentrations of PTHrP rise through 
pregnancy (albeit within the normal reference range) and continue to rise after 
birth at least as far as 6 weeks into the post natal period. It would appear likely 
that this post-natal rise in plasma PTHrP is secondary to the very high levels of 
PTHrP usually found in breast milk. Khosla et al.(395) reported that, though 
breast milk PTHrP levels may rise greatly, maternal plasma PTHrP 
concentrations usually remain within the reference range as was the case in this 
study. It has been suggested that suckling is the major stimulus to PTHrP 
secretion (396), however since only 1 of the 10 patients in this study was breast 
feeding, and this patient did not have the highest plasma PTHrP concentration, 
this would seem unlikely. More likely is the suggestion that PTHrP secretion 
may be associated with increases in circulating serum prolactin (397) 
independent of suckling.
Though the breast is the probable major source of plasma PTHrP in the 
puerperium, the placenta is the likely major source during pregnancy. This is 
suggested in this study by the close relationship up to the time of delivery 
between PTHrP and alkaline phosphatase which is known to be produced by the 
placenta (398). This would be consistent with the work of Rodda et al.(95) who 
showed PTHrP to be present in sheep placenta, with in that case highest levels 
found in mid gestation. After delivery, with placental separation ALP levels start 
to fall, however PTHrP levels continue to rise presumably due to breast 
production as suggested above.
96
NcAMP is generally considered to be a reliable indicator of PTH and/or PTHrP 
bioactivity (76,84). No significant changes were seen in NcAMP during 
pregnancy though levels did tend to rise in the post partum period at which point 
PTH and PTHrP levels were at their highest. In normal circumstances bioactive 
PTH is responsible for the production of over 90% of NcAMP (76). PTHrP, 
however, is also a potent stimulator of NcAMP production (84). When both PTH 
and PTHrP are present in the circulation together, such as is the case in this 
study, the usual close association between these parameters would appear to be 
lost - presumably as both are simultaneously exerting a potent stimulative effect 
on NcAMP production. Furthermore, concentrations of both PTH and PTHrP 
generally remain within their respective normal reference ranges and any 
stimulus to NcAMP production is likely to be weak.
Previous studies have suggested that while total serum calcium may fall slightly 
during pregnancy due to haemodilution, no significant changes are noted in 
ionised calcium (399,400). In this study albumin adjusted calcium was measured, 
which has been previously shown to correlate closely with ionised calcium in the 
non-pregnant state (152). As other workers have described with ionised calcium
(399,400), no significant change in albumin adjusted calcium was noted in this 
study in pregnancy or the puerperium.
In studies where radioimmunoassays for PTH have been used, it has been 
suggested that PTH levels increased during pregnancy with a state of secondary 
hyperparathyroidism being present (401,402). In this study, however, and other 
more recent studies where immunoradiometric assays have been used (399,400), 
PTH levels tend to fall and rise again after delivery. This rise in PTH post 
delivery is likely to indicate a state of secondary hyperparathyroidism which may 
exist to compensate for the transfer of calcium into breast milk. This may also 
explain the low fasting urinary calcium/creatinine ratio seen at this time (403). It
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is likely that bone resorption is increased after delivery in order to mobilise 
calcium. As bone resorption and formation are usually coupled, it is likely that 
bone formation rates are also increased. The finding of increased levels of 
osteocalcin in the puerperium in this study would be in keeping with this 
hypothesis (404). Similar increases in serum osteocalcin concentrations have 
been noted by other workers (405,406). Seki et al.(400) noted a significant 
correlation between PTH and osteocalcin; this was not a feature of this present 
study; though the pattern of change of PTH and osteocalcin through pregnancy 
and the puerperium was similar. 1,25-dihydroxyvitmin D3 has also been shown 
to rise through pregnancy (400). This is likely to be due to both an increase in 
vitamin D binding protein (407) and an increase in the rate of conversion of 
vitamin D3 to l,25(OH)2D3 due to the action of placental 1-alpha hydroxylase 
(408). Furthermore, since PTH has a potent stimulative effect on l,25(OH)2D3 
production (14), l,25(OH)2D3 levels are generally high in the puerperium
(400,401). Osteocalcin production is in turn stimulated by l,25(OH)2D3 (409) 
and this relationship may also contribute to the increases noted in serum 
osteocalcin concentrations.
Fasting urinary calciurn/creatinine fell significantly during pregnancy and fell 
further in the puerperium. The reasons for this are not clear; hypocalciuria has 
previously been shown to be associated with pre-eclampsia (410,411,412), 
however none of the patients studied developed pre-eclampsia or hypertension. A 
more likely explanation is that the hypocalciuria present reflects the presence of 
a maternal negative calcium balance due to the transfer of calcium from mother 
to fetus in pregnancy and, as suggested above, mother to breast milk in the 
puerperium.
In summary it would appear that the changes in plasma concentrations of PTHrP 
may be observed in pregnancy and the puerperium. It is likely that the placenta
and breast are the main sources of this increased production of PTHrP. It is not 
clear, however, whether these changes in plasma PTHrP concentrations have a 
significant effect on maternal calcium homoeostasis independent of PTH and 
l,25(OH)2D3.
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3.3 Acute effects of in travenous 1a-hvdroxvcholecalciferol 
(alfacalcidol) on parathyroid horm one, osteocalcin  and 1.25- 
dihvdroxw itam in P3
3.3.1 Introduction
The previous two studies were concerned principally with the direct and indirect 
assessment of parathyroid hormone-related protein (PTHrP). Currently available 
biochemical assays can also give useful information concerning the 
physiological and pathophysiological interactions between the other major 
hormones and proteins involved in the parathyroid hormone (PTH)/vitamin D 
axis both in the normal state and in patients with various disorders of bone and 
calcium metabolism.
In recent years 1,25-dihydroxyvitamin D3 (l,25(OH)2D3) has been increasingly 
recognised as a key hormone in the control of PTH secretion (413). Conversely 
PTH is also of major importance in the metabolism of l,25(OH)2D3, with one of 
its principal actions being stimulation of the la-hydroxylase enzyme which leads 
to increased conversion of 25-hydroxyvitamin D3 (25(OH)D3) to the active 
metabolite of vitamin D, l,25(OH)2D3 (14).
Further evidence of the interactions between PTH and l,25(OH)2D3 comes from 
the fact that chronic oral administration of l,25(OH)2D3 has been successfully 
used to suppress excess parathyroid hormone (PTH) secretion in conditions such 
as chronic renal failure. However, the doses required are usually associated with 
the development of hypercalcaemia (30). It has been noted, however, that 
adequate PTH suppression can be achieved without this concomitant rise in 
serum calcium when either l,25(OH)2D3 or la-hydroxycholecalciferol
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(alfacalcidol) (which leads to an acute rise in l,25(OH)2D3) is given 
intravenously rather than orally (31).
Administration of intravenous alfacalcidol is, therefore, a useful way of 
stimulating an acute rise in l,25(OH)2D3 which would allow the acute effects of 
l,25(OH)2D3 upon other peptides to be studied.
In this study the acute effects of a single intravenous bolus of alfacalcidol upon 
the PTH/vitamin D axis is described.
3.3.2 Patients and Methods
A single intravenous bolus of 2ug alfacalcidol was given to 6 normal males 
(mean age 33 years, range 30-36), 6 women with primary hyperparathyroidism 
(PHPT) (mean age 72 years, range 65-78) and 6 women with established 
osteoporosis (mean age 63 years, range 52-70). The diagnosis of primary 
hyperparathyroidism was made on the basis of the presence of hypercalcaemia 
associated with either elevated or inappropriately detectable PTH. The diagnosis 
of osteoporosis was made on the basis of the presence of a least one vertebral 
compression fracture on X-ray associated with a bone density, measured by 
DXA, of at least one standard deviation below that of age-matched controls.
All studies commenced at 9am with the subject fasting, blood was drawn through 
an indwelling peripheral intravenous cannula at time zero, just before 
administration of alfacalcidol, and at 1 hour, 2 hours, 3 hours, 5 hours, 8 hours,
12 hours and 24 hours afterwards. All subjects were ambulant during the day, 
took usual meals at 0900, 1200, and 1700 and went to sleep at midnight. 
Measurement was made at each time-point of serum calcium, albumin and 
alkaline phosphatase, intact PTH(l-84), l,25(OH)2D3, and osteocalcin.
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Statistical comparison within each given treatment group was carried out using 
Sheffe’s test for multiple simultaneous comparisons, while one way analysis of 
variance was used to assess differences between the groups. Comparison 
between the baseline parameters in all three groups was carried out using a 
Mann-Whitney U-test.
3.3.3 Results
In each group l,25(OH)2D3 levels rose to a peak 2-3 hours after administration of 
alfacalcidol (figure 3.9). Thereafter levels fell slowly though mean values tended 
to remain above baseline even at 24 hours. As might be expected basal 
l,25(OH)2D3 concentrations were highest in the PHPT group (table 3.2). Highest 
peak levels were also found in PHPT group at (mean ± SEM) 150±15pmol/l 
versus 114±15 (controls) (p<0.01) and 127±15 (osteoporosis) (p<0.05). One way 
analysis of variance showed that the rise in l,25(OH)2D3 was greater in the 
PHPT patients than in the normal subjects and osteoporotic patients (F=4.1, df= 
1/64, p<0.05). No statistically significant difference in the l,25(OH)2D3 response 
was evident between the normal control subjects and the osteoporotic patients.
Changes in PTH observed are shown in figure 3.10. Again as expected highest 
basal values are seen in the PHPT group (table 3.2). While there was an initial 
trend downwards in PTH concentrations in both the PHPT patients and controls, 
this was not statistically significant.
Changes in adjusted serum calcium are shown in figure 3.11. As with PTH and 
l,25(OH)2D3, basal serum calcium was highest in PHPT group (table 3.2). After 
administration of alfacalcidol no significant changes in serum calcium 
concentrations were noted during the period of monitoring in any of the three 
study groups.
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Changes in serum 1,25-dihydroxyvitamin D3 (l,25(OH)2D3) concentrations in 
the three treatment groups. Alfacalcidol was administered after time 0. Points 
shown are means ± SEM.
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Changes in serum parathyroid hormone (PTH) concentrations in the three 
treatment groups. Alfacalcidol was administered after time 0. Points shown are 
means ± SEM.
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Changes in adjusted serum calcium in the three treatment groups. Alfacalcidol 
was administered after time 0. Points shown are means ± SEM.
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Changes in serum osteocalcin and alkaline phosphatase are shown in figures 3.12 
and 3.13. While basal levels of ALP tended to be highest in the PHPT group this 
was not statistically significant (table 3.2). Basal levels of osteocalcin, however, 
were significantly higher in the PHPT group (table 3.2). Following 
administration of alfacalcidol no significant changes in either ALP or osteocalcin 
levels were seen and there were no differences in the response to alfacalcidol 
between the three groups.
3.3.4 Discussion
This study illustrates the changes which occur in l,25(OH)2D3 after a single 
intravenous injection of alfacalcidol. In all treatment groups peak concentrations 
of l,25(OH)2D3 were found between 2 and 3 hours after intravenous alfacalcidol 
with levels still tending to be elevated at 24 hours.
Prolonged courses of intravenous l,25(OH)2D3 or la-hydroxycholecalciferol 
(alfacalcidol) therapy have been shown to successfully suppress the excess PTH 
secretion associated with chronic renal failure without the development of 
concomitant hypercalcaemia (31). Where alfacalcidol is used 25-hydroxylation 
must first take place for the formation of l,25(OH)2D3 (414). It is generally 
believed that this metabolic step is not stringently regulated in human liver cells 
(415). Although, in contrast, activity of this enzyme may be more tightly 
regulated in some other species (416).
The results in this present study are similar to those described by Papapoulos et 
al.(417) in a group of patients with chronic renal failure on regular 
haemodialysis. In that study the response of l,25(OH)2D3 to intravenous 
alfacalcidol appeared to be linear in the dose range l-4ug. Papapoulos et al.(417) 
also found that l,25(OH)2D3 remained significantly elevated for a prolonged
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Figure 3.12
Changes in serum osteocalcin concentrations in the three treatment groups. 
Alfacalcidol was administered after time 0. Points shown are means ± SEM.
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period - returning to normal only after 1 week. Mawer et al.(418) described 
similar changes in serum l,25(OH)2D3 after the oral administration of 
l,25(OH)2D3. While peak changes in l,25(OH)2D3 have been shown to occur 
within 15 minutes of the intravenous administration of l,25(OH)2D3 (419), the 
slower time to peak l,25(OH)2D3 concentrations obtained in this study 
presumably reflects the time required for hepatic 25-hydroxylation to take place.
Both the basal concentration and the absolute increase in l,25(OH)2D3 was 
significantly higher in the PHPT group. Since all three groups received the same 
dose of alfacalcidol this would suggest that the activity of hepatic 25-hydroxylase 
is increased in patients with primary hyperparathyroidism. However, contrary to 
the experience of Silverberg et al.(420) there was no evidence of impairment of 
l,25(OH)2D3 formation in those patients with osteoporosis. This study, however, 
cannot exclude other explanations for the changes in l,25(OH)2D3 observed in 
the PHPT patients such as impaired l,25(OH)2D3 metabolism or clearance.
The activity of the renal la-hydroxylase enzyme has been shown to decline with 
increasing age (421), however similar age effects on the 25-hydroxylase enzyme
would not explain the changes seen in this study. The greatest rise in
l,25(OH)2D3 (and therefore the greatest 25-hydroxylase activity) was seen in the
PHPT patients who were also the oldest.
No significant changes were noted in intact PTH concentrations in this present 
study. Llach et al.(422) similarly failed to demonstrate any changes in 
immunoreactive PTH concentrations after the acute administration of 2.7ug oral 
l,25(OH)2D3. The reasons for this apparent lack of effect on PTH secretion 
remain unclear particularly since Chertow et al.(423) showed that, in vitro, 
l,25(OH)2D3 inhibits the release of PTH from parathyroid slices within 2 hours.
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This work was carried out in the rat and certainly species differences may, at 
least in part, explain this discrepancy.
Intravenous alfacalcidol and l,25(OH)2D3 are being increasingly used to treat the 
secondary hyperparathyroidism associated with chronic renal failure 
(31,417,424,425). These studies have generally been carried out over weeks or 
months and are associated with significant PTH suppression, usually without 
concomitant hypercalcaemia. This may be due either to a direct effect of l,25(OH)2D3 
in suppressing PTH synthesis (426) or an alteration to the set point for serum 
calcium such that PTH is suppressed at a lower serum calcium concentration 
than pretreatment (31).
No significant rise in serum calcium was noted in any of the 3 groups studied. In 
fact, the mean serum calcium concentration tended to fall in the normal subjects 
in the initial 12 hours after administration of alfacalcidol. This was also noted by 
Llach et al.(422), where again this change was transient and not statistically 
significant.
In addition to suppressing PTH synthesis, an increase in the concentration of 
l,25(OH)2D3 is known to stimulate osteoblastic production of osteocalcin (409).
In this study basal levels of osteocalcin were higher in the patients with PHPT, in 
keeping with their increased bone turnover. By contrast, as has been described 
previously (404), osteocalcin levels in the osteoporotic patients were no different 
from normal. The acute administration of intravenous alfacalcidol, however, was 
not associated with any increase in osteocalcin concentrations in any of the three 
groups studied. As is the case with PTH this may be because l,25(OH)2D3 is 
likely to exert its effect on osteocalcin by stimulating synthesis rather than 
secretion. Duda et al.(427) demonstrated significant increases in osteocalcin in 
both normal and osteoporotic postmenopausal women after oral administration of
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2ug l,25(OH)2D3 daily. In that study, however, increases were first described 
between days 1 and 3. No comment was made on changes within 24 hours. 
Similar results were noted by Gram et al.(428) where again 2ug l,25(OH)2D3 
was given orally, in that case to normal males. This led to significant increases in 
osteocalcin after 1 week, however again no measurements were made within this 
period. Duda et al.(427) also noted that while osteocalcin levels increased, serum 
alkaline phosphatase concentrations did not change. The reason for this 
discrepancy between alkaline phosphatase and osteocalcin was not apparent.
In conclusion this study describes for the first time the changes in l,25(OH)2D3 
which occur in normal subjects and patients with primary hyperparathyroidism 
and osteoporosis after a single intravenous injection of alfacalcidol. These results 
would suggest that liver 25-hydroxylase activity is increased in primary 
hyperparathyroidism. Furthermore l,25(OH)2D3 does not appear to alter serum 
PTH concentrations in the acute situation. Similarly l,25(OH)2D3 does not 
appear to have an acute effect on stimulating serum osteocalcin concentrations. 
These results would suggest that the changes of PTH suppression and osteocalcin 
stimulation seen in longer-term studies occur via changes in hormone synthesis 
rather than secretion.
CHAPTER A
DUAL-ENERGY X-RAY ABSORPTIOMETRY fHYA) im 
EVALUATION OF OSTEOPOROSIS
4.1 Bone turnover and densitom etry  in type I d iabe tes mellitus
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4.1.1 Introduction
The development of dual-energy X-ray absorptiometry (DXA) has represented a 
significant technological breakthrough in the assessment of osteoporosis. This 
technique allows both accurate and precise measurement of bone density at the 
lumbar spine (L2-4) and neck of femur with negligible patient radiation exposure 
(274). Furthermore this technique allows significantly faster scan times than was 
the case with dual-photon absorptiometry which therefore permits access to this 
facility to greater number of patients (272,273).
The improved precision and accuracy of this technique over previously available 
methods means that reliable bone density data can be obtained in cross-sectional 
and longitudinal studies investigating both the effect of anti-osteoporotic therapy 
and the prevalence of osteoporosis secondary to other medical conditions.
One such example is in the assessment of patients with diabetes mellitus where a 
possible association with osteoporosis has been recognised for many years (349). 
However, densitometric studies carried out in patients with type I diabetes 
mellitus using either single photon absorptiometry (351,352) or dual photon 
absorptiometry (353) have, on the whole, been inconclusive with some 
confirming and others refuting this association. Some evidence also exists that 
diabetic patients have an increased incidence of bone fracture (359,360) but 
again this evidence is conflicting. In this study dual-energy X-ray absorptiometry 
(DXA) was used to assess lumbar and femoral neck bone densities in a cohort of 
20 premenopausal women with type I diabetes mellitus. In addition, 
measurement was made of a number of biochemical indices of bone turnover.
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4.1.2 Patients and methods
Twenty females with type I diabetes mellitus, mean age 32 years (range 23-42) 
and mean diabetes duration 8.8 years (range 2-22), presenting consecutively for 
review were recruited and compared with a group of 27 age matched female 
controls, mean age 34 years (range 24-42). These control females had been 
recruited by a local advertising campaign to take part in a study investigating 
normal bone density in the West of Scotland. Each diabetic patient was paired by 
age with at least one non-diabetic control. Where more than one age matched 
control was available, the mean of their bone densities was calculated and used 
to compare with the appropriate diabetic patient. None of the diabetic patients or 
control subjects suffered from any other medical condition or were taking any 
medication thought likely to interfere with their bone metabolism. All subjects 
were premenopausal at the time of study. Furthermore none of the diabetic 
patients had biochemical evidence of renal impairment and the mean daily dose 
of insulin in the diabetic patients was 44 units per day (range 18-86).
A single measurement was obtained of L2-4 spinal density and neck of femur 
density and a fasting blood and urine sample obtained. All bone density 
measurements obtained were adjusted for body weight using standard software. 
Assessment of medium-term diabetic control was made by measurement of 
glycated haemoglobin (HbAl). Body mass index (BMI) was calculated using the 
formula - weight (kg)/height(m)2.
Statistical analyses between groups was carried out using a paired Student's t- 
test. 95% confidence intervals (95% Cl) for differences between means are also 
shown. The results obtained for each group tended to be skewed and the data 
was, therefore, logarithmically transformed prior to a t-test being carried out. 
Correlations were performed using Spearman Rank Correlations.
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4 .1 .3  R esu lts
These patients were well matched in terms of size as the mean BMI of the 
diabetic patients was 26.5±1.3 kg/m2 versus 24.2±1.2kg/m2 for the controls 
(p=NS, 95% Cl; -2.7 to 5.6). Mean HbAl in the diabetic patients was 10.2% 
(range 6.7-19.5) (normal 4.9-8.3%) compared with 6.1% (range 4.4-7.4) in the 
controls (p<0 .0001).
Results for L2-4 and neck of femur bone densities in the diabetic patients and 
their controls are shown in figures 4.1 and 4.2. Mean (±SEM) L2-4 density was 
significantly higher in the diabetic patients at 1.224±0.021g/cm2 versus 
1.142±0.015g/cm2 (controls), p=0.016 (95% Cl for difference between means: 
0.011 to 0.110g/cm2). Mean (±SEM) neck of femur density, however, did not 
differ significantly between the two groups (0.963±0.026g/cm2 [diabetic] versus 
0.960±0.028g/cm2 [controls]; p=NS)(95% Cl for difference between means: - 
0.089 to 0.067g/cm2).
Biochemical results for the diabetic patients and control subjects are shown in 
table 4.1. Mean (±SEM) serum alkaline phosphatase (figure 4.3) was 
significantly higher in the diabetic patients at 185±16U/1 versus 135±10U/1 
(controls), p<0.01 (95% Cl: 12 to 70U/1). Mean fasting HP/Cr ratio was also 
elevated in the diabetic patients at 0.028±0.003 versus 0.017±0.002 (controls): 
p=0.002 (95% Cl: 0.004 to 0.015) (figure 4.4). Mean fasting urinary 
calcium/creatinine ratio was elevated in the diabetic patients at 0.40±0.06 versus 
0.21±0.03: p=0.013 (95% Cl: 0.05 to 0.33). No difference was evident, however, 
in serum calcium, PTH or l,25(OH)2D3. In addition NcAMP was within the 
normal reference range in the diabetic patients indicative of normal PTH activity. 
Mean 7GT was normal in both groups. No significant correlation was evident
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Figure 4.1
Spinal (L2-4) bone density in the diabetic patients and age-matched control subjects. 
Horizontal bars indicate means with standard errors (SEM) also shown. Difference 
between means: p=0.016.
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Figure 4.2
Neck of femur bone density in the diabetic patients and age-matched control 
subjects. Horizontal bars indicate means with standard errors (SEM) also shown. 
Difference between means: p=NS.
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Figure 4.3
Serum alkaline phosphatase in the diabetic patients and age-matched control 
subjects. Horizontal bars indicate means with standard errors (SEM) also shown. 
Shaded area indicates normal reference range for alkaline phosphatase. 
Difference between means: p<0.01.
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Figure 4.4
Urinary hydroxyproline/creatinine ratio (HP/Cr) in the diabetic patients and age- 
matched control subjects. Horizontal bars indicate means with standard errors 
(SEM) also shown. Shaded area indicates normal reference range for HP/Cr. 
Difference between means: p=0.002.
Table 4.1
Biochemical resu lts of the diabetic patien ts and non-diabetic control
su b jec ts  (Values show n are  m eans)
Diabetic Non-Diabetic P
ALP (U/L) 181 135 <0.01
SEM, range 16,100-320 10,55-195
7GT (U/L) 18 20 NS
SEM, range 2,10-33 1,11-30
HP/Cr (mmol:mmol) 0.028 0.017 0.002
SEM, range 0.002,0.011-0.057 0.002,0.007-0.035
Ca/Cr (mmol:mmol) 0.40 0.21 0.013
SEM, range 0.06,0.15-0.83 0.03,0.07-0.53
Calcium (mmol/1) 2.41 2.39 NS
SEM, range 0.01,2.30-2.50 0.02,2.30-2.50
Mean PTH (pmol/1) 2.4 2.7 NS
SEM, range 0.4,<0.8-9.3 0.2,1.5-4.3
Mean NcAMP(nmol/l GF) 15.7 - -
SEM, range 1.0,7.7-25.9 -
Mean l,25(OH)2D3 (pmol/1) 82 73 NS
SEM,range 11,31-158 12,43-115
ALP - alkaline phosphatase 7GT - gamma glutamyl transferase 
HP/Cr - urinary hydroxyproline/creatinine ratio 
Ca/Cr - urinary calcium/creatinine ratio
PTH - parathyroid hormone NcAMP - nephrogenous cyclic adenosine 
monophosphate
l,25(OH)2D3 - 1,25-dihydroxyvitamin D3
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between the diabetic patients L2-4 density and HbAl (r=0.41, p=NS), duration of 
diabetes (r=0.22, p=NS) or daily dose of insulin taken (r=0.13, p=NS).
4.1.4 Discussion
The results from this study suggest that while, on the basis of biochemical 
criteria, bone turnover is apparently increased in premenopausal female 
diabetics, these patients show no densitometric evidence of osteopenia and may 
even have higher than normal bone density at the lumbar spine.
In this study bone densities in the diabetic patients were paired with at least 1 
non-diabetic control subject. While the mean bone density for the control 
subjects in this study was apparently a little lower than the UK reference range 
quoted by Lunar Corporation, this difference is small with overall the control 
subjects having a bone density of 97.2% of the Lunar reference population. It is 
possible this difference simply reflects that the norm for the Glasgow population 
is a little lower than the UK Lunar reference data.
Several studies in the past have suggested that type I diabetes mellitus is 
associated with an increased incidence of osteoporosis. These studies have 
generally been carried out in children and adolescents (350,351), and usually 
show only small reductions in bone density. These findings are not universal, 
however, as at least one recent study has failed to show any evidence of 
osteoporosis in young males with type I diabetes and bone densities below 
normal in this study were only noted in 6 .6 % of females (429). Furthermore, 
studies published to date have generally used single photon absorptiometry 
(SPA) which can only be applied to peripheral sites (most commonly forearm) 
and measures mainly cortical bone. Relatively little data exists on spine and hip 
density in patients with diabetes: in one study Auwerx et al.(353), using dual
I l l
photon absorptiometry (DPA), demonstrated mean L2-4 density to be below the 
age adjusted reference range in 14 diabetic women. However, this study did not 
include a non-diabetic control group. It is possible in this present study that other 
features such as the presence of large osteophytes or calcification in the aorta 
could give falsely elevated L2-4 density results. Though it is not possible to 
exclude these problems as spinal X-rays were not carried out, it would seem an 
unlikely explanation given the relative youth of the subjects studied.
Results from this present study indicate that bone turnover may be increased in 
the diabetic patients as illustrated by the elevated levels of serum alkaline 
phosphatase and urinary hydroxyproline excretion. However increased bone 
turnover need not necessarily always be associated with the development of 
osteopenia if bone formation and resorption rates are similar (430). Although 
further increases in bone resorption such as may be seen after the menopause 
might, in this situation, be expected to result in a period of rapid bone loss and 
osteoporosis.
Previously, bone resorption has been shown to be elevated in patients with 
diabetes, as assessed by urinary hydroxyproline excretion (431), urinary calcium 
excretion (357,369) and bone histomorphometry (365). Histomorphometric 
studies have also suggested the presence of a high turnover state (365) akin to 
primary hyperparathyroidism, though this has generally not been confirmed in 
biochemical studies where bone formation rates, as measured by osteocalcin, are 
low (432). However, serum concentrations of ALP in this present study were 
significantly higher in the diabetic patients and in some instances above the 
reference range. Since ^3T was within the reference range in the diabetic 
patients and similar to that seen in the non-diabetic controls and since 'jGT rises 
in parallel with ALP due to their similar pathway of secretion, it is likely that this
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elevation in serum ALP is of bony origin and indicative of increased osteoblastic 
activity.
Studies in animal models of diabetes have found low serum concentrations of 
l,25(OH)2D3 (433). However this observation has only been made in human 
diabetes in children or adolescents with poorly controlled diabetes or 
ketoacidosis (434). In contrast, levels of l,25(OH)2D3 in this study were not low 
and if anything tended to be a little higher in the diabetic patients. It is possible, 
though, that small differences in l,25(OH)2D3 concentrations may exist which 
have not been observed due to the relatively small numbers of patients in this 
study.
Early studies in diabetic rats suggested that PTH concentrations were elevated 
(435). This finding has not been confirmed in more recent studies (436) and was 
not observed in this study, nor would PTH activity appear to be increased as 
NcAMP levels were normal.
The reason why the diabetic patients in this study have increased bone density is 
unclear. Certainly insulin is known to increase serum levels of insulin-like 
growth factor-1 (IGF-1) (437) and it is known that both insulin and IGF-1 
promote osteoblast replication and function (438). It is possible, therefore, that 
this in turn leads to an increased rate of bone formation.
Another feature of note is that in many previous studies diabetes related 
osteopenia has occurred soon after the onset of the disease (439) and bone loss 
did not increase further with increasing duration of diabetes (357). This may be 
due to the absolute or near absolute deficiency of insulin which accompanies the 
onset of diabetes mellitus, which is then corrected with the introduction of 
insulin therapy.
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A number of epidemiological studies have suggested that diabetes mellitus is 
associated with an increased risk of fracture (359,360,440) and a pooled estimate 
of the published data suggests an increased risk of fracture of approximately 
twofold in patients with diabetes (361). Against this, however, a case control 
study from the Mayo clinic failed to show any excess fracture incidence in 
diabetic patients (362). It is possible that diabetes has an adverse effect on 
fracture incidence by mechanisms independent of bone mass such as the 
occurrence of an increased incidence of falls due to the presence of neuropathy 
or hypoglycaemia (361), indeed in cases described by Nabarro (363), he 
attributed the presence of vertebral compression fractures to hypoglycaemic 
seizures.
In conclusion this study shows that when a highly accurate and precise measure 
of bone density is used, there is no evidence of spinal or femoral neck osteopenia 
in premenopausal women with type I diabetes mellitus. These patients, however, 
do have biochemical evidence of increased bone turnover. Should this increased 
bone turnover persist in the very long term an increased rate of bone loss might 
be expected after the menopause. Further studies are required to address this 
question.
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4.2 Severe haem ophilia A and osteopenia: a densitom etric and 
biochem ical a sse ssm e n t
4.2.1 Introduction
The previous study illustrated the value of DXA in being able to confirm or 
refute the presence of osteopenia. In this next study DXA was used to assess 
bone density in a group of patients with severe haemophilia A - a condition 
which hitherto has not been known to be associated with osteopenia.
In 1989 a 31 year old man with severe haemophilia A presented to the regional 
adult haemophilia centre at Glasgow Royal Infirmary with severe back pain. X- 
rays of spine confirmed the presence of compression fractures of DV9, DV10 
and LV2. There was no history of significant antecedent trauma nor did this 
patient have any apparent risk factors for osteoporosis. Following this, a 20 year 
old male with severe haemophilia A presented with a fractured neck of femur 
after an epileptic seizure. At this point, the question was therefore raised as to 
whether osteopenia may be associated with haemophilia A.
In this study bone density was measured at the lumbar spine (L2-4) and the neck 
of femur in 19 men with severe (factor VIIIc level <liu/dl) haemophilia A.
4.2.2 Patients and methods
A total of 26 patients were identified as suffering from severe haemophilia A 
from the records of the regional adult haemophilia centre at Glasgow Royal 
Infirmary and these patients were invited to attend for measurement of bone 
densitometry and to have a blood sample taken. 19 patients (mean age 41 years, 
range 18-69) accepted this invitation and each of these brought a true fasting
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(second voided) urine sample at time of attendance. Only those patients who did 
not suffer from human immunodeficiency virus (HIV) infection were considered 
for recruitment into this study, though 18/19 of these patients were hepatitis C 
antibody positive.
Bone density at the lumbar spine (L2-4) and neck of femur was measured, as was 
measurement of serum alkaline phosphatase (ALP), gamma glutamyl transferase 
(yGT) parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 (l,25(OH)2D3), 
testosterone, sex hormone binding globulin (SHBG), leutinising hormone (LH), 
follicle stimulating hormone (FSH), nephrogenous cyclic adenosine 
monophosphate (NcAMP) and urinary calcium/creatinine (Ca/Cr) and 
hydroxyproline/creatinine (HP/Cr) ratios. Using the values obtained for 
testosterone and SHBG a figure was obtained for the free androgen index (FAI) 
as described in section 2.1.7.
At the time of study a group of 19 age matched male control subjects were 
recruited from members of hospital staff. These subjects underwent similar 
investigation to the haemophiliac patients. For statistical analysis each subject 
was paired by age with one of the haemophiliac patients.
Other than severe haemophilia A, all of the patients (and control subjects) 
studied were otherwise well and suffered from no other condition (other than 
hepatitis - see above) nor were they taking any medication thought likely to 
interfere with their bone and calcium homoeostasis. No haemophiliac patient was 
a carrier of hepetitis B antigen and none had clinical evidence of liver disease.
Comparisons between the two study groups was carried out using a two-tailed 
paired Student's t-test. Results of SHBG and FAI were only available for 17 
haemophiliac patients and 12 control subjects, results of yGT were only available
116
in 17 haemophiliacs and 17 controls and results for urinary HP/Cr were only 
available for 15 haemophiliacs and 15 controls. Statistical comparison between 
the two groups for these parameters was carried out using a Mann-Whitney U- 
test. Results described are means ± SEM.
4.2.3 Results
Bone density at both L2-4 and neck of femur was significantly lower in the 
haemophiliac patients compared with the control subjects. Density at L2-4 
(figure 4.5) was 1.109g/cm2 ± 0.042 in the haemophiliac patients versus 
1.234g/cm2 ± 0.027 (controls); p=0.018 and at the neck of femur (figure 4.6) was 
0.877g/cm2 ± 0.034 (haemophiliacs) versus 1.067g/cm2 ± 0.032 (controls); 
p=0.0003. Serum alkaline phosphatase (ALP) (figure 4.7) was significantly 
higher in the haemophiliac patients at 200U/1 ±10  versus 158UA ± 8 (controls); 
p=0.004. Gamma glutamyl transferase (figure 4.8) was significantly higher in the 
haemophilia patients at 42U/1 ± 7 compared to the controls (20UA ± 2); p=0.007. 
Serum testosterone (figure 4.9) was also elevated in the haemophilia patients at 
26.0nmol/l ± 2.5 versus 17.4 ±1.6 (controls); p=0.009. However along with this 
elevated testosterone, SHBG (figure 4.9) was also significantly higher at 
56nmol/l ± 6 (haemophilia patients) versus 27nmolA ± 3 (controls); p=0.0005 
and FAI (figure 4.10) was significantly lower at 44 ± 5 (haemophiliac patients) 
versus 69 ± 7 (controls); p=0.008. No significant difference was evident between 
either group for LH, FSH, PTH, albumin adjusted calcium, l,25(OH)2D3, 
NcAMP, urinary Ca/Cr or urinary HP/Cr (table 4.2).
Seven of the haemophiliac patients gave a history of having sustained a 
peripheral fracture requiring medical attention since the age of 16. These were 
fractures of femur, ankle (x2), wrist, clavicle (x2) and metacarpals. None of the 
control subjects gave a history of fracture since aged 16.
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Figure 4.5
Spinal (L2-4) bone density in the haemophiliac patients and age-matched control 
subjects. Horizontal bars indicate means with standard errors (SEM) also shown. 
Difference between means: p=0.018.
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Figure 4.6
Neck of femur bone density in the haemophiliac patients and age-matched control 
subjects. Horizontal bars indicate means with standard errors (SEM) also shown. 
Difference between means: p=0.0003.
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Figure 4.7
Serum alkaline phosphatase in the haemophiliac patients and age-matched 
control subjects. Horizontal bars indicate means with standard errors (SEM) also 
shown. Shaded area indicates normal reference range for alkaline phosphatase. 
Difference between means: p=0.004.
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Figure 4.8
Serum gamma glutamyl transferase (gamma GT) in the haemophiliac patients 
and control subjects. Horizontal bars indicate means. Shaded area indicates 
normal reference range for gamma GT. Difference between means: p=0.009.
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Figure 4.9
Serum testosterone and sex hormone binding globulin (SHBG) concentrations in 
the haemophiliac patients and control subjects. Horizontal bars indicate means.
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Figure 4.10
Free androgen index (FAI) in the haemophiliac patients and control subjects. 
Horizontal bars indicate means. (FAI = serum testosterone/sex hormone binding 
globulin xlOO).
Table 4.2
Biochemical param eters in the haem ophiliac patien ts and control 
sub jects. Points show n are  m eans (SEM).
Haemophiliac patients Control subjects
LH(UA) 6.9(0.8) 5.6(0.9)
range 2.3-11.0 1.9-12.0
FSH(UA) 3.0(0.4) 2 .2 (0 .2)
range 1.3-7.6 1.1-4.0
PTH (pmol/1) 2 .5 (0 .2) 2.5(0.2)
range
(normal 1-5)
1.5-3.9 1.1-4.3
calcium(mmol/l) 2.37(0.03) 2.36(0.04)
range
(normal 2.20-2.60)
2.31-2.41 2.30-2.45
1,25 (OH)2D3 (pmol/1) 65(7) 62(5)
range
(normal 20 -120)
31-146 34-113
NcAMP(nmol/l GF) 14.4(2.5) 16.1(3.4)
range
(normal 5-27)
4.7-26.0 7.7-23.9
Ca/Cr 0.39(0.04) 0.38(0.05)
range
(normal <0.5)
0.18-0.46 0.19-0.40
HP/Cr 0.029(0.006) 0.021(0.005)
range
(normal <0.033)
0.010-0.059 0.009-0.028
LH - leutinising hormone FSH - follicle stimulating hormone
PTH - parathyroid hormone l,25(OH)2D3 - 1,25-dihydroxyvitamin D3
NcAMP - nephrogenous cyclic adenosine monophosphate 
Ca/Cr - urinary calcium/creatinine ratio 
HP/Cr - urinary hydroxyproline/creatinie ratio
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4.2 .4  D iscu ssio n
The major complications of severe haemophilia are recurrent haemarthroses 
resulting in chronic arthritis and bleeding into muscles which may cause nerve 
compression (441). While radiological surveys of haemophiliacs have shown 
local osteopenia secondary to chronic arthritis (442), this study describes for the 
first time an association between haemophilia A and generalised osteopenia. This 
osteopenia being noted specifically at both the lumbar spine and neck of femur.
This study also suggests that the degree of osteopenia found in the haemophiliac 
patients will be associated with a significantly increased risk of fracture. At least 
7 of the haemophiliac patients admitted to having sustained a significant bony 
fracture in their adult life (as opposed to none of the control subjects). However, 
it was not possible from the history to ascertain accurately if these were 
relatively "atraumatic" fractures; and further long-term prospective studies are 
required to address this issue.
Osteoporosis in males is uncommon (443) and the cause of the association 
between severe haemophilia A and osteopenia noted in this study is not 
immediately apparent. Hypogonadism is an important cause of male osteoporosis 
(444). While it would appear that the patients with haemophilia in this study had 
elevated levels of serum testosterone, the fact that SHBG was also significantly 
elevated means that the free androgen index in these patients was significantly 
below that in the control subjects. This increase in SHBG noted in the 
haemophiliac patients may be due to the presence of underlying hepatic disease 
which is a common feature in patients with haemophilia, with, in this study, there 
being evidence of previous hepatitis C infection in 18/19 of the haemophiliac 
patients studied. Hepatic dysfunction in non-haemophiliacs is known to stimulate 
increased production of SHBG (445), though the exact mechanism of this
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remains unclear. The fact that yGT was significantly elevated in the 
haemophiliac patients would be consistent with this hypothesis of hepatic 
dysfunction having a causal role in increasing SHBG. Mean gonadotrophin 
levels were not significantly different between the haemophiliac patients and 
controls, however, the fact that the free androgen index was significantly lower 
in the haemophiliacs implies the presence of, at least, relative hypogonadism.
Associated with the presence of hypogonadism, it is possible that the 
haemophiliac patients fail to achieve their anticipated peak bone mass and, as is 
the case in post-menopausal osteoporosis, bone resorption is likely to be 
increased out of proportion to bone formation (444,446) - the consequence of 
both these potential problems being osteoporosis. Identification of those patients 
with significant osteopenia by measurement of bone density and FAI is 
potentially of some importance as preventive therapy with androgen replacement 
may reduce subsequent fracture risk (450).
Fasting urinary calcium/creatinine ratio is a relatively crude marker of bone 
resorption (41) and this was not elevated in the haemophiliac patients. Similarly 
urinary hydroxyproline excretion was not significantly elevated in the 
haemophiliacs. However since HP/Cr results were not available for all the 
subjects studied, it remains possible that the lack of a significant elevation in 
hydroxyproline excretion is due to a type 2 statistical error. In the previous study 
serum ALP was taken as a marker of bone formation, however in that study yGT 
was normal and the increase in ALP seen in the diabetic patients was therefore 
likely to be of bone origin. Alkaline phosphatase was also significantly elevated 
in the haemophiliac patients but since these patients also had elevated levels of 
yGT this increase in ALP is more likely to be of hepatic origin. Further studies 
using more specific markers of bone formation such as osteocalcin or ALP 
isoenzymes are required.
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The major clinical feature of severe haemophilia is excessive bleeding due to 
impaired coagulation from deficiency of factor VIIIc. Long term treatment with 
heparin, a potent natural anticoagulant, is also associated with osteopenia (447). 
The pathogenesis of heparin-induced osteopenia is not clear, though it may be 
due to a direct effect of heparin on osteoclast activation (448). In addition 
heparin-induced osteopenia is also associated with low levels of serum 
l,25(OH)2D3 (449). It is possible, therefore, that severe chronic coagulation 
deficiencies (due to factors as yet unrecognised) may in themselves be associated 
with osteopenia. However, it should be noted that in the present study levels of 
l,25(OH)2D3 were normal, unlike the situation described with heparin (449).
Since patients with severe haemophilia are prone, from birth, to recurrent 
episodes of bleeding especially into joints and muscles, they may be less mobile 
than control subjects and this relative immobilisation may then lead to 
osteopenia (190). The two index cases described were certainly both confined to 
bed for prolonged periods in the past, however this was not a notable feature with 
the remaining patients. A more likely scenario is that periods of immobilisation 
(and therefore excessive increased bone resorption) have a detrimental effect on 
a skeleton already "at risk" from generalised osteopenia.
In conclusion, this study describes for the first time a possible association 
between haemophilia, premature fractures and osteoporosis possibly associated 
with chronic hepatitis. Further, larger, studies are required to confirm this 
association and to investigate the degree of fracture risk. Since bone biopsy for 
histomorphological analysis carries a risk of bleeding in such patients, further 
studies of biochemical indices of bone turnover are required. If increased fracture 
risk is substantiated then severe haemophiliacs should be considered for routine 
bone densitometric assessment and if necessary anti-osteoporotic therapy.
CHAPTER 5
IMAGING IN PRIMARY HYPERPARATHYROIDISM
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5.1 A com parison betw een 10MHz uitrasound and 201-thallium/99m- 
technetium  subtraction scanning  in primary hyperparathyroidism .
5.1.1 Introduction
The value of routine pre-operative localisation of parathyroid adenomas and/or 
hyperplasia continues to be the subject of some controversy (165). High success 
rates of surgery with an experienced surgeon have cast doubt on whether any 
form of imaging technique is necessary (451). These techniques have, however, 
over the past decade improved in sensitivity (176,451,452) and there is some 
evidence now that pre-operative localisation may both shorten operation (and 
anaesthetic) time and reduce the number of unsuccessful operations (176).
Many different imaging modalities are now available and include 
thallium/technetium subtraction scanning (179), high resolution (10MHz) 
ultrasound (180), computed tomography (CT) (181) and magnetic resonance 
imaging (MRI) (182). In this study the efficacy of the two most widely available 
techniques - 10MHz ultrasound and thallium/technetium subtraction scanning - 
were compared prospectively.
5.1.2 Patients and methods
10MHz ultrasound (US) and 20 l-thallium/99m-technetium (Tl/Tc) subtraction 
scanning was carried out in 30 consecutive patients presenting with primary 
hyperparathyroidism (PHPT). The diagnosis of PHPT was made on the basis of 
the presence of hypercalcaemia in association with either elevated or 
unsuppressed parathyroid hormone (PTH) concentrations. All ultrasound scans 
were carried out using a Diasonic DRF 400 ultrasound machine and a 10MHz 
stand-off probe by one operator with the patient in a supine position with his
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neck hyperextended. This operator was "blinded" to the results of the 
thallium/technetium scan which was generally carried out first. 25 of these initial 
30 patients went forward to neck exploration. All surgery was carried out by the 
same experienced surgeon who had full access to both imaging results at the time 
of operation. All tissue removed at surgery was examined by a pathologist and 
any parathyroid tissue found was weighed in order to give an assessment of the 
gland size. Surgery was not carried out in 5 of the patients initially studied - in 
each case this was because conservative management was felt to be more 
appropriate than surgery.
Details of patients studied and their pre-operative biochemical parameters are 
shown in table 5.1. Size of the abnormal parathyroid gland removed is also 
shown.
Since the data on the size of the abnormal parathyroid glands is skewed, the 
results are shown as medians and their associated range. For statistical 
comparison these data were logarithmically transformed and a Student's t-test 
carried out. Correlations where shown were made by regression analysis. 
Sensitivities and specificities for each technique were calculated assuming that in 
each patient there were four possible sites for a parathyroid adenoma.
5.1.3 Results
The operative findings were the standard against which these two imaging 
methodologies were compared. Since only 25 of the original 30 patients went on 
to neck exploration, the data analysis is confined to these 25 patients.
A single parathyroid adenoma was identified at surgery in 23/25 patients. In one 
instance 2 hyperplastic parathyroids were removed (with subsequent restoration
Table 5.1
Clinical and biochemical param eters of patien ts stud ied  (values 
show n are m edians).
Number of patients 30 (23 female, 7 male)
Age (years) 62.5
SEM, range 2.3,30-83
Serum calcium (mmolA) 2.93
SEM, range 0.05, 2.70-4.00
PTH (pmol/1) 10.5
SEM, range 1.8, 2.7-56.0
Median gland size (mg) 540
range 50-6820
PTH - parathyroid hormone
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of normocalcaemia) and in one no abnormal parathyroid tissue was found (and 
the patient remained hypercalcaemic). Post-operatively normocalcaemia 
supervened in each of the 23 patients where a parathyroid adenoma was 
removed.
Thallium/technetium subtraction scanning correctly localised the abnormal 
parathyroid tissue in 10/24 instances. The sensitivity of this technique was 42% 
and specificity 97%. 10MHz ultrasound correctly localised the abnormal 
parathyroid tissue in 9/24 instances (in one patient no abnormal parathyroid 
tissue was found at surgery). The sensitivity of this technique was 38%, with a 
specificity of 89%. In 9 instances both these imaging modalities were positive 
together and were in agreement, and in 8 of these instances correctly predicted 
the localisation of the parathyroid adenoma. However, in 11 patients (44%) both 
modalities were negative - though in 2 of these patients the thallium/technetium 
scan was difficult to interpret due to the presence of a multinodular thyroid. 
These two patients had large parathyroid adenomas at surgery (2500mg, 600mg).
The ability of these modalities to correctly identify abnormal parathyroid tissue 
tended to vary with the size of the abnormal gland (figure 5.1). Where both 
techniques failed to identify the abnormal parathyroid tissue, gland size was 
smaller at (median, range) 170mg (50-2500mg) compared with where 
thallium/technetium subtraction scanning was positive (750mg, 150-6820mg; 
p<0.03), 10MHz ultrasound was positive (960mg, 100-6820mg; p<0.03) and 
both techniques combined were positive (980mg, 600-6820mg; p=0.002). While 
thallium/technetium subtraction scanning tended to be able to localise smaller 
glands than 10MHz ultrasound (and both techniques combined), this was not a 
statistically significant difference.
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Figure 5.1
Parathyroid gland size in those patients with positive thallium/technetium (TVTc) 
scans, positive 10MHz ultrasounds or both positive compared with those patients 
where both investigations were negative.
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A significant positive correlation was evident between PTH concentration and 
the size of the parathyroid adenoma (r-squared = 0.78, p<0.0001) and PTH 
concentration and pre-operative serum calcium concentration (r-squared = 0.63, 
p<0.0001). A weaker, though again significant correlation, was evident between 
the pre-operative serum calcium concentration and the size of the parathyroid 
adenoma (r-squared = 0.52, p<0.0001).
5.1.4. Discussion
The role of parathyroid imaging as a routine procedure prior to 
parathyroidectomy remains controversial. A recent "Consensus" statement from 
the National Institutes of Health in the United States has suggested that 
parathyroid imaging should be reserved only for patients who have had a failed 
neck exploration (165). Some evidence exists, however, that the use of pre- 
operative parathyroid imaging may both reduce operating time and result in an 
increased number of successful operations (176).
Many different techniques have been used in an attempt to localise parathyroid 
adenomas. At the present time the most widely used techniques include 
thallium/technetium subtraction scanning, 10MHz ultrasound, computed 
tomographic (CT) scanning and magnetic resonance imaging (MRI) (451). Only 
one study to date has prospectively compared these 4 modalities (184). 
Specificities of all 4 of these techniques was generally high (87-95%), however 
sensitivities were not so good, with thallium/technetium scanning best at 73% 
and high resolution ultrasound poorest at 55%.
Direct comparison between thallium/technetium scanning and high resolution 
ultrasound generally shows both techniques are comparable with specificities 
very high and sensitivities in the range 74-80% (185,186). Roses et al.(453),
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however, in a study of 36 patients with PHPT noted a sensitivity of only 49% for 
thallium/technetium subtraction scanning and 34% for ultrasound. Results were 
similar in this present study, with thallium/technetium subtraction scanning only 
having a sensitivity of 42% in localising parathyroid adenomas with the 
sensitivity of 10MHz ultrasound being even less good at 38%. These sensitivities 
are less good than the figures quoted in many of the initial studies using these 
modalities. Many of the initial studies with thallium/technetium scanning quoted 
sensitivities of the order of 65 to 90% (178,179,183). Similarly sensitivities of 
around 70 to 80% were quoted for 10MHz ultrasound (180). However, other 
more recent studies have not been able to achieve sensitivities as high as in these 
initial series (184,451,452). The reason for this discrepancy is not clear, however 
the most important variable in localising a parathyroid adenoma appears to be 
gland size (184). With respect to thallium/technetium subtraction scanning 
Gimlette et al.(454) noted the lower limit of detectability to correspond to a 
gland size of around 250mg. The smallest gland detectable in this present study 
was 150mg, though in keeping with Gimlette's data (454) the median gland size 
in those patients with positive thallium/technetium scans was significantly higher 
at 750mg. With the use now of multichannel serum calcium analysers, 
hypercalcaemia is now to be found commonly as a chance occurrence and the 
average degree of hypercalcaemia at presentation is less marked than was 
previously the case (47). Since, as has been demonstrated in this study, serum 
calcium concentration is related to gland size, it may be that the mean size of 
parathyroid adenomas being treated surgically today is less than was previously 
the case and therefore any imaging technique is likely now to be less effective. 
Another possible factor to be taken into account is the fact that parathyroid 
hyperplasia is less easy to localise on imaging (184) - possibly because the 
glands tend to be smaller than parathyroid adenomas (452) - and if a greater 
proportion of patients in any given group had primary hyperparathyroidism 
secondary to hyperplasia rather than a solitary adenoma, then the sensitivity of
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the localising technique used may be less good. This could not account for the 
poor sensitivities seen in this study as parathyroid hyperplasia was only present 
in 1/25 patients.
Where both these techniques are carried out the overall sensitivity is higher than 
with either thallium/technetium scanning or ultrasound alone. Krubsack et 
al.(184) noted an overall sensitivity of 85% when thallium/technetium scanning 
and ultrasound were combined. Combining three or even four imaging 
techniques, however, did not add further to the sensitivity observed. Similarly 
Gooding et al.(186) found combining thallium/technetium scanning with 
ultrasound to be more sensitive than either technique alone and these authors 
recommended that both these techniques should be used together in the pre­
operative assessment of the patient with primary hyperparathyroidism as both 
these techniques appear to be complementary. However, given the fact that 
ultrasound involves no exposure to radioactivity, the logical sequence of 
investigation would be to carry out high resolution ultrasound first. If this is 
positive, proceed to surgery. If this is negative a thallium/technetium scan should 
also then be carried out prior to surgery. While this sequence of investigation 
would appear attractive the fact that 44% of patients in this study had negative 
results for both techniques would appear to limit their usefulness even when 
combined.
This studv has only investigated the use of imaging at the time of first neck 
exploration and furthermore only those patients with adenomas in the neck were
studied. The effect of surgery in distorting tissue planes is such that
thallium/technetium scanning is probably the investigation of choice in patients
who have had a previous unsuccessful neck exploration (455). However, some
evidence exists that in this situation an experienced operator may achieve similar
results to Tl/Tc scanning with high resolution ultrasound (186). Furthermore
thallium/technetium scanning is probably also the technique of choice where a 
mediastinal adenoma is suspected (179). Advances are also taking place in 
attempting to improve the sensitivity of nuclear medicine imaging, particularly 
with the use of 99m-technetium-sestamibi in place of 201-thallium (456) - 
however, the place of this technique in routine imaging remains to be 
established.
While evidence exists that preoperative parathyroid localisation may be 
beneficial, results from this study suggests that neither thallium/technetium 
subtraction scanning nor high resolution ultrasound are sufficiently sensitive 
alone to be of value in the routine assessment of patients with primary 
hyperparathyroidism. This is particularly the case where hypercalcaemia is 
relatively mild. There may be a place, however, for combining these two 
techniques. Further studies are required to specifically address this issue.
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5.2 Augm entation of parathyroid 201-Thallium/99m-Technetium 
scanning  by infusion of trisodium  edetate.
5.2.1 Introduction
The previous study illustrated that, in general, conventional imaging methods do 
not have the necessary sensitivity to be useful in the routine pre-operative 
assessment of primary hyperparathyroidism. In this study an attempt was made 
to increase the metabolic activity of the parathyroid glands in an attempt to 
stimulate increased parathyroid uptake of radiolabelled thallium.
5.2.2 Patients and methods
Six patients (four female) were studied (table 5.2). As before, the diagnosis of 
primary hyperparathyroidism was made by the finding of hypercalcaemia and a 
PTH concentration elevated or inappropriate to the prevailing serum calcium. All 
of the patients included in this study had had a negative standard 201 - 
thallium/99m-technetium (Tl/Tc) subtraction scan carried out in the preceding 6 
months, and thus acted as their own control.
Ninety minutes before the repeat scan was carried out these patients were 
commenced on an infusion of the calcium chelating agent, trisodium edetate at a 
dose of 24mg/kg/hour. This was administered in 500ml 0.9% saline along with 
10ml 1% lignocaine to relieve any local arm discomfort which may be associated 
with this infusion. Blood samples were taken before and during this infusion 
from the opposite arm.
Table 5.2
Clinical and biochem ical param eters of patien ts stud ied  (values 
show n are m eans: calcium  adjusted  for serum  albumin)
Age (years) 71.8
range 57-80
Serum calcium (mmol/1) 2.80
range 2.70-2.95
PTH (pmolA) 6.0
range 3.5-9.0
PcAMP (nmol/1) 24.9
range 17-30.2
PTH - parathyroid hormone
PcAMP - plasma cyclic adenosine monophosphate
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Statistical analyses of changes in calcium, PTH and plasma cAMP (PcAMP) 
before and during infusion of trisodium edetate was carried out using a paired 
Student's t-test.
5.2.3 Results
Following the repeat scan three patients had areas of discordant thallium uptake 
on the subtraction images (figures 5.2a&b, 5.3a&b and 5.4a&b), consistent with 
the presence of a parathyroid adenoma. The scans in the remaining three patients 
were again negative. Of the three patients with positive scans, two went on to 
have surgery and a parathyroid adenoma was found at the site corresponding to 
the scan appearances in both instances. It is not known whether the remaining 
patients had adenomas as the one further patient with a positive scan refused 
surgery and those with negative scans were managed conservatively.
During the infusion of trisodium edetate the mean fall in total serum calcium 
(±SEM) was 0.42mmol/l (±0.04, p<0.0001), the mean rise in PTH was 
15.6pmol/l (±3.3, p<0.0005) and the mean rise in PcAMP was 2.44nmol/l 
(±1.50, p=NS). Interestingly PcAMP only rose in three patients and only one of 
those subsequently developed a positive scan.
There were no side-effects from the infusion of trisodium edetate and no patient 
was symptomatic from their relative hypocalcaemia.
5.2.4 Discussion
The study described in section 5.1 along with previous studies by other authors 
have suggested that parathyroid localisation by Tl/Tc subtraction scanning may 
be less good where primary hyperparathyroidism is mild and the adenomatous
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Figure 5-2a
Patient 1
Original 201-thallium/99m-technetium (Tl/Tc) subtraction scan carried out prior
to trisodium edetate augmented scan.
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Figure 5-2b
Patient 1
201-thallium/99m-technetium (Tl/Tc) subtraction scan carried out after infusion of
trisodium edetate. Arrow indicates area of discordant thallium uptake corresponding
to site of parathyroid adenoma.
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Figure 5-3a
Patient 2
Original 201-thallium/99m-technetium (Tl/Tc) subtraction scan carried out prior
to trisodium edetate augmented scan.
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Figure 5-3b
Patient 2
201-thallium/99m-technetium (Tl/Tc) subtraction scan carried out after infusion of
trisodium edetate. Arrow indicates area of discordant thallium uptake corresponding
to site of parathyroid adenoma.
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Figure 5-4a
Patient 3
Original 201-thallium/99m-technetium (Tl/Tc) subtraction scan carried out prior
to trisodium edetate augmented scan.
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Figure 5-4b
Patient 3
201-thallium/99m-technetium (Tl/Tc) subtraction scan carried out after infusion of
trisodium edetate. Arrow indicates area of discordant thallium uptake corresponding
to site of parathyroid adenoma.
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gland is small (184,457). The results in this study would suggest that this 
modified method may be useful for these patients should their initial scan be 
negative.
It has been previously noted that creating relative hypocalcaemia in patients with 
primary hyperparathyroidism (even though the albumin adjusted calcium 
remains above the reference range) will trigger PTH secretion (160). Thallium is 
thought to substitute for potassium in the ATPase dependent sodium/potassium 
pump (458). Thallium, therefore, acts as a specific marker of cellular activity and 
uptake of thallium is greater where cellular metabolic activity is increased. It 
may be that by triggering PTH secretion, the metabolic activity of the 
parathyroids has been increased to the extent that greater thallium uptake will 
ensue. In this context it is interesting and surprising that PcAMP, which is 
thought to be a marker of cell metabolic activity (459), was not raised in each 
case and in 2/3 instances where it was raised the repeat scan was negative. 
However, it is also known that changes in other hormones affect PcAMP 
including catecholamines and glucagon (459) and it is possible that changes in 
these hormones may be contributing to the variability seen with PcAMP.
The reason for some scans remaining negative is unclear, though it is possible 
that these patients either had very small adenomas or parathyroid hyperplasia 
which tends not to show well on 201Tl/99mTc subtraction scanning (184).
The infusion of trisodium edetate was well tolerated in all patients. The most 
common complaint with administration of this drug is local discomfort in the 
area of the vein into which the drug is being infused. This side-effect was 
virtually eliminated by adding a small amount of lignocaine to the infusion.
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Although significant rises in PTH were seen, this was associated with only 
relatively modest changes in serum calcium which in all cases fell to levels 
within the normal reference range and therefore, as might have been expected, no 
patient developed symptoms of hypocalcaemia.
In summary it would appear that by creating relative hypocalcaemia and 
transiently increasing PTH secretion localisation of parathyroid adenomas may 
be improved on Tl/Tc subtraction scanning. Because of the additional 
complexity of administering an infusion of the chelating agent, this technique is 
probably best reserved for those patients who have had negative conventional 
Tl/Tc subtraction scans and/or unsuccessful surgery.
CHAPTER 6
PAM1PR0NATE IN THE MANAGEMENT OF HYPERCALCAEMIA
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6.1 A com parison of low versus high dose  pam idronate in cancer- 
assoc ia ted  hypercalcaem ia
6.1.1 Introduction
The previous chapters have illustrated the clinical application of currently 
available biochemical and imaging techniques in the understanding and 
management of various aspects of metabolic bone diseases. The next two 
chapters illustrate the use of the bisphosphonate, pamidronate in the treatment of 
various disorders of bone and calcium metabolism.
Bisphosphonates have been shown to be effective in the management of cancer- 
associated hypercalcaemia (130,134-140), and have now probably become the 
treatment of choice (134). The optimum dose of pamidronate, however, remains 
controversial (140,141-143). On the basis of data from Thiebaud et al.(141), it is 
currently recommended that the dose of pamidronate be titrated against the 
prevailing serum calcium, with 30mg suggested for mild hypercalcaemia 
(<3.00mmol/l) rising up to 90mg for severe hypercalcaemia (>4.00mmol/l). In 
previous studies, however, no evidence of any difference in calcium lowering 
response has been reported in the ranges 15-45mg (140) or 30-60mg (142).
In this study the effects of randomly allocating 30mg and 90mg doses was 
investigated in patients with varying degrees of cancer-associated 
hypercalcaemia.
6.1.2 Patients and methods
32 patients with cancer-associated hypercalcaemia were randomly allocated to 
receive either 30mg pamidronate intravenously in 500ml 0.9% saline over 4
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hours (n=16) or 90mg pamidronate in 1 litre 0.9% saline given over 24 hours 
(n=16). These dilutions and infusion intervals were chosen in keeping with what 
is currently recommended by the manufacturers (Ciba Geigy Ltd, Horsham, UK). 
All treatments were given after 48 hours of rehydration with a minimum of 4 
litres 0.9% saline. After pamidronate was given, saline rehydration was 
continued for a further 48 hours with each patient receiving a minimum of 2 
litres saline per day.
None of the patients had received chemotherapy or radiotherapy in the 4 weeks 
up to, or for at least 10 days after pamidronate therapy. None had been 
previously treated with a bisphosphonate or other anti-hypercalcaemic drug. 
Chemotherapy was commenced in 1 patient with myeloma in the 30mg group 
and 2 patients with myeloma in the 90mg group at between 10 and 14 days post 
pamidronate therapy.
An assessment was made of the presence and extent of bony metastases on the 
basis of a radionuclide bone scan as described in section 3.1.
Measurement was made of serum calcium and urinary calcium/creatinine 
(Ca/Cr) ratio at days 0 (pre-treatment), 1,2,3,6 and 9.
Differences between and within treatment groups was assessed by two-way 
analysis of variance (ANOVA) and Chi squared test. Results are described as 
means ±SEM.
6.1.3 Results
Relevant clinical and biochemical details for each group are shown in table 6.1. 
There was no significant difference between the groups in terms of serum
Table 6.1
Pre-treatm ent biochemical param eters, tum our types and bone
m etas ta ses  in the two treatm ent groups. (Values show n are  m eans)
30mg group 90mg group
Serum calcium(mmol/l) 3.23 3.31
(+/-SEM, range) (0.08,2.80-3.85). . . . (0.07,2.90-3.75)
Serum creatinine(umol/l) 103 97
(+/-SEM,range) (15,55-150) (13,60-150)
PTH(pmol/i) <0.8 <0.8
(14/16 patients) (14/16 patients)
NcAMP(nmol/l GF) 40.4 53.8
(+/-SEM,range) (12.7,1.8-182.8) (9.3,6.3-118.4)
Urine Calcium/creatinine 2.12 1.65
(+/-SEM, range) (0.36,0.55-4.77) (1.65,0.77-4.83)
TmP04(mmol/l GF) 0.65 0.74
(+/-SEM,range) (0.08,0.34-1.10) (0.08,0.31-1.40)
Tumour types:
Bronchial 6 6
Breast 4 3
Others* 6 7
Bone metastases:
None 2 2
Light load 12 10
Heavy load 2 3
Unknown 1
*Other tumour types were:
30mg: myeloma (2), renal, tongue, bladder, anaplastic (unknown primary). 
90mg: myeloma (2), renal, bladder (2), mouth, adenocarcinoma (unknown 
primary).
PTH - parathyroid hormone
NcAMP - nephrogenous cyclic adenosine monophosphate 
TmP04 - renal tubular threshold for phosphate reabsorption
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calcium, creatinine, PTH, NcAMP, urinary Ca/Cr or TmP04. PTH values were 
just detectable in 2 patients in each group (1.4,1.9pmol/l [30mg group] and 
1.4,1.6pmol/l [90mg group]), though this was measured after 48 hours of saline 
rehydration in which time there was a slight fall in serum calcium. Tumour types 
were well matched in both groups with bronchial carcinoma being most common 
followed by breast carcinoma. Presence and extent of bone metastases was also 
similar in the two groups.
The response of serum calcium following treatment is shown in figure 6.1. It can 
be seen that serum calcium fell to a nadir of 2.48mmol/i (±0.06) at day 6 in the 
30mg group and to 2.51mmol/l (±0.03) at day 9 in the 90mg group. Using 
analysis of variance there was no relationship between serum calcium and the 
dose of pamidronate given (F=2.90, df= 1/180, p=NS), though serum calcium 
fell significantly in both groups post-treatment (F=48.5, df= 5/180, p<0.01). At 
the mean serum calcium nadir, 10 patients in the 30mg group were 
normocalcaemic compared with 8 patients in the 90mg group (Chi squared = 
0.31, p=NS). Even when the results for those patients with more severe pre­
treatment hypercalcaemia (ie serum calcium >3.30mmol/l, n=7 in each group) 
(figure 6 .2) were analysed, while again pamidronate was successful in restoring 
normocalcaemia (F=30.5, df= 5/72, p<0.01), there was no significant difference 
between the two groups (F=0.06, df= 1/72, p=NS). Furthermore, there were no 
major differences in the tumour types between these two subgroups (table 6 .2). 
The nadir in serum calcium was again at day 6 in the 30mg group at 2.56mmol/l 
(±0.12) and at day 9 in the 90mg group at 2.57mmol/l (±0.09).
Though the nadir serum calcium was obtained at day 6 in the 30mg group and 
day 9 in the 90mg group, the differences between day 6 and 9 were marginal and 
not indicative of a significant difference in response.
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Figure 6.1
Changes in serum adjusted calcium in the two treatment groups. Points shown 
are means ± SEM. Pamidronate was given on day 0 (n=16 for each group).
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Figure 6.2
Changes in serum adjusted calcium following pamidronate treatment in the 
subgroup of patients with more severe hypercalcaemia (pre-treatment calcium 
>3.30mmol/l). Points shown are means ± SEM. Pamidronate was administered 
on day 0 (n=7 in each group).
Table 6.2
Tumour types in the subgroup  with more severe  hypercalcaem ia 
(serum  calcium  >3.30mmol/l).
30mg 90mg
Bronchus(2) Bronchus(2)
Breast (2) Breast (2)
Tongue Tongue
Myeloma Myeloma (2)
Bladder
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Hypocalcaemia did not occur in either treatment group nor were there any 
significant side-effects associated with either treatment regimen other than 
asymptomatic post-treatment pyrexia in 2 patients in each group.
Similarly for urinary Ca/Cr (figure 6.3), the nadir in both groups was reached at 
day 6 of 0.33 (±0.05) in the 30mg group and 0.37 (±0.10) in the 90mg group 
(F=21.5, df= 5/180, p<0.01). Again no significant differences were evident 
between the two treatment groups (F=1.5, df= 1/180, p=NS). There was a 
suggestion of a slight rise in Ca/Cr in the 30mg group but this was marginal and 
not statistically significant.
Normocalcaemia was achieved in 11/11 patients where pre-treatment Nc AMP 
was within the reference range as opposed to 7/17 patients where NcAMP was 
elevated (figure 6.4). Mean nadir of serum calcium was 2.48mmol/l (range 2.30- 
2.60) in the normal NcAMP group versus 2.67mmol/l (range 2.30-3.30) in the 
elevated NcAMP group (p=0.01, Mann-Whitney U-test).
Follow up values for serum calcium were available in 6 patients in the 30mg 
group and 8 patients in the 90mg group. Relapse in hypercalcaemia was defined 
as a rise in serum calcium to within 0.05mmol/l of the pre-treatment value (135). 
The mean number of days to relapse was 38 (range 18-90) in the 30mg group and 
34 (range 11-105) in the 90mg group. Pre-treatment serum calcium was similar 
in both these subgroups (3.32mmol/l, range 2.75-3.75 [30mg group] and 
3.41mmol/l, 2.90-3.75 [90mg group]). Tumour types in these two subgroups 
were similar (table 6.3), which excludes tumour variation as the reason behind 
the lack of a dose-response.
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Figure 6.3
Changes in fasting urinary calcium/creatinine (Ca/Cr) ratio (mmol/mmol). Points 
shown are means ± SEM. Pamidronate was given on day 0. (n=16 for each 
group).
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Figure 6.4
Nadir serum calcium obtained in patients with normal and elevated 
nephrogenous cyclic adenosine monophosphate (NcAMP) pre-treatment. Bars 
represent means.
Table 6.3
Tumour types in those  patien ts w ho show ed a relapse in 
hypercalcaem ia after treatm ent
30mg 90mg
Bronchus(2) Bronchus(3)
Breast Breast
Tongue Tongue
Myeloma Myeloma
Bladder Anaplastic carcinoma
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6 .1 .4  D iscussion
Both treatment regimens in this study were equally effective in both restoring 
serum calcium to normal and in maintaining normocalcaemia with no evidence 
of an improved rate of response with the higher dose.
While NcAMP and TmP04 were a little higher and urinary Ca/Cr lower in the 
90mg group pre-treatment, these differences were not statistically significant and 
are unlikely to account for the treatment effect observed.
The hypercalcaemia was due to a variety of tumours which were represented 
approximately equally in both treatment groups. Furthermore, tumour types were 
well matched in the subgroups described, and pre-treatment serum calcium levels 
were similar in those patients who relapsed. This would make it unlikely that the 
lack of a difference in response to the two different doses was due to differences 
in the spread of tumour types or serum calcium levels in the two groups. 
Similarly, the presence and extent of bone metastases were similar in both 
groups.
NcAMP values were generally raised in both groups; in the face of low or 
generally undetectable PTH levels this suggests that parathyroid hormone-related 
protein (PTHrP) was probably responsible for most instances of hypercalcaemia. 
It is postulated that bisphosphonates tend to be less effective where a PTHrP 
mediated mechanism of hypercalcaemia is thought to operate, as illustrated, for 
example, where TmP04 is low (146). This would also appear to be the case in 
this study where those patients with elevated levels of NcAMP (and presumably 
also PTHrP) appear to respond less well to pamidronate than when NcAMP 
levels are lower. However, since pre-treatment NcAMP levels were similar in 
both groups this fact would not account for the treatment effect observed.
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The calcium lowering effect of pamidronate is due to a combination of inhibition 
of osteoclastic recruitment and formation, which is seen with very low doses of 
pamidronate (460,461), and direct osteoclastic cytotoxicity (462). This former 
effect means that pamidronate may be effective even in very low doses. Previous 
work by Body et al.(143) has shown the presence of a dose response at very low 
doses (<0.05mg/kg body weight) and at standard doses, such as would be used 
therapeutically, there was no significant difference in efficacy. This has also 
been the experience in the clinical situation at Glasgow Royal Infirmary (140). 
Ralston et al.(140) previously reported that there is no difference either in 
calcium lowering effect or in duration of effect when pamidronate is used at 
doses of 15, 25 and 45mg nor does the duration of infusion create any difference. 
Only when doses as low as 5mg are used does the calcium lowering effect appear 
to diminish. Davis and Heath (142) have similarly shown no difference in 
calcium lowering action between 30mg and 60mg doses.
While Thiebaud et al.(141) have suggested that a dose response effect exists at 
all doses from 30mg through to 90mg, this study was not properly prospective 
nor were patients randomly allocated to treatment groups as those patients with 
modest hypercalcaemia were excluded from the 90mg group. Furthermore, 
patients in this study who were given higher doses of pamidronate tended to have 
poorer renal function than those treated with lower doses and this raises the 
possibility that the apparently greater calcium lowering effect at high dose may 
have come from an improvement in renal function rather than a greater effect on 
suppressing bone resorption.
While higher doses of pamidronate may obviously be indicated in certain cases 
of resistant hypercalcaemia (144,145), the data from this study would suggest 
that, in routine practice, on average there is little difference in the acute response 
to 30mg and 90mg pamidronate. In the first instance, therefore, a single infusion
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of 30mg pamidronate in 500ml 0.9% saline infused over 4 hours is recommended 
in the treatment of cancer-associated hypercalcaemia.
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6.2 Factors predicting the acu te  effect of pam idronate on serum  
calcium  in cancer-associated  hypercalcaem ia.
6.2.1 Introduction
In the previous study measurement of NcAMP pre-treatment seemed to be of 
some value in predicting the effect of pamidronate upon serum calcium levels. In 
this study a retrospective analysis was made between various pre-treatment 
biochemical and clinical variables and the acute serum calcium response to 
pamidronate in cancer-associated hypercalcaemia.
6.2.2 Patients and methods
Results from 35 patients with cancer-associated hypercalcaemia treated with 
different doses of pamidronate were reviewed. The dose of pamidronate that 
these patients had received had been determined randomly.
Thirteen patients received 30mg and nine 45mg pamidronate as a single 
intravenous infusion in 500ml 0.9% saline administered over 4 hours. A further 
13 patients received 90mg pamidronate in 1 litre 0.9% saline administered over 4 
hours. Five of the patients given 30mg and ten of those given 90mg had been 
included in the previous study.
Patient characteristics are shown in tables 6.4 and 6.5. Treatment was 
administered and all measurements were made after rehydration with a minimum 
of 4 litres 0.9% saline over 48 hours. No patient received any other treatment 
which would interfere with their calcium metabolism either during the period of 
study or for at least 1 month prior to study and no patient had been previously 
treated with a bisphosphonate.
Table 6.4
Pre-theraDV biochemical param eters of the three treatm ent aroups.
Values show n are m eans.
30mg 45mg 90mg
Serum calcium (mmol/1) 3.25 3.41 3.32
(pre-treatment)
SEM 0.09 0.15 0.08
range 2.90-3.85 2.85-4.35 2.90-3.75
Serum calcium (mmol/1) 2.62 2.56 2.63
(nadir)
SEM 0.08 0.07 0.04
range 2.30-3.25 2.20-2.75 2.35-2.85
PTH generally undetectable (see text)
11/13 patients 7/8 11/13
NcAMP (nmol/1 GF) 45.4 41.9 52.5
SEM 13.2 7.9 10.0
range 9.1-182.8 15.5-74.6 6.3-118.4
TmP04 (mmol/1 GF) 0.63 0.78 0.75
SEM 0.10 0.09 0 .12
range 0.34-1.30 0.48-1.40 0.36-2.05
TmCa (mmol/1 GF) 2.66 2.73 2.40
SEM 0.09 0.16 0.07
range 2.14-3.37 2.27-3.71 1.94-2.83
NaE (mmol/l GF) 4.3 3.9 3.5
SEM 1.1 1.7 0.9
range 1.5-11.2 2.2-5.5 0.3-11.0
CaE (umol/L GF) 197 224 151
SEM 43 65 21
range 46-461 42-574 29-362
Urine calcium/creatinine
(mmol/mmol) 2.09 1.65 1.46
SEM 0.38 0.50 0.18
range 0.55-4.77 0.56-4.78 0.37-2.58
Table 6.5
Pre-therapy biochem ical and clinical param eters of the su b g ro u p s of 
good and poor responders . Values show n are m eans. **p=0.004.
Good Responders Poor Responders
Serum calcium (mmol/1) 3.31 3.32
(SEM, range) 0.08,2.90-4.35 0.08,2.85-3.85
NcAMP (nmol/1 GF) 29.6 65.0**
(SEM, range) 6.3,6.3-182.8 9.4,18.8-118.4
TmP04 (mmol/1 GF) 0.75 0.65
(SEM, range) 0.06,0.44-1.40 0.09,0.34-1.10
TmCa (mmol/1 GF) 2.56 2.53
(SEM, range) 0.10,2.14-3.71 0.07,1.94-2.92
Dose pamidronate
30mg 8 5
45mg 4 5
90mg 6 7
Tumour types
Bronchial 6 6
Breast 3 6
Others* 9 5
Bone metastases
None 2 3
Light 10 10
Heavy 3 2
Unknown 3 2
*Other tumour types were:-
Good Responders: myeloma (2), bladder (2), renal (3), tongue, neck. 
Poor responders: bladder, renal adenocarcinoma (2), tongue, larynx.
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The main parameters measured were NcAMP, TmP04 and TmCa pre-treatment. 
Furthermore, an assessment was made of the presence and extent of bone 
metastases by review of standard radionuclide bone scan films as described in 
section 3.1.
Analysis of the data was carried out by comparing the nadir of serum calcium 
obtained in days 1-9 of treatment with the pre-treatment level of NcAMP, 
TmP04 and TmCa by Kendall Rank Correlations. Since we have already shown 
in the previous study that the dose of bisphosphonate administered does not 
influence the acute response of serum calcium, this was not considered further in 
these correlations. Correlations between NcAMP and TmP04 and NcAMP and 
TmCa were also made using Kendall Rank Correlations. Differences between 
groups were assessed using a Student's t-test.
6.2.3 Results
Patients were subdivided into two groups by the post-treatment serum calcium 
values; those who were rendered normocalcaemic (adjusted calcium 
<2.60mmol/l); "good responders") and those who remained hypercalcaemic 
(adjusted calcium >2.60mmol/l); "poor responders").
It can be seen from table 6.4 that the three treatment groups were similar 
biochemically. From table 6.5 it can be seen that there was no significant 
difference in the dose of pamidronate given between the good and poor 
responders, or in the pre-treatment serum calcium or TmCa. Furthermore, tumour 
types and presence and extent of bone metastases were also similar in these two 
groups. Pre-treatment NcAMP values were significantly higher in the poor 
responders (mean±SEM: 65.0±9.4nmol/l GF versus 29.6±6.3nmol/l GF, 
p=0.004). However, while pre-treatment TmP04 values tended to be lower in
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poor responders (mean±SEM: 0.65±0.09mmol/l GF versus 0.76±0.06mmol/l GF) 
this was not statistically significant (figures 6.5 and 6 .6).
A significant correlation was present between pre-treatment NcAMP and nadir 
serum calcium (r=0.45, p=0.0001) (figure 6.7). A significant negative correlation 
was also present between pre-treatment TmP04 and nadir serum calcium (r= - 
0.41, p=0.003) (figure 6 .8). No significant correlation was found between TmCa 
and nadir serum calcium (r=0.11, p=NS) (figure 6.9). A significant negative 
correlation was evident between NcAMP and TmP04 (r= -0.35, p=0.003), 
however, there was no significant correlation between NcAMP and TmCa or 
TmP04 and TmCa.
The correlations do not hold in every case. For example, in figure 6.5, one 
patient has very high pre-treatment NcAMP (182.8nmol/l GF) but shows a good 
response in terms of serum calcium (nadir 2.40mmol/l). The reason for these 
discrepancies is not clear.
When the normal ranges for NcAMP, TmP04 and serum calcium are considered 
(figures 6.6 and 6.7), 13/18 patients with NcAMP values <27nmol/l GF were 
rendered normocalcaemic by pamidronate whereas 16/17 patients with NcAMP 
values >27nmol/l GF remained hypercalcaemic. NcAMP as a predictor of the 
acute response of serum calcium to pamidronate, therefore, has a sensitivity of 
83% and a specificity of 72%. Although 7/12 patients with pre-treatment TmP04 
values >0.70mmol/l GF were also rendered normocalcaemic, normocalcaemia 
was also achieved in 7/23 patients where TmP04 was <0.70mmol/l GF. TmP04, 
therefore, as a predictor of the acute response of serum calcium has a sensitivity 
of 66% and a specificity of 58%.
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Figure 6.5
Pre-treatment levels of nephrogenous cyclic adenosine monophosphate 
(NcAMP) shown against patients divided into good and poor responders (good 
responders = nadir serum calcium within the reference range) (p=0.004). Bars 
represent means. Dose of pamidronate administered is also shown.
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Figure 6.6
Pre-treatment levels of renal tubulular threshold for phosphate reabsorption 
(Tm P04) shown against patients divided into good and poor responders (good 
responders = nadir serum calcium within the reference range) (p=NS). Bars 
represent means. Dose of pamidronate administered is also shown.
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Figure 6.7
Level of pre-treatment nephrogenous cyclic adenosine monophosphate (NcAMP) 
expressed against nadir value of serum calcium obtained in the first 9 days of 
treatment (r=0.45, p=0.0001). Vertical dotted lines indicate the upper limit of the 
reference range for serum calcium and horizontal dotted lines the upper limit of 
the reference range for NcAMP.
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Figure 6.8
Level of pre-treatment renal tubular threshold for phosphate reabsorption 
(TmP04) expressed against nadir serum calcium obtained in the first 9 days of 
treatment (r= -0.41, p=0.003). Vertical dotted lines indicate the upper limit of the 
reference range for serum calcium and horizontal dotted lines indicate the lower 
limit of the reference range for TmP04.
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Figure 6.9
Level of pre-treatment renal tubular threshold for calcium reabsorption (TmCa) 
expressed against nadir serum calcium obtained in the first 9 days of treatment 
(r=0.11, p=NS). Vertical dotted lines indicate the upper limit of the reference 
range for serum calcium and the horizontal lines indicate the upper limit of the 
reference range for TmCa.
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Only 5 of the 35 patients had detectable PTH, and in these patients the PTH 
concentrations remained at the lower limit of the reference range.
6.2.4 Discussion
In this study, of all the clinical and biochemical variables which were assessed, 
only NcAMP provided the necessary degree of sensitivity (93%) and specificity 
(72%), for the accurate prediction of response to pamidronate therapy in clinical 
practice.
As described previously, the presence of factors indicative of PTH-like activity 
in the absence of PTH, implies the presence of PTHrP (85,92). Although the 
presence of other factors such as interleukin-1 (IL-1) may be implicated to a 
greater or lesser extent in some instances of cancer-associated hypercalcaemia, 
the presence of these other factors would not cause a rise in NcAMP (463). 
PTHrP is thought to cause hypercalcaemia by increasing bone resorption and 
increasing the renal tubular reabsorption of calcium (83-85,88). Since 
pamidronate acts by inhibiting bone resorption (460,461,462) and does not have 
a direct renal effect, it is likely to be most effective where hypercalcaemia is due 
to increased bone resorption alone. When PTHrP levels are thought to be 
elevated, therefore, pamidronate is likely to be less effective. These data would 
be consistent with this theory.
These results differ from those of Gurney et al.(146), who looking at only 15 
patients, suggested that those patients who had a lower pre-treatment TmP04 
responded less well to pamidronate. While TmP04 may indeed tend to be lower 
in poor responders (as has been shown in this study), the spread of the data is 
such that TmP04 cannot be used with any confidence for predictive purposes. 
Gurney et al.(146) failed to show any correlation between pre-treatment NcAMP
144
and serum calcium response. This was probably due to the small numbers of 
patients in their study where NcAMP data was available. However, in agreement 
with Gurney et al.(146), data from this present study showed that TmCa did not 
predict the response of serum calcium to pamidronate. This is perhaps because 
both an increase in bone resorption and an increase in PTH (and probably also 
PTHrP) mediated renal tubular calcium reabsorption are associated with an 
elevated TmCa (464), and this parameter cannot distinguish between humoral 
and non-humoral hypercalcaemia.
In summary, this study shows that pre-treatment levels of NcAMP but not 
TmP04 or TmCa may predict the acute response of serum calcium to 
pamidronate. In clinical practice it appears there is a sub-group of patients who 
are resistant even to large doses and multiple infusions of pamidronate (144,145), 
and a single measurement of NcAMP - or probably also PTHrP - seems likely to 
predict these patients. Their treatment, however, remains problematical. 
Assuming that the hypercalcaemia is being driven by PTH-like factors, such as 
PTHrP, what is needed is a specific agent which will block the action of these 
tumour products at the site at which they act - the PTH receptor.
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6.3 The u se  of ionised calcium in monitoring the calcium  lowering 
effect of pam idronate
6.3.1 Introduction
In the previous two studies the measurement obtained of serum calcium was 
adjusted to take into account the prevailing serum albumin concentration. Since 
serum albumin levels are generally low in patients with cancer (150), it is 
important that these are taken into account in the assessment of hypercalcaemia. 
Failure to do so will result in the incidence of hypercalcaemia being significantly 
underestimated (147). Although calcium in serum is highly protein bound (20), it 
is also known that changes in this calcium/protein binding may occur in critically 
ill patients (465,466) and this may render the usual formulae for calculation of 
adjusted calcium less useful (148). Measurement of ionised calcium is useful in 
such situations (465). In order to determine whether measurement of adjusted 
calcium is a valid way of following the actions of a calcium lowering drug, serial 
measurements of ionised calcium were carried out in patients with cancer- 
associated hypercalcaemia before and after treatment with pamidronate.
6.3.2 Patients and methods
Eight consecutive patients with cancer-associated hypercalcaemia were studied 
and their details are shown in table 6 .6 . Following 48 hours of intravenous 
rehydration with a minimum of 4 litres 0.9% sodium chloride solution, these 
patients were treated with a single intravenous infusion of pamidronate of either 
30mg or 90mg. Serum ionised calcium (ICa), adjusted calcium (AdjCa) and total 
calcium (TotCa) was then measured daily for 7 days. The dose of pamidronate 
given was chosen essentially randomly. Five of the patients included in this study 
had also been included in the study described in 6.1. No patients in this present
study were receiving any drugs thought likely to interfere with their calcium 
homoeostasis either during or for a minimum of 6 months prior to this study. 
Furthermore, no patients were given any drugs which may potentially alter their 
plasma protein binding and none required blood transfusion during the study 
period. All blood samples were obtained after overnight fast with the patient in 
recumbency. Prolonged venous stasis was avoided during venepuncture.
Statistical methods used were the Wilcoxon test for paired samples and Linear 
Regression Analysis.
6.3.3 Results
As expected mean serum calcium fell to within or just above the reference range 
irrespective of whether ionised calcium, adjusted calcium or total calcium was 
measured (figure 6.10). Nadir (mean±SEM) ICa was reached at day 7 
(1.28mmol/l±0.04, p<0.001), as was nadir AdjCa (2.61mmol/l±0.04, p<0.001) 
and nadir TotCa (2.26mmol/l±0.05, p<0.001). TotCa, however, had been within 
the reference range for serum calcium from day 3 post-treatment.
The correlations between ICa and AdjCa and ICa and TotCa at each day of 
treatment are shown in table 6.7. It can be seen that there was a very close 
correlation between both AdjCa and ICa and TotCa and ICa pre-treatment Post­
treatment, however, the correlation between TotCa and ICa was inconsistent and 
at times no significant correlation was present between these two variables. This 
was particularly the case on days 1 and 2 and 6 and 7 post-treatment. In contrast, 
though the post-treatment correlation between AdjCa and ICa was also 
somewhat variable, this correlation did generally remain close enough to make 
measurement of adjusted calcium a reasonably accurate reflection of ionised 
calcium levels. The greatest discrepancy between ICa and AdjCa was seen at
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Figure 6.10
Changes in ionised, adjusted and total calcium after treatment. Pamidronate was 
administered on day 0. Points shown are means ± SEM. *p<0.01 **p<0.001
Total Calcium
Table 6.7
C orrelations between ionised calcium  and ad justed  and total 
calcium s before and after treatm ent.
Adjusted Calcium P Total Calcium P
Day 0 r=0.95 0.0001 r=0.86 0.0001
Day 1 r=0.74 0.04 r= -0.14 NS(0.77)
Day 2 r=0.51 NS(0.26) r=0.31 NS(0.68)
Day 3 r=0.91 0.0001 r=0.80 0.01
Day 4 r=0.80 0.05 r=0.82 NS(0.35)
Day 5 r=0.77 0.05 r=0.76 0.05
Day 6 r=0.71 0.04 r=0.15 NS(0.86)
Day 7 r=0.62 NS(0.09) r=0.15 NS(0.77)
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days 2 and 7 post-treatment. One patient with myeloma was included in this 
study and, even in this case, ICa and AdjCa correlated closely after treatment 
(r=0.73). Serum albumin levels pre-treatment were all generally low (mean 
30g/l, range 22-35) and were <30g/l in 3/8 cases. Pre-treatment venous pH 
values were all within the reference range of 7.35-7.45. No significant change in 
pH was noted with treatment.
6.3.4 Discussion
The amount of "free" or ionised calcium in the circulation depends largely on the 
concentration of circulating albumin (467). Serum albumin levels are typically 
low in patients with cancer-associated hypercalcaemia (150) and furthermore, the 
binding affinity of calcium for albumin is not constant at albumin concentrations 
below 30g/l (150) - such as was the case for 3/8 of the patients in this study. 
However, results from this study show that the correlation between ionised 
calcium and adjusted calcium is very close and even after pamidronate therapy, 
while the correlation may be more variable, the discrepancy observed is, on 
average, not likely to be of major clinical relevance.
Correlation between ionised calcium and total calcium pre-treatment was also 
close, though after treatment this relationship tended to be less consistent. 
Furthermore if total calcium was used as a measure of the serum calcium 
response to treatment, many patients would be erroneously described as 
normocalcaemic. In this study total calcium was within the reference range from 
day 3 post-treatment, whereas ionised and adjusted calcium concentrations did 
not fall to the upper limit of the reference range until day 7. The greatest 
discrepancy between ICa and both TotCa and AdjCa was noted in the initial 
period just after pamidronate treatment and again around day 7 after treatment. 
One possible explanation for the discrepancy noted in the initial 48 hours after
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therapy is that intravenous pamidronate may generate an acute phase response 
with pyrexia often prominent (468). A rise in interleukin-6 (IL-6) levels has been 
noted in association with this pyrexia (469) and this in turn may stimulate a rise 
in acute phase proteins (470) which may have a significant effect on calcium 
binding. A less likely explanation is that pamidronate itself is binding calcium 
and therefore reducing ionised calcium levels while at the same time leaving 
both total and adjusted calcium levels unchanged. While it is true that 
bisphosphonates will generally bind divalent cations strongly (471), these drugs 
in general, including pamidronate, have a very short plasma half-life being 
quickly excreted in urine or taken up into bone (472). Any direct effect on serum 
calcium levels are, therefore, likely to be very transient.
The reason why the correlation between ICa and TotCa and AdjCa is less good 
around 7 days after treatment is not clear. By this stage after treatment many 
patients are symptomatically improved (109) and may be more mobile than was 
the case before pamidronate therapy. This increase in mobility may alter plasma 
protein concentrations and when this alteration is not taken into account (as 
where total calcium is measured), the correlation with ICa becomes less reliable. 
This, of course, would not explain changes in the relationship between ICa and 
AdjCa. A second possible explanation is that changes may be occurring which 
affect the measurement of ICa itself. It is known that measurement of ICa 
depends to some extent on the prevailing serum albumin concentrations with ICa 
levels rising where albumin rises (151). In this present study, though no 
statistically significant changes in serum albumin were observed after treatment, 
the mean post-treatment albumin level was lower and it is possible that minor 
changes in serum albumin may have occurred and this in turn may have had a 
direct effect on ICa measurement. This would, therefore, affect the correlation 
both with TotCa and AdjCa.
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It has been suggested that calcium binding to plasma proteins may be altered in 
certain disease states such as myeloma due to the presence of excess 
immunoglobulin. This might mean a normal ionised calcium concentration 
accompanying an increased adjusted calcium concentration. Two case reports 
have described this scenario (473,474). Myeloma was the diagnosis in one 
patient in this study, however this problem was not encountered. Ionised and 
adjusted calcium correlated closely.
Discrepancies between albumin adjusted calcium and ionised calcium 
concentrations have been described in critically ill patients where adjusted 
calcium concentrations may be low though ionised calcium normal (466). It has 
been suggested that this misclassification is due to the presence in the circulation 
of an (unidentified) factor which alters the binding of calcium to albumin (465). 
This problem was not apparent in the patients followed in this study. This may 
suggest that this putative factor is not present in patients with cancer. An 
alternative explanation would be that these patients were at an earlier stage in 
their illness and therefore less unwell than the "critically ill" patients (466) 
studied previously. This would seem unlikely as it has been shown that the 
median life expectancy for patients with cancer-associated hypercalcaemia is 
only 30 days (109).
In this study all ionised calcium measurements were corrected to pH 7.40 to 
correct for losses in carbon dioxide that may have occurred between the time of 
venepuncture and calcium measurement (375). It has been suggested that 
critically ill patients may have alterations in serum pH and that ionised calcium 
results should not, therefore, be pH adjusted (148). The data from this study 
show venous pH to be within normal limits and correction of ionised calcium 
concentrations to pH 7.40 is therefore both valid and desirable.
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Though measurement of ionised calcium is certainly the "gold standard" use of 
this technique presents several practical problems compared with measuring total 
calcium then adjusting for the prevailing albumin concentration. In particular 
samples must be collected anaerobically and analysed as soon as possible, 
generally within 1 hour of collection. As a result few laboratories use ionised 
calcium as a routine measurement and only some studies use this method to 
monitor the effect of treatment after administration of a calcium lowering drug.
In those studies where ICa, TotCa and AdjCa were measured simultaneously 
(475), formal correlations between these parameters were not made and it is 
therefore not possible to draw any conclusion about which method is preferable 
to use.
This study would suggest that while the relationship between ionised calcium 
and adjusted calcium may vary when pamidronate is given, this alteration is 
slight and on average, unlikely to be of any major clinical significance. 
Furthermore, measurement of total (unadjusted) calcium is potentially 
misleading. In routine circumstances, therefore, measurement of adjusted 
calcium is sufficient when monitoring the response to treatment in patients with 
cancer-associated hypercalcaemia.
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6.4 Immobilisation-related hypercalcaem ia: a possib le  novel 
m echanism  and resp o n se  to pam idronate
6.4.1 Introduction
Immobilisation-related hypercalcaemia is characterised by increased bone 
resorption and osteopenia. Increased osteoclastic activity is seen in bone biopsies 
of such patients (196) and biochemical studies have demonstrated increased 
urinary hydroxyproline excretion (197).
Pamidronate acts by inhibiting bone resorption and, as such, might be expected 
to be effective in the treatment of immobilisation-related hypercalcaemia. The 
studies described in sections 6.1 and 6.2 both suggested that pamidronate is less 
effective where parathyroid hormone-related protein (PTHrP) is thought to be 
operative in the pathogenesis of the hypercalcaemia. Since this is not thought to 
be the case in immobilisation-related hypercalcaemia, if this hypothesis is indeed 
correct, the calcium lowering effect of pamidronate may be more sustained, and 
effective at lower doses in patients with immobilisation-related hypercalcaemia 
than is usually the case in cancer-associated hypercalcaemia.
Immobilisation-related hypercalcaemia is usually associated with conditions 
where bone turnover is already increased such as in children, adolescents (191) 
and in patients with Paget's disease of bone (192). This study describes a series 
of patients where these predisposing factors were not present.
6.4.2 Patients and methods
The details of the patients studied are shown in table 6 .8 . All were normally 
hydrated both clinically and biochemically prior to treatment. All infusions of
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pamidronate were given intravenously in 500ml 0.9% saline over 4 hours. A 
diagnosis of sepsis was made in each patient on the basis of elevated white cell 
counts, erythrocyte sedimentation rates (ESR) and positive bacterial culture from 
the site of infection, and in all cases (except patient 3) from blood cultures. At 
the time of study all patients were receiving appropriate antimicrobial therapy. 
None of these patients (was receiving any therapy thought likely to interfere in 
their calcium homoeostasis except patient 4 who was receiving 50mg per day 
prednisolone, though this had been commenced 4 months prior to the 
development of hypercalcaemia.
In patients 1 and 2, PTH was measured by a double antibody radioimmunoassay 
and patients 3,4 and 5 intact PTH(l-84) was measured (see 2.1.2).
Transiliac bone biopsies were carried out after tetracycline double labelling using 
a Meunier trephine needle in patients 2 and 4 prior to treatment.
Statistical assessment of changes in serum calcium and urinary 
calcium/creatinine were carried out using a Mann-Whitney U-test
6.4.3 Results
The response of serum calcium and urinary calcium/creatinine ratio following 
pamidronate treatment is shown in figures 6.11 and 6.12. It can be seen that all 
patients were normocalcaemic by day 3 post-treatment. Patients 1-3 began to 
mobilise soon after pamidronate treatment and remained normocalcaemic. 
Patients 4 and 5 remained immobile and recurrence of hypercalcaemia occurred 
at days 33 and 26 respectively. Calcium/creatinine ratios fell in all patients with a 
nadir at day 3. Figure 6.13 shows the relationship between serum calcium and the 
amount of calcium excreted per unit glomerular filtrate. Values tended to lie to
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Figure 6.11
Changes in adjusted serum calcium after pamidronate therapy (dotted line indicates 
upper limit of the reference range).
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Figure 6.12
Changes in urinary calcium/creatinine ratio following pamidronate therapy 
(dotted lines indicate upper limit of the reference range).
5001
400
HI
uw 300-e
o
(J
X0
e
1  200-
CQ
u
100-
2.0 3.0 3.5 4.0
Patient 1 
Patient 2
Patient 3 
Patient 4 
Patient 5
Corrected serum calcium
Figure 6.13
Relationship between adjusted serum calcium and calcium excretion (CaE). 
Dotted lines indicated two standard deviations from the mean of the normal 
relationship (from Peacock et al.(36)). Arrows indicate post-treatment changes in 
CaE/serum calcium relationship.
the right of the normal reference range described by Peacock et al.(36), though 
this was marginal.
From table 6.8 it can be seen that serum PTH was undetectable in all patients 
except patient 2 where it was measured at the low end of the reference range. As 
might be expected l,25(OH)2D3 levels (where measured) and 25(OH)D3 levels 
were low, possibly reflecting poor nutritional state, lack of sunlight exposure or 
general illness. In patient 5, 25(OH)D3 levels were normal, although this patient 
was receiving total parenteral nutrition which included 200  units per day of 
vitamin D. Hydroxyproline/creatinine (HP/Cr) ratios were markedly elevated in 
all patients pre-treatment. Median value was 0.101 (range 0.045-0.180). 
Similarly pre-treatment urinary calcium/creatinine ratios were markedly 
elevated. Median was 2.50 (range 0.69-3.63).
Marked osteopenia was present histologically in patients 2 and 4 with trabecular 
bone volumes of 21% and 16% respectively (normal >25%). Bone formation 
rates were normal with osteoid surfaces of 9% and 17% (normal <24%). Bone 
resorption, however, tended towards the upper limit of normal with resorption 
surfaces of 6.3% and 5.2% (normal <7.0%). There was no histological evidence 
of hyperparathyroidism and mineralisation was normal. The presence of 
osteopenia was later confirmed clinically in patient 4, as this patient sustained an 
atraumatic vertebral compression fracture.
Relapse was defined as a rise in serum calcium to 2.80mmol/l. In the two 
patients where this occurred a further infusion of pamidronate at the same dose 
as the initial infusion restored normocalcaemia. The duration of normocalcaemia 
varied after this second infusion from 14 days (patient 5) to 97 days (patient 4). 
This may have been because patient 4 became at least partly mobile. Both
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patients were fully mobile after they had received a total of three infusions each 
and normocalcaemia was maintained thereafter.
6.4.4 Discussion
Immobilisation-related hypercalcaemia, though apparently uncommon, is 
important in that complications such as renal stones and osteoporosis may occur. 
In one series (476), over 50% of children immobilised due to spinal cord injury 
who were hypercalcaemic developed urolithiasis. The prolonged period of 
negative calcium balance which occurs as a result of the hypercalciuria 
predisposes to osteoporosis and fracture, an example of this was seen in patient 4 
in this study.
Previous work using radiolabelled calcium (477) and the incorporation of 
tetracycline into bone (44) has suggested that the mechanism of the 
hypercalciuria and osteoporosis is due to increased bone resorption and 
decreased bone formation. The high urinary hydroxyproline/creatinine and 
calcium/creatinine ratios in this study would be consistent with this proposed 
increase in bone resorption. The data from the two bone biopsies in this study, 
however, suggest that bone formation rates are within normal limits.
The patients in this study were significantly older than would usually be the case 
in immobilisation-related hypercalcaemia as this condition usually occurs in 
children and/or adolescents where bone turnover is higher (191). Furthermore, 
there was a greater time interval between the onset of immobilisation and the 
development of hypercalcaemia than is usual. The main feature which all these 
cases had in common was major sepsis with elevated white cell counts in all 
cases. Cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), tumour 
necrosis factors alpha and beta (TNFa,TNFp) and transforming growth factors
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alpha and beta (TGFa,TGFP) have all been demonstrated to be associated with 
increased bone resorption and, in some instances, hypercalcaemia (106,107). 
Furthermore, elevated levels of IL-1 have been described in patients with 
infection post-surgery (478). Unfortunately at the time of this study it was not 
possible to measure these cytokines. However, it may be postulated that the 
presence of some or all of these factors was contributory to the pathogenesis of 
the hypercalcaemia.
Although some calcium excretion (CaE) and associated serum calcium values 
were, when plotted graphically, to the right of the line defining their normal 
relationship (figure 6.13), these were borderline and not indicative of any major 
increase in the renal tubular calcium reabsorption component of the raised serum 
calcium. This feature may simply reflect the fact that these patients did not 
receive intravenous saline rehydration prior to therapy.
Other workers have suggested that calcitonin (197), etidronate (131) and 
clodronate (201) are of some value in the treatment of immobilisation-related 
hypercalcaemia and hypercalciuria. A recent case report, concerning a single 
patient, has also demonstrated that intravenous pamidronate may be useful in the 
management of this condition (202).
The data presented in 6.1 and 6.2 has demonstrated that in patients with cancer, 
PTHrP mediated hypercalcaemia may respond less well to pamidronate, and it 
was suggested that larger doses of this drug be reserved for these patients. This 
study shows that the converse is also true. Immobilisation-related 
hypercalcaemia is not PTHrP mediated and in this study doses of as low as lOmg 
pamidronate were effective and had a sustained calcium lowering effect.
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In conclusion, therefore, pamidronate is both safe and effective as a treatment for 
the hypercalcaemia and hypercalciuria which may accompany immobilisation. 
Furthermore, it would appear that sepsis, possibly by way of cytokine release, 
may also contribute to the pathogenesis of this syndrome.
CHAPTER 7
THE USE OF PAMIDRONATE IN THE TREATMENT OF PAGET'S
DISEASE OF BONE AND OSTEOPOROSIS
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7.1 The u se  of pam idronate in the m anagem ent of P aget's  d isease  of 
bone
7.1.1 Introduction
The results from the previous chapter showed that pamidronate is generally 
effective in inhibiting the increased bone resorption often associated with 
hypercalcaemia. Increased bone resorption is one of the cardinal features of 
Paget's disease of bone. Calcitonin (222,224,232-236) and mithramycin (224) are 
potent inhibitors of bone resorption and have been shown to be effective in 
treating Paget's disease. Significant problems exist, however, with respect to the 
development of resistance to calcitonin (124,479) and the toxicity of 
mithramycin (118-120).
The bisphosphonates have also been shown to be effective in the management of 
Paget's disease (133). Recent work has suggested that pamidronate is both safe 
and effective in the management of this condition (251-257) however, optimum 
dosage regimens are yet to be defined. Furthermore, it is not yet established 
whether a dose/response effect exists with pamidronate in the management of 
Paget's disease. This study aimed to address these points.
7.1.2 Patients and Methods
Patients with symptomatic Paget's disease were recruited for this study. The 
diagnosis of Paget's disease was based on finding characteristic abnormalities in 
biochemistry, radiology and radionuclide bone scanning. Where possible, further 
confirmation was obtained by transiliac bone biopsy. A total of 39 patients were 
included (table 7.1) and the study consisted of two main treatment regimens.
Table 7.1
Profile of patients with P aget's  d isease  before treatm ent
Group 1 
(n=15)
Group 1A 
(n=6)
Group 2 
(n=24)
Sex(male/female) 7/8 3/3 10/14
Mean age (years) 70 67 66
range 41-87 41-75 56-85
Mean ALP (U/L) 770 1725 880
95% Cl 210-5700 950-5700 175-5600
Mean number lesions 4 6 4
range 2-10 5-10 2-11
Mean WBR (%) 49.7 57.9 50.5
95% Cl 35.6-57.7 45.6-73.6 34.8-58.4
ALP = serum alkaline phosphatase 
95% Cl = 95% confidence interval
WBR = whole body retention of radiolabelled bisphosphonate
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Fifteen patients (group 1) received weekly infusions of 30mg pamidronate for 6 
weeks. Severe Paget's disease was considered to be represented by a pretreatment 
serum alkaline phosphatase (ALP) of >1000U/l (i.e. four times the upper limit of 
the reference range). Six patients fell into this category and these 6 comprised a 
subgroup (group 1 A) that received infusions of 60mg per week for three weeks 
in addition to the initial 6 , 30mg infusions (table 7.1). Group 2 consisted of 24 
patients who received infusions of 45mg pamidronate every three months for 1 
year, irrespective of their pre-treatment ALP levels. The total dose of 
pamidronate given was the same in both groups, i.e 180mg, although group 1A 
received a total dose of 360mg. All infusions were given in 500ml 0.9% sodium 
chloride solution and infused intravenously over 4 hours. Five patients in group 1 
and 2 patients in group 2 had previously been treated with oral etidronate. None, 
however, had received treatment in the year prior to this study and all were 
considered to have relapsed biochemically.
Symptomatic responses were assessed by visual analogue scores in 12 patients in 
group 1. A randomly selected group of 6 of these patients was given placebo 
infusions of 0.9% sodium chloride solution weekly for three weeks prior to 
commencing pamidronate. This phase of the study was carried out in a single­
blind manner.
Biochemical variables were measured in group 1 patients after 1 month of 
treatment, at the end of treatment, at 6 months and at 1 year. In group 2 patients 
measurements were made at intervals of three months throughout the study.
As the data were skewed, they were logarithmically transformed and a Student's 
t-test was used to assess within the group. One way analysis of variance was used 
to assess changes between different treatment groups. Correlations were carried 
out using Spearman rank coefficients.
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7 .1 .3  R esu lts
The levels of serum ALP and urinary hydroxyproline/creatinine (HP/Cr) ratios 
are expressed as means with 95% confidence intervals (95% Cl).
Serum ALP decreased steadily throughout the year in the two treatment groups 
(figure 7.1). At the end of 1 year mean ALP was 230UA in group 1 (95% Cl: 188 
to 281, p<0 .00001) and 297UA (227 to 389, p<0 .00001 ) in group 2 . Figure 7.2 
shows the decrease in serum ALP in both groups as their absolute values. In 
group 1, the ALP level in most patients decreased to within or just above the 
reference range, irrespective of the pretreatment level of ALP. In group 2, 
however, although there was a significant decrease in ALP levels, this was less 
marked in the more severely affected patients (i.e. those with a pretreatment ALP 
>100UA). In group 1A, 4 of the 6 patients with a pretreatment ALP >100U/1 
achieved normal levels of ALP and in the remaining 2 the ALP level decreased 
to less than 500U/1. In all 9 of the remaining patients in group 1, the ALP 
decreased to within the normal reference range. In group 2, 10 patients had an 
ALP level greater than 1000UA. None of these patients achieved a normal level 
of ALP. Of the remaining 13 patients in this group, all but 1 patient achieved a 
normal ALP level and in this patient the level of ALP was just above the upper 
limit of the reference range at 310UA. Pretreatment values for these patients are 
shown in table 7.1.
The maximum decrease in HP/Cr (figure 7.3) occurred at the end of treatment in 
group 1, with a mean of 0.022 (0.015 to 0.033, p<0.001), and at 3 months after 
the start of treatment in group 2, with a mean of 0.029 (0.022 to 0.037, p<0.003). 
In 2 patients in group 1 and 5 patients in group 2, HP/Cr remained elevated.
Group 1 Group 2
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Changes in levels of serum alkaline phosphatase (ALP). Values shown are means 
with 95% confidence intervals on a log scale. *p<0.002, **p<0.0001, 
***p<0.00001  (versus pre-treatment values).
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Changes in levels of serum alkaline phosphatase (actual values). Dotted line 
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Changes in fasting urinary hydroxyproline/creatinine (HP/Cr) ratio. Values 
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There was a significant positive correlation between serum ALP and HP/Cr both 
before (r=0.63, p=0.0002) and after treatment (r=0.41, p=0.01). No statistically 
significant difference was present between groups 1 and 2 in terms of serum ALP 
or HP/Cr.
A significant overall improvement in symptoms, assessed by visual analogue 
pain scores, was seen during treatment (figure 7.4). Where placebo infusions 
were given there was little change in pain scores, though these did subsequently 
improve (after 3 weeks) when these patients received the active drug.
There was a significant decrease in the whole body retention of radiolabelled 
bisphosphonate at 24 hours over the year of follow up from a mean of 49.3% to 
41.0% (p<0.01).
Treatment was well tolerated by most patients, with asymptomatic pyrexia 
occurring in only 19%. This is a lower figure than might be expected, perhaps 
because the first 15 patients treated received pamidronate as outpatients and 
asymptomatic pyrexia would not have been noticed. Three patients in group 2 
experienced mild rigors and influenza-like symptoms in the first 24 hours after 
the infusion. These symptoms did not recur with subsequent infusions.
7.1.4 Discussion
This study shows that pamidronate given at wide intervals over 1 year is as 
effective for the treatment of active Paget's disease as a short course of weekly 
treatment. The findings of this study also suggest that there is a dose/response 
relationship with pamidronate in the treatment of Paget's disease. The more 
severely affected patients had a less marked reduction in serum ALP when given 
the same dose of pamidronate as less severely affected patients. Also, the 6 most
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Figure 7.4
Pain score measurements for the 12 individual patients assessed. The bold lines 
indicate those patients who received placebo infusions and the pain score 
changes during this time. A fall in pain score measurement represents a 
symptomatic improvement.
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severely affected patients who comprised group 1 A, who received a higher total 
dose of pamidronate than the remaining 9 patients, subsequently had a better 
response. A possible explanation for this observation may be that in more 
severely affected patients, who generally have a greater number of active pagetic 
lesions, the drug is spread more widely and therefore is present at lower 
concentrations at the affected sites than in less severely affected patients. These 
observations are similar to those of Cantrill et al.(256) who found that the 
decrease in serum ALP was less marked where the initial ALP level was higher.
It is difficult to compare results between reported studies as Paget's disease may 
be of different severity in different groups. In addition, some patients might have 
been treated previously with bisphosphonates which remain in the skeleton for 
prolonged periods and can affect the response to further treatment (249). The 
decrease in ALP observed in this study, however, is similar to that noted by 
others with pamidronate whether given orally or intravenously (251).
The optimum length of treatment is controversial. Some workers have found that 
short courses of daily or weekly treatment lead to significant suppression of 
serum ALP that is still present 1 year after the start of treatment (251,256). In 
one study a single dose of 60mg of pamidronate was given intravenously once 
and this led to significant suppression of ALP to about 30% of the pretreatment 
level and this suppression was still evident after 1 year of follow up. All but one 
of these patients, however, had mild disease and the one patient present with 
severe disease responded poorly to this regime (257). In this present study, in 
group 1 patients who received 6 once weekly infusions, the ALP level continued 
to decrease after treatment was discontinued, and decreased at a similar rate to 
that observed in group 2 patients who received a single infusion every 3 months.
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There are some features of this study which are interesting and unexpected. In a 
small number of patients the urinary excretion of hydroxyproline increased to 
greater than the pretreatment levels. In these patients, however, the levels of 
serum ALP fell with treatment. Although it is possible that this decrease in ALP 
may be caused by the relative inhibition of mineralisation caused by 
pamidronate, the concurrent decrease in the whole body retention of 
radiolabelled bisphosphonate suggests that it is more likely that bone turnover 
has been reduced and that these urinary hydroxyproline measurements obtained 
reflect the difficulty in obtaining true fasting urine samples from outpatients.
This apparent variability in hydroxyproline excretion has been previously noted 
in Paget's disease treated with pamidronate (255). HP/Cr ratios began to increase 
after the end of treatment (group 1) or after 3 months (group 2). This is 
particularly surprising in group 2 as further treatment with pamidronate was 
being given to these patients. This may either be due to an "escape" 
phenomenon, or it may be that there is a subgroup of osteoclasts that are 
relatively resistant to pamidronate.
Although symptoms are notoriously difficult to assess, often because of 
associated osteoarthritis, there appears to have been a significant decrease in pain 
and discomfort after treatment. Side effects occurred rarely and were self- 
limiting.
In conclusion, pamidronate appears to be safe and effective in the treatment of 
Paget's disease. A dose/response effect appears to exist, with more severely 
affected patients requiring a higher total dose of pamidronate to achieve disease 
suppression. In the short term an effective and convenient dosage regimen for 
patients with levels of serum ALP up to four times the upper limit of the 
reference range is 45mg pamidronate by intravenous infusion every 3 months for
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1 year. For those patients with ALP levels greater than this, larger doses may be 
more effective. Recommendations for the very long term remain conjectural.
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7.2 Intravenous pam idronate in the treatm ent of o steopo rosis  
a ssoc ia ted  with corticosteroid dependen t lung d isease
7.2.1 Introduction
Increased bone resorption is generally a prominent feature in most examples of 
osteoporosis (264). This is particularly true of corticosteroid-associated 
osteoporosis where this is one of the principal mechanisms involved in the 
pathogenesis of this condition (332,333). In view of this, considerable interest 
has concentrated on the therapeutic use of anti-resorptive agents. Some evidence 
exists for a role for calcitonin in the treatment of osteoporosis (299,300), 
however most interest has recently centred on the use of bisphosphonates - in 
particular cyclical etidronate/calcium regimens (303,304).
In the previous study intravenous pamidronate was shown to be effective at 
reducing the increased bone turnover associated with Paget's disease. In this 
study the use of intravenous pamidronate was investigated in the setting of 
corticosteroid-associated osteoporosis.
7.2.2 Patients and Methods
Patients were recruited for this study from the chest clinics at Glasgow Royal 
Infirmary and associated hospitals. These patients all presented consecutively for 
routine review. Patients were included who had been taking an average minimum 
of 7.5mg prednisolone (or equivalent) per day for a minimum of 2 years, 
irrespective of whether or not they were thought to have significant osteoporosis. 
No significant changes in oral corticosteroid dose administered to these patients 
was noted during the year of treatment. Patients were excluded if they were on 
any other therapy or were suffering from any other medical condition thought
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likely to interfere with their bone metabolism. Twenty patients were recruited for 
this study, however 1 patient died (from respiratory failure) having only had one 
infusion of pamidronate, 1 moved away from Glasgow and 1 defaulted from 
further follow-up after only 1 infusion. Results at 1 year of follow-up, therefore, 
were available in 17 patients -15 suffering from asthma and 2 from sarcoidosis. 
The two patients with sarcoidosis had consistently normal 1,25 dihydroxyvitamin 
D3 (l,25(OH)2D3) levels and were normocalcaemic. Patient details are shown in 
table 7.2. Patients were seen at three monthly intervals. Patients were treated 
with 30mg pamidronate given as an intravenous infusion in 500ml 0.9% sodium 
chloride solution over 4 hours once every 3 months. The first infusion was given 
as an in-patient in order to observe for side-effects. At the time of review each 
patient had received 5 infusions (150mg pamidronate). An assessment of each 
patients dietary calcium intake was made prior to treatment. In 5 patients this 
was thought likely to be less than lOOOmg per day and in each case, 1 Sandocal 
400 tablet twice daily was prescribed, otherwise no formal calcium 
supplementation was given.
Plain radiographs of dorso-lumbar spine were obtained pre-treatment and after 1 
year of therapy. These were reported by an experienced radiologist and graded 
into normal, wedge deformity, bi-concave deformity or compression deformity. 
Each category was further classified as grade 1 or grade 2 depending upon the 
degree of deformity present The radiologist reviewing these X-rays was unaware 
of when these X-rays were carried out in relation to the administration of 
pamidronate.
Pre-treatment bone densities in these 17 patients was compared with a cohort of 
100 normal age and sex matched volunteers. These subjects had all been 
recruited into a longitudinal study monitoring long-term changes in bone density 
following a local advertising campaign. This group comprised 80 females
Table 7.2
Patien t's clinical and biochemical details pre-treatm ent (values 
show n are m eans)
Number of patients 17*
Age (years) 52.9
range 35-68
Steroid dose (prednisolone/day) 14mg
range 7.5-40mg
Duration of treatment (years) 14
range 3-30
Time post menopause (years) 15.5
range 1-24
Number with pre-treatment
vertebral fractures 14
Pre-treatment PTH (pmol/1) 3.6
SEM, range (normal l-5pmol/l) 0.5, 0.8-9.0
Pre-treatment 25(OH)D3 (nmol/1) 36
SEM, range (normal 15-100nmol/l) 5, 14-98)
Pre-treatment l,25(OH)2D3 (pmol/1) 82
SEM, range (normal 20-120pmol/l) 8,22-185
*17 patients - 5 male, 3 premenopausal female, 9 postmenopausal female
PTH - parathyroid hormone 
25(OH)D3 - 25-hydroxyvitamin D3 
l,25(OH)2D3 - 1,25-dihydroxyvitamin D3
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(median age 52 years, range 33-71) and 20 males (median age 38 years, range 
29-57). These subjects were all apparently healthy and did not suffer from any 
condition or take any medication thought likely to interfere with their bone 
metabolism. X-rays were not carried out in this group.
Statistical comparison of pre and post-treatment data was carried out using a 
two-tailed paired Student's t-test. Comparison of pre-treatment bone density with 
normal controls was carried out using an unpaired t-test and correlations between 
serum alkaline phosphatase (ALP) and fasting urinary hydroxyproline/creatinine 
(HP/Cr) were carried out using Spearman rank correlations.
7.2.3 Results
82% of patients included in this study had previously sustained at least 1 
vertebral compression fracture on the basis of plain radiology. Pre-treatment L2- 
4 and NOF bone density (meanlSEM) was significantly lower than in the group 
of age/sex matched controls (L2-4: 0.906g/cm2±0.050 [steroid patients] versus 
1.142g/cm2±0.016 [controls]; p=0.0002, NOF: 0.793g/cm2±0.030 [steroid 
patients] versus 0.93610.013 [controls]; p<0.00001). Thus these patients had 
evidence of significant osteoporosis.
After 1 year of treatment there was a significant rise in L2-4 density to 
0.927g/cm2±0.047, p=0.031. This represents a mean increase of 3.5% (95% 
confidence interval: 1.1% to 5.2%) (figure 7.5). Post therapy NOF density was 
0.748g/cm2±0.025; p=NS, which represents a mean change of 1.8% (95% Cl: - 
2.0% to 2.3%) (figure 7.6). In three instances L2-4 density decreased over the 
year of treatment and in one case no change was noted. In each of these instances 
pre-treatment bone densities were relatively normal and were all greater than
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Figure 7.5
Changes in L2-4 spinal density following pamidronate treatment (expressed as a 
percentage of pre-treatment level). Vertical bar represents 95% confidence 
interval.
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Figure 7.6
Changes in neck of femur (NOF) density following pamidronate treatment 
(expressed as a percentage of pre-treatment level). Vertical bar represents 95% 
confidence interval.
1.000g/cm2. Those patients who responded best to treatment tended to have the 
lowest pre-treatment bone densities.
Radiologically 1 patient suffered a new wedge fracture at D9 and 3 patients 
showed progression of wedging of 3 individual vertebrae.
Pre-treatment levels of PTH, 25(OH)D3 and l,25(OH)2D3 were generally within 
the reference range - 4 patients had elevated PTH values (5.8, 9.0, 8.3, 
6.3pmol/l), none had subnormal l,25(OH)2D3 levels. Mean (±SEM) pre­
treatment HP/Cr ratio was elevated at 0.040±0.006 indicative of increased bone 
resoiption. Pre-treatment serum ALP was within the reference range. There was 
a significant fall both in serum ALP (figure 7.7) with treatment from 
(mean±SEM, 220U/1116 to 174±9; p<0.002) and HP/Cr (0.040+0.006 to
0.024±0.003; p<0.01) (figure 7.8). No significant correlation was evident either 
pre or post-treatment between ALP and HP/Cr.
Five patients developed pyrexia (range 37.5°C - 38.8°C) following treatment, 
which was asymptomatic in 4 instances. This commenced approximately 24 
hours after the infusion finished, lasted 12-18 hours and resolved spontaneously. 
This side-effect is well recognised after intravenous pamidronate (468) and only 
occurred after the first infusion. No change was noted in peak expiratory flow 
rate after infusion.
7.2.4 Discussion
On the basis of their pre-treatment bone densities and the presence of fractures 
these patients would appear to have significant osteoporosis. Furthermore, 
intravenous pamidronate would appear to be effective in both reducing bone
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Figure 7.7
Changes in serum alkaline phosphatase (ALP) with treatment for each individual 
patient. Dotted line indicates upper limit of the reference range. Horizontal bars 
represent pre and post-treatment means.
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Figure 7.8
Changes in fasting urinary hydroxyproline/creatinine ratio following 
pamidronate treatment for each individual patient. Dotted line indicates upper 
limit of reference range. Horizontal bars represent pre and post-treatment means.
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turnover and increasing bone density in these patients with asthma and 
sarcoidosis.
Though data from Gennari (480) suggest that bone loss with corticosteroids 
occurs only in the first 6 months of therapy, it is likely that bone loss continues 
both with age and continued corticosteroid usage (336). This view is supported 
by the data from this study showing increased urinary HP/Cr (and therefore 
increased bone resorption) prior to therapy.
In the preceding study, intermittent infusions of pamidronate were shown to be 
effective in the management of Paget's disease of bone. Although the dose of 
pamidronate administered in this study was lower, bone turnover in 
corticosteroid-associated osteoporosis is likely to be increased to a lesser extent 
than in Paget's disease. Furthermore, the data presented in Chapter 6 showed 
that, in the setting of cancer-associated hypercalcaemia, 30mg pamidronate is 
generally as effective in inhibiting osteoclastic bone resorption as higher doses.
To date, most studies using bisphosphonates for the treatment of osteoporosis 
have used oral therapies. Intravenous preparations have some theoretical 
advantages in that they overcome the problem of poor absorption of these drugs 
(237,470) and they ensure that patient compliance with therapy can be accurately 
assessed. There has been considerable recent interest in the use of etidronate 
given in a cyclical manner for two weeks at a time alternating with 11 weeks of 
calcium supplementation, in the treatment of postmenopausal osteoporosis
(303,304). The use of intermittent infusions, as in this study, would be analogous 
to these cyclical oral regimens. As bisphosphonates, and pamidronate in 
particular, bind avidly to hydroxy apatite (129) and therefore have a prolonged 
biological half-life, the cyclical nature of the treatment regimen may not be 
necessary but rather the dose of bisphosphonate used should be low enough so as
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not to inhibit mineralisation - a known side-effect of bisphosphonate therapy 
(153). With intravenous therapy, however, an intermittent treatment regimen is 
convenient both for the patient and the attending physician.
Little information is available concerning the use of bisphosphonates in 
corticosteroid-associated osteoporosis. However, a previous study by Reid et 
al.(347) has suggested that oral pamidronate administered continuously is 
effective in increasing bone density in corticosteroid-associated osteoporosis and 
this increase in bone density can be maintained for at least 2 years (348).
The mean increase in L2-4 density of 3.4% is of a similar order of magnitude to 
that noted after etidronate at 1 year in postmenopausal osteoporosis (303,304). 
The fact that there was no significant change in NOF density would suggest that 
the increase in L2-4 density was not achieved at the expense of worsening of 
osteoporosis at the hip. This lack of effect on NOF density was also noted in the 
study using etidronate in postmenopausal osteoporosis by Watts et al.(304). The 
data from this present study and from those using cyclical etidronate/calcium
(303,304) would suggest that this treatment is likely to be most effective where 
osteopenia is more severe to begin with. Intermittent intravenous pamidronate 
therapy, therefore, should probably be reserved for those patients who have 
already sustained an osteoporosis related fracture or who have densitometric 
evidence of osteopenia.
While increases in bone density are important, the main end-point in studies of 
this kind must be fracture rates. The fact that fractures appear to have continued 
to occur is not surprising as, although these patients show an increase in bone 
density, they still probably lie below the fracture threshold. Obviously, in the 
absence of a control group, it is not possible to be certain of the significance of 
these further fractures. Certainly in the study of Storm et al.(303), no significant
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change in vertebral fracture rate was seen until at least 12 months into the study. 
This is also likely to be the case with pamidronate. However, further studies with 
larger patient numbers and longer term follow-up are required to address this 
issue.
Mean HP/Cr pre-treatment was elevated implying increased rates of on-going 
bone resorption. Following treatment bone resorption is reduced and bone 
formation would also appear to be reduced (as illustrated by the fall in serum 
ALP) while bone density increases. A possible explanation for this paradoxical 
effect is that resorption is inhibited and there then follows a delay before local 
coupling mechanisms result in a decrease in bone formation and, therefore, bone 
formation goes unopposed for some weeks (481).
Several studies have suggested that vitamin D levels are low in corticosteroid- 
associated osteoporosis (199,330). This was not the case in this study, where in 
agreement with Hahn et al.(482) l,25(OH)2D3 levels were normal or high. 
Similarly, biochemical secondary hyperparathyroidism was found in only 4 of 
our patients, a lower number than might be expected (331). These results would 
imply that the most important mechanism in the pathogenesis of this condition is 
the direct effect of corticosteroids upon bone resorption and formation.
In summary it would appear that intermittent intravenous infusions of 
pamidronate are effective at reducing the increased bone turnover of 
corticosteroid-associated osteoporosis. Furthermore, this regimen can 
significantly increase bone density which ultimately should lead to a decrease in 
the rate of new fractures. In addition this regimen would appear to be well 
tolerated and acceptable both to the patient and the attending physician. Long 
term controlled studies with this therapy are now indicated.
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CHAPTER 8
CONCLUDING DISCUSSION AND AREAS FOR FUTURE RESEARCH
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8.1 Concluding d iscussion  and a reas  for future research
The work presented in this thesis illustrates the potential application of currently 
available investigative techniques in the diagnosis and management of various 
disorders of bone and calcium homoeostasis and illustrates the potential 
therapeutic value of the bisphosphonate, pamidronate.
Many examples of the application of biochemical techniques exist. One of the 
most fascinating is the unravelling of the pathogenesis of cancer-associated 
hypercalcaemia. In many instances in the past this was thought to be due to the 
excessive release of skeletal calcium by accelerated osteoclastic bone resorption 
associated with metastatic bone disease. However, the use of biochemical 
markers of PTH activity, such as NcAMP and TmP04, along with accurate 
direct measurement of PTH, led to the insight that in many cases, cancer- 
associated hypercalcaemia is due to elaboration of PTHrP by the tumour itself 
(73,77-81,83-85). It is likely that both PTHrP and osteolysis secondary to 
metastatic bone disease vary in relative importance as the cause of the 
hypercalcaemia in different primary cancers. Chapter 3.1 illustrates the presence 
of a PTH-like factor (presumably PTHrP) in 45-60% patients with breast cancer- 
associated hypercalcaemia depending upon whether urinary cAMP excretion 
(UcAMP) or TmP04 are measured. Since this work was carried out, assays for 
the direct measurement PTHrP have become available. Bundred et al.(483) found 
detectable concentrations of PTHrP in 12/13 (92%) of hypercalcaemic breast 
cancer patients with bone metastases compared with 10 of 28 (36%) of 
normocalcaemic patients with bone metastases. Although it would appear that 
PTHrP plays an important role in the pathogenesis of breast cancer-associated 
hypercalcaemia, the natural history of this condition has yet to be completely 
mapped out. In particular, in normocalcaemic patients, the significance of both 
an elevated NcAMP (as noted in chapter 3.1) or PTHrP (483) is not clear. It is
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certainly possible that these patients may be at risk of developing 
hypercalcaemia and perhaps should be targeted for prophylactic bisphosphonate 
therapy. Certainly, it would appear that measurement of both PTH and PTHrP is 
likely to be of value in the diagnosis and monitoring of cancer-associated 
hypercalcaemia (484).
The value of direct measurement of PTHrP is further illustrated in chapter 3.2. In 
this study, where changes in plasma PTHrP through normal pregnancy were 
studied, these concentrations were generally within the reference range. In this 
context it is unlikely that indirect markers of PTH-like activity are of sufficient 
sensitivity to monitor changes in plasma PTHrP. This study would appear to 
confirm the potential role for PTHrP in both maternal-fetal calcium transport and 
breast-breast milk calcium transport. Whether or not PTHrP in this setting has an 
endocrine role, or merely reflects spill over into the circulation from areas of 
high local PTHrP concentrations remains unclear. Further human studies 
investigating the localisation of PTHrP in the placenta are now indicated. 
Furthermore, it is possible that PTHrP might be added to the list of biochemical 
markers of placental function.
Biochemical investigation has allowed greater understanding of areas of bone 
and calcium homoeostasis other than just the pathogenesis of hypercalcaemia 
and the discovery of PTHrP. It is now apparent that PTH and l,25(OH)2D3 are of 
considerable importance in maintaining both normocalcaemia and normal bone 
turnover (1,412). Up until very recendy PTH has not been available for use 
therapeutically. Some recent evidence, however, has suggested that synthetic 
PTH may be useful in the treatment of osteoporosis (313). These data, though 
exciting, remain preliminary. l,25(OH)2D3 and its pharmacological precursor, 
la(OH)D3 (alfacalcidol), have been available for therapeutic usage for some 
time. These preparations have been shown to be useful in the treatment of
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hypocalcaemia, for example that secondary to hypoparathyroidism, and 
osteomalacia. Since l,25(OH)2D3, physiologically, has an inhibitory effect on 
PTH secretion, this preparation is potentially useful in the treatment of primary 
or secondary hyperparathyroidism (31,416,418,421-424). Studies have, however, 
shown it to be of limited value in the treatment of primary hyperparathyroidism, 
though it is certainly of some value in the management of secondary 
hyperparathyroidism, such as is associated with chronic renal failure (416,423). 
Unfortunately oral l,25(OH)2D3 and alfacalcidol tend to be associated with 
hypercalciuria and ultimately hypercalcaemia which limits their usefulness (30). 
Recent evidence has shown that hypercalcaemia does not occur when 
l,25(OH)2D3 or alfacalcidol are administered intravenously (417,419,424,425). 
The effect of intravenous alfacalcidol on normal subjects and patients with 
osteoporosis and primary hyperparathyroidism is described in chapter 3.3. This 
shows that peak levels of l,25(OH)2D3 are seen 2-3 hours after administration of 
alfacalcidol, however PTH suppression (or osteocalcin stimulation) are not seen. 
Further studies are required to look at the effects of longer term administration of 
this drug.
Another important advance seen in the last decade in the study of disorders of 
bone and calcium metabolism was the introduction of technologies which would 
allow accurate and precise measurement of bone density. One of the most useful 
methods currently available is dual-energy X-ray absorptiometry (DXA) which 
allows direct measurement of bone density in those areas where fractures are 
most important in terms of their associated morbidity and mortality i.e. the neck 
of femur and spine. DXA is also a safe technique with minimal exposure to 
ionising radiation. It is also relatively quick and therefore bone density can be 
potentially measured in a large number of patients (274). There is little evidence 
at present to support the use of this technology to carry out widespread 
population screening for osteoporosis (485), though a recent Consensus
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conference recommended its "routine" use in certain "at risk" patient groups 
(286). As well as its ability to measure bone density in large numbers of patients, 
DXA allows detailed assessment of bone density in specific sub-populations 
such as patients with diabetes mellitus as described in chapter 4.1 and 
haemophilia (chapter 4.2).
The existence of a possible association between diabetes mellitus and 
osteoporosis has been discussed for many years (349). Most studies of this 
subject to date have yielded conflicting results, probably because patient groups 
studied have been very heterogeneous. The work described in chapter 4.1 
suggests that osteopenia may not be associated with type 1 diabetes, but rather 
bone density may even be slightly increased. Further work is required to 
investigate this further, in particular the possible role of insulin-like growth 
factor 1 (IGF-1) in stimulating this increase in bone density. Furthermore the 
effects of improving glycaemic control upon bone density and turnover requires 
further study. As suggested above part of the reason for the conflicting results in 
studies of diabetes related osteopenia is the heterogeneous nature of the patient 
groups studied. It is possible, therefore, that osteopenia may be present in a sub­
group of the diabetic population. Given that data presented in this thesis suggests 
that diabetes is associated with a high bone turnover state, it is very likely that in 
situations where bone resorption is increased such as after the menopause, bone 
loss will be significant and result in osteoporosis. This is an area that deserves 
further study.
The association between haemophilia and osteopenia described in this thesis 
(chapter 4.2) is novel and warrants further investigation. Preliminary 
investigations described would suggest that these patients have relative 
hypogonadism and further work is required to look at the role of androgen 
supplementation in these patients. If the prime problem in these patients is
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indeed hypogonadism then it might be expected that bone formation be reduced 
and bone resorption increased. Since invasive histomorphometric bone turnover 
assessment is impractical in this situation, further investigation of biochemical 
indices of bone turnover are indicated. Future studies should also be directed at 
whether these bone density changes are restricted to those patients with severe 
haemophilia or if they correlate with the factor VIIIc level present.
As well as being able to define the presence of absence of osteopenia in 
population groups, the precision of DXA allows longitudinal studies of bone 
density. This is illustrated in chapter 7.2 where intermittent intravenous infusions 
of the bisphosphonate, pamidronate, were shown to result in a significant in 
crease in lumbar spine bone density.
Although DXA is undoubtedly a very useful tool, the capital expenditure on 
purchase of the machine is high as is the cost of a dedicated technician to run it.
It is unlikely that these machines will be available widespread throughout the UK 
and other methodologies will have to be used to screen populations, where this is 
thought to be of benefit. This could be done by use of single photon 
absorptiometry (SPA) of the forearm (271) or by use of broad band ultrasound of 
the os calcis (486).
The introduction of multichannel biochemical analysers along with the 
availability of precise measurement of PTH has meant an increase in the 
frequency of diagnosis of primary hyperparathyroidism (46). In addition 
advances have been made in the technologies available for pre-operative 
parathyroid imaging. There is now good evidence that knowledge of the site of 
the putative parathyroid adenoma prior to surgery both lessens the chance of a 
negative neck exploration and shortens anaesthetic time (176). In chapter 5.1 the 
two methods of parathyroid imaging most widely available in the UK - 10MHz
178
ultrasound and thallium/technetium subtraction scanning - were compared. This 
study showed that though specificities of these techniques are high, sensitivities 
are low and neither of these techniques can be recommended for routine pre- 
operative use. There was a suggestion in this study that more useful information 
might be obtained where both these techniques are used together, though further 
studies are required to address this issue. In chapter 5.2 an attempt was made to 
improve the sensitivity of thallium/technetium subtraction scanning by 
transiently lowering serum calcium at the time of the scan. This preliminary 
study showed that this technique could be used to stimulate parathyroid thallium 
uptake, however, the technique itself is rather cumbersome and not likely to be 
of routine use. Much interest currently lies in imaging with 99m-Technetium- 
sestamibi which would appear to be preferentially taken up by parathyroid tissue 
(453). Use of this technique appears to result in improved localisation sensitivity 
for both parathyroid adenomas and hyperplasia.
Considerable advances have also been made in the pharmacological treatment of 
many disorders of bone and calcium metabolism in the past decade.
One of the most significant therapeutic advances has been the introduction of the 
bisphosphonates into clinical practice. These drugs are structurally similar to 
pyrophosphate with the exception of a carbon atom substituting for oxygen. This 
renders the bisphosphonates resistant to pyrophosphatases (127) and as they are 
actively taken up into bone, they may have very long biological half-lives (127). 
These drugs act by inhibiting osteoclastic bone resorption (129), usually by a 
direct toxic effect upon the osteoclast. The aminobisphosphonates, of which 
pamidronate is an example, may also have an effect on inhibiting osteoclast 
formation from monocyte precursors (458). Bisphosphonates are particularly 
effective in situations where bone resorption is high such as hypercalcaemia 
associated with cancer (130), immobilisation (131) and hyperthyroidism (132),
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Paget's disease of bone (133) and post-menopausal, senile and corticosteroid- 
associated osteoporosis (303,304,347).
Pamidronate is currently licensed for use in the treatment of cancer-associated 
hypercalcaemia in the UK. It is recommended that the dose of this drug be 
titrated against the prevailing serum calcium i.e. the higher the calcium, the 
higher the dose of pamidronate should be. The evidence for this assertion is 
weak. Chapter 6.1 shows that, on average, there is no difference between 30mg 
and 90mg pamidronate in terms of its calcium lowering effect (these two doses 
are the highest and lowest recommended). There are, however, undoubtedly 
some patients who require a larger dose of pamidronate. The reasons for this are 
explored further in chapter 6.2. This study shows that the calcium lowering effect 
of pamidronate is less pronounced where there is evidence of PTHrP-mediated 
hypercalcaemia. The study described in chapter 6.2 was carried out before 
measurement of PTHrP was generally available and, therefore NcAMP, TmP04 
and TmCa are used as markers of PTH-like activity. Further studies are indicated 
comparing the calcium lowering effect of bisphosphonates to the pretreatment 
concentration of PTHrP. In the absence of a measurement for PTHrP or NcAMP 
or TmP04, the dose of pamidronate should be higher (60-90mg) in the presence 
of squamous cancer or breast cancer as it is likely that PTHrP is involved in the 
pathogenesis of the hypercalcaemia in a large proportion of cases with these 
tumour types and the dose should be lower (30-45mg) in association with, for 
example haematological malignancy, where PTHrP is likely to be absent or low.
A further example of non-PTHrP driven hypercalcaemia is immobilisation- 
related hypercalcaemia. From the evidence presented in chapters 6 .1 and 6.2 it 
might be expected that patients with immobilisation-related hypercalcaemia 
would be particularly sensitive to bisphosphonate therapy. This, indeed, appears 
to be the case (chapter 6.4). The cases presented in chapter 6.4 further raise the
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question as to whether this hypercalcaemia may be cytokine driven. Certainly, 
interleukin- 1 has been shown in the rat model to increase bone resorption and 
cause hypercalcaemia (106). Further studies are required to investigate this 
hypothesis further in man.
Bone resorption is generally also considerably increased in Paget's disease of 
bone. Bisphosphonates are therefore effective in this condition. It would appear 
that a dose/response effect exists (chapter 7.1) and that an intermittent treatment 
regimen with intravenous pamidronate is effective and can result in effective 
biochemical disease suppression. Intravenous therapy is, in general terms, likely 
to be both uncomfortable and inconvenient. There is now, therefore, considerable 
interest in the newer oral bisphosphonates such as risedronate, tiludronate and 
alendronate which are considerably more potent than even pamidronate and are 
likely to be effective in the treatment of Paget's disease.
Bone resorption is usually increased in corticosteroid-associated osteoporosis. 
The data presented in chapter 7.2 would suggest that intermittent infusions of 
intravenous pamidronate can both reduce this bone resorption and also stimulate 
an increase in bone density at least at the lumbar spine. Although there is a large 
volume of literature concerning the treatment of post-menopausal osteoporosis, 
there is relatively little on the treatment of corticosteroid-associated osteoporosis. 
The data presented in this thesis would suggest that pamidronate is likely to be of 
benefit, however longer term controlled trials are required to address the question 
of fracture risk. A large multi-centre study has been set up in the UK by the 
British Thoracic Society which will look at the effect of oral etidronate on bone 
density and fracture risk in patients with corticosteroid dependent lung disease.
The work described in this thesis describes how various investigative techniques 
that are available today can be applied to clinical situations. It is likely with the
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development of sensitive assays for PTHrP that more will be learned about the 
physiological role of this hormone. In addition considerable advances are being 
made in the biochemical assessment of bone turnover with indices such as 
measurement of urinary excretion of the collagen cross-links, pyridinoline and 
deoxypyridinoline, likely to supersede urinary hydroxyproline excretion as 
markers of bone resorption (319,487) and measurement of serum procollagen 
peptide III likely to supersede serum alkaline phosphatase and osteocalcin as a 
marker of bone formation (488). These measurements will allow more 
information to be obtained on bone turnover in various physiological and 
pathological states, making recourse to invasive histological assessment of bone 
turnover less necessary. Techniques such as those described above and those 
used in this thesis can also be applied to the monitoring of various treatment 
strategies, including the use of pamidronate as described here. It is likely that the 
future of bisphosphonate therapy will lie with the newer potent oral formulations 
which are now entering clinical trial. Hope now exists for the effective treatment 
of conditions such as Paget's disease of bone and osteoporosis which until 
recently have been considered by many to be untreatable.
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